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Chapter 1 
INTRAGRAFT CYTOKINE GENE EXPRESSION: IMPLICATIONS FOR 
CLINICAL TRANSPLANTATION (overview) 
This chapter is based on the article published in: 
Transplant International (in press) 
Carla C. Baan and Wil/em Weimar 
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ABSTRACT 
As the knowledge of the cytokine network in experimental transplant models grows, 
we need to understand how and to what extent cytokines mediate the various donor-
directed immune events in clinical situations. This overview on clinical cytokine 
measurements shows that specific intragraft cytokine messengerRNA (mRNA) 
expression profiles can be associated with acute rejection, may reflect the efficacy of 
immunosuppression, and can trace patients at risk for the development of early 
chronic rejection. Moreover, the literature also showed that acute rejection and 
immunological quiescence in man are not restricted to the cytokine patterns 
according to the type 1/type 2 paradigm. This apparent lack of association may be 
caused by the immunosuppression used in the clinic but may also be the result of 
the infinite diversity of donor and recipient factors of which polymorphisms in 
cytokines and cytokine receptor genes may playa central role. 
INTRODUCTION 
Studies in animal transplant models have clearly proven the value of cytokine 
measurements. These stUdies learned us a lot about the cytokine network during the 
full spectrum of transplant associated immune responses. However, it is important to 
understand to what extent these mostly clear findings can be translated to the clinic 
and whether alterations in the cytokine pattern may help the clinician to adapt the 
immunosuppressive regimen in a given individual. 
Measurements of cytokines became very popular with the introduction of the reverse 
transcriptase-polymerase chain reaction (RT-PCR) and the availability of enzyme 
linked immunosorbent assay (ELISA) kits in the early 90's. These techniques made 
it possible to monitor both cytokine messenger RNA (mRNA) expression in tissues 
and cytokine protein concentrations in body fluids. In situ hybridization, bioassays, 
and immunohistochemistry were also applied to determine the presence of 
cytokines. All these methods resulted in a tremendous amount of articles on cytokine 
measurements analyzing various stages of the immune response after 
transplantation. Indeed studies in experimental animal transplant settings showed 
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that cytokines played key roles at each of these stages. However, in contrast to the 
clearcut data derived from studies under strict controlled laboratory conditions the 
results in clinical transplant settings proved to be significantly more difficult to 
interpret. From large database studies it is already known that graft rejection and 
patient survival are influenced by infinite diversity of donor and recipient factors, 
including age and accompanying diseases of organ donor and recipient, former 
blood transfusions, HLA compatibility match grade, and history of viral infections. 
Moreover, in clinical transplantation nowadays a variety of immunosuppressive 
schedules can be used that can affect various steps in the cascade of immune 
activation, albeit not always to the same degree in each patient. Consequently, the 
variability between individual patients . will affect the results of cytokine 
measurements. Most of the data relating local cytokine production with immune 
mechanisms after clinical transplantation is based on in situ detection of 
transcriptional factors by RT-PCR. This technique is suitable to measure a broad 
panel of cytokine mRNAs in small amounts .of tissue such as biopsies. These 
cytokine measurements may provide information on immune events (acute and 
chronic rejection and graft acceptance) in individual patients. This review, 
summarizes these intragraft cytokine measurements after heart, liver and kidney 
transplantation and will discuss the typical pitfalls associated with patient directed 
research which may influence the outcome of intragraft cytokine mRNA 
measurements. 
CHARACTERISTICS OF CYTOKINES 
Cytokines are soluble polypeptides which function as a paracrine or autocrine 
mediator acting over short distances regulating a variety of immune and 
inflammatory responses. Since the discovery of the T cell growth factor, presently 
known as IL-2, in 1978, the field of soluble mediators has been explosively explored 
(30). A complete network of interleukins, interferons, chemokines and growth factors 
has been characterized. Cytokines secreted under normal or pathological conditions 
affect proliferation, differentiation, and the function of cells involved in numerous 
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physiological processes. Their biological activity is mediated by specific membrane 
receptors which can be expressed on a variety all cell types. Cytokines can have 
stimulatory and inhibitory properties, may synergise or antagonize the action of 
individual components in the network. Additionally, one factor may replace or 
compensate for the lack of another cytokine (redundancy) but in the context of a 
particle immune function e.g. graft rejection individual cytokines may have a 
dominating role. In the field of organ transplantation this may hold especially true for 
T cytokines. In 1991 Romagnani showed that human T helper (Th) cells like mouse 
CD4+ T cells express functionally distinct cytokine profiles (57,73). The Th1fTh2 
paradigm was born. According to this theory, Th1 cells produce interleukin (IL)-2, 
interferon (IFN)-y, tumor necrosis factor (TNF)-Il and favour cellular immune 
responses, delayed type of hypersensitivity, macrophage activation, while Th2 cells 
secrete IL-4, IL-5, IL-6, IL-10 favour tolerance, and stimulate B cell differentiation 
and antibody responses (62). Recently, it has become evident that this dichotomy is 
not confined to CD4 helper T cells alone (58). CD8 effector cells and yfJ T cells may 
also secrete cytokines in a polarized fashion. This has led to the more generalized 
nomenclature: type 1 and type 2 cytokines (18). 
CYTOKINE MEASUREMENTS IN EXPERIMENTAL TRANSPLANT SETTINGS 
Studies in experimental transplant settings had shown that immune responses 
towards an organ are regulated by cytokine interactions (24,36). From these and 
other studies, we learned that endothelium damage by ischemia, reperfusion and 
surgery triggers non-specific inflammatory responses mediated by members of the 
different cytokine families (24,31,36,38,51). Damaged endothelial cells release 
increased amounts of the IL-111 and IL-6, IFN-y, the chemokines macrophage 
chemoattractant protein (MCP)-1, macrophage inflammatory protein (MIP)-1a and 
MIP-111 and IL-8, colony stimulating factors, and multiple growth factors such as 
TNF-a, platelet derived growth factors (PDGF), insulin growth factor-1, transforming 
growth factor (TGF)-I1, basic fibroblast growth factor (FGF) (4,25,70,76). Thus, as a 
result of the surgical procedure a complete network of cytokines is already activated, 
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even before allogeneic reactions can be encountered. Cytokine production by 
activated endothelium results in upregulated HLA expression and increased 
adherence of monocytes and T cells which is followed by infiltration into surrounding 
tissue. For instance, TNF-a and IL-1B induce vascular endothelial cells to transcribe 
the vascular adhesion molecule-1 (50). Consequently, the triggering step is crucial 
because non-specific endothelium injury can be the initial factor in the development 
of acute and chronic graft rejection. 
The first experimental studies analyzing molecular pathways involved in acute 
rejection and graft acceptance showed that these mechanisms are dominated by 
intragraft production of either type 1 cytokines or type 2 cytokines, respectively. In 
rodents and cynomolgus monkeys, acute rejection was accompanied by intragraft 
type 1 (IL-2, IFN-y) mRNA expression, suggesting that these cytokines control the 
rejection process after kidney, heart and liver transplantation (24,56,89,101). Studies 
in experimental models also showed that graft acceptance can be identified on basis 
of a clear intragraft mRNA profile. In the majority of these studies, graft acceptance 
is associated by diminished type 1 cytokine and enhanced type 2 cy10kine 
production (16,19,77,88). However, it is evident from studies using genetically 
manipulated animals that type 1 cytokines are not always required for rejection and 
that type 2 cytokines do not always initiate permanent engraftment. IL-2 and IFN-y 
knockout mice reject their transplants in the presence of type 2 cytokines (45,85) 
and IL-4 knockout mice accept their graft in the presence of type 1 cytokines (59). 
These studies indicate that immunological phenomena such as graft rejection and 
acceptance are not exclusively restricted to the type1/type 2 dichotomy. Alternative 
and/or redundant pathways may contribute to the alloimmune response associated 
with these phenomena. Interestingly, results from the double IL-2 and IL-4 knockout 
model suggested that also T cell growth factors produced by non T cells are able to 
induce allograft rejection (74). 
Evidence for a significant role of cytokines in the etiology of chronic allograft 
rejection or transplant arteriosclerosis has been found in experimental transplant 
studies as well. These studies are focused on cytokine production by injured 
endothelial cells and smooth muscle cells and on chemokine production by activated 
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macrophages. Semi-quantitative RT-PCR analysis in rat aortic allografts showed 
that mRNA expression of various cytokines (e.g. IL-1B, TGF-B, PDGF, TNF-a, 
insulin growth factor-1, acid FGF, basic FGF) are upregulated (38,70). Chemokines 
produced by the infiltrated mononuclear cells may also playa critical role in chronic 
rejection processes. In the Lewis to F344 cardiac rat model, mRNA expression of 
the chemokines MCP-1, allograft inflammatory factor-1, allograft inflammatory factor-
2 is elevated (76,92). In this model, transplant arteriosclerosis is also associated by 
intragraft IFN-y and IL-6 mRNA expression located in the infiltrating cells. 
Thus, analysis in animal transplant settings showed that cytokines play key roles at 
every stage of the immune response after transplantation. Especially the association 
between acute cellular rejection and production of type 1 cytokines within the graft 
prompted many investigators to analyse the role of these cytokines after clinical 
kidney, liver and heart transplantation. 
T-CELL ACTIVATION AND THE EFFECT OF IMMUNOSUPPRESSIVE AGENTS 
ON CYTOKINE PRODUCTION 
The immune response after transplantation is largely governed by actions of T cells. 
Initiation of T cell responses requires interaction of the T cell receptor with 
processed donor antigen, binding of CD4 and CD8 proteins with HLA class II and 
class I molecules, and secondary costimulatory signals between ligands on the T-
cell (CD28, CD40Ligand, CD2, LFA-1) and their counterparts (B7/CTLA-4, CD40, 
LFA-3, ICAM) present on antigen presenting cells including dendritic cells, M(jl, B-
cells and T-cells (figure 1; 42,49,79,82). In addition to cell surface events soluble 
mediators (IL-1, IL-6) also contribute to T cell activation (78). The interactions trigger 
a number of intracellular events leading to production of cytokines and their 
receptors and cellular proliferation. These intracellular events involve the activation 
of tyrosine kinases, tyrosine phosphorylation of cellular proteins followed by elevated 
intracellular free calcium concentrations and activation of the calcium- and 
phospholipid dependent protein kinase C (14,75). This cascade leads to the initiation 
of transcription of cytokines and receptors. 
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Figure 1. Interaction betvleen antigen presenting cells (APe) and T-cells (adapted from Dallman, The 
Handbook of Transplant Immunology 1995) 
Transcription of cytokine genes is regulated by the binding of regulatory proteins 
(NF-AT, AP-1, OCT) to specific DNA sequences in the enhancer region of the gene 
(72). The immunosuppressive action of cyclosporin A (CsA) and tacrolimus/FK506 is 
based on inhibition of the T cell signal transduction pathways (figure 2). In activated 
T cells, the rise of calcium activates the calmodulin-dependent phosphatase 
calcineurin. CsA and tacrolimus/FK506 inhibit calcineurin activity when it forms a 
complex with immunophilins resulting in reduced cytokine production (33,40). In 
contrast to activation signals provided through the T cell receptor, the effects of the 
CD28 costimulatory signals are not inhibited by CsA and tacrolimus/FK506 (99). 
Glucocorticosteroids inhibit cytokine gene expression at multiple sites of the 
activation cascade. Steroids blocks cytokine production of T cells by inhibiting the IL-
1 and IL-6 production of antigen presenting cells, by inhibiting calcineurin-dependent 
pathways (65), and by interfering with the binding and/or transcriptional activity of 
NF-AT, OCT, AP-1 of the IL-2 gene (65,93). In contrast, both rapamycin, although 
structurally very similar to tacrolimus/FK506, and mycophenolate mofetil, have no 
effect on cytokine mRNA transcription (103). Rapamycin blocks cytokine driven T 
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Figure 2. The molecular mechanisms of 
immunosuppressive agents (adapted from 
Halloran, The Handbook of Transplant 
Immunology 1995) 
cell proliferation by affecting proteins that are involved in cell cycle pathway and 
mycophenolate mofetil blocks the purine de novo synthesis which is required for 
DNA synthesis (15). Another approach to inhibit allogeneic immune responses is to 
block T-cell co-stimulation. Blockade of the CD28/B7 and/or CD40/CD40Ligand 
interactions results in prolonged survival of allografts which can be associated by 
shifts in the type 1/type 2 balance (49,68,77). Since cytokines appear to play major 
roles in transplant pathology, their receptors may also be good target for selective 
immune therapy strategies. In view of the importance of IL-2 in the rejection process, 
monoclonal antibodies were developed to block the IL-2 dependent signalling 
pathway (44,60,84,96,97). The high affinity IL-2Receptor (IL-2R) consists of three 
transmembrane protein chain termed a, r.., y. The a-chain is not expressed on 
resting T cells, but is induced following activation. Moreover, the a-chain is 
necessary for the formation of the signal transducing high affinity receptor (43). 
Significant signal transduction components of cytokine receptors are members of the 
Janus-family kinases (JAKs) and signal transducers and activators of transcription 
(STATs). Cytokines may use common JAKs and STATs which may at least in part 
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explain phenomena of cytokine pleiotropy and redundancy (43). For example the y-
chain or the common Yc subunit of the IL-2R is a component of high affinity receptors 
for IL-2, IL-4, IL-7, IL-9 and IL-15 while the overlapping biological properties of IL-4 
and IL-13 may be explained by an another common receptor (17). Thus, blockade of 
cytokine receptors by monoclonal antibodies is a method to inhibit cytokine driven 
signal transduction pathways. 
Interference at any level of the T cell activation cascade by immunosuppressive 
agents is associated by changes in cytokine mRNA expression within the allograft. 
Therefore, monitoring of intragraft cytokine mRNA expression by RT-PCR is an ideal 
tool to determine the immune-status of graft infiltrating cells. This type of analysis 
may be helpful to treat patients more specifically with immunosuppressive therapies. 
However, exlrapolation of in vitro or experimental data to the clinic requires care. 
Interpretation of cytokine measurements may be hindered by all kinds of patient 
related complications. 
INTRAGRAFT CYTOKINE MEASUREMENTS AFTER CLINICAL ORGAN 
TRANSPLANTATION: 
acute rejection 
In transplantation immunology, shifts in the cytokine balance are often used to study 
mechanisms regulating acute rejection (type 1 response) or down-regulation of the 
immune response (type 2 response). Consequently, most of the cytokine 
measurements in the clinical field were also focused on mediators produced by 
activated infiltrating T lymphocytes (table 1). In clinical kidney transplantation, the 
first prove of a predominance of type 1 cytokines during early stages of allograft 
rejection was reported by Dallman et al. (23). In that report, intragraft IL-2 mRNA 
expression measured in fine needle aspirates preceded clinical rejection. Another 
study using fine needle aspirates also showed an association between intragraft 
type 1 (IFN-y) cytokine mRNA expression and clinical acute rejection (61). In 
contrast, Krams et al. did not find a relation between IL-2 positivity and different 
stages of rejection (46). They only occasionally found message coding for the IL-2 
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gene in solid biopsies from rejecting or rejected kidneys. The group of Hutchinson 
was also not able to confirm an association between intragraft IFN-y mRNA 
expression and kidney graft rejection (41). Conflicting data on the involvement of 
type 1 were reported from stUdies using in situ hybridization too. Studies by 
Vandenbroeke et al. (98) and Grimm et al. (35) showed that neither IL-2 nor IFN-y 
mRNA expression was associated with acute kidney allograft rejection, whereas 
Loong and colleagues found enhanced cytokine protein production of both type 1 
(IL-2, TNF-a), their receptors (IL-2R), and type 2 (IL-4, IL-6, IL-10) cytokines in 
rejecting kidneys (52). In line wilh this observation is the study by Xu et al (102). In 
this study, intragraft expression of both type 1 (IL-2) and type 2 (IL-10) cytokines 
was upregulated during renal allograft rejection. Such a prominent role for type 2 
cytokine in the rejection process after kidney transplantation was published by 
several groups. Krams et al (46) found in rejection biopsies and rejected kidneys IL-
4 and IL-5 mRNA expression whereas Strehlau et al. (86) found heightened IL-10 
mRNA expression in the absence of IL-4 mRNA. 
As in kidney transplantation controversial data on monitoring type 1 cytokines during 
rejection are reported in clinical liver and heart transplantation. Indeed, several 
investigators demonstrated that type 1 cytokines were detected or upregulated in 
rejecting livers (8,13,20,29,32), and hearts (9,22,34) but these and other studies 
also demonstrated that both hepatic and cardiac allograft rejection may occur in the 
absence of type 1 cytokines (48,53,105). Thus, unlike the situation in animal models, 
the role of type 1 cytokines in the acute rejection process after clinical 
transplantation is less clear. From clinical studies it is obvious that allograft rejection 
may not only occur in the presence of both type 1 and type 2 cytokines but also in 
their absence. However, the presence of type 1 cytokines is nearly always 
associated with rejection and is downregulated again after successful antirejection 
treatment (7,39). Absence of IL-2 mRNA expression can be found during 
immunological quiescence, but may also simply indicate that the IL-2 mRNA signal 
has vanished already during the rejection process. IL-2 is an early gene in the 
course of an immune response and Dallman did show that IL-2 mRNA expression 
preceded the clinical rejection (21,23). Moreover, kinetics of IL-2 mRNA expression 
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showed that IL-2 mRNA is only briefly expressed by graft infiltrating lymphocytes. 
After stimulation with donor antigen, IL-2 mRNA expression was detectable as early 
as 1-2 h, reached maximum levels between 2-48 h, while base-line levels were 
again approached by 20-72 h (11). Accordingly, timing is a factor which significantly 
complicates cytokine measurements. The IL-2 mRNA signal could have been easily 
missed. Another explanation for IL-2 negative rejection is redundancy in the cytokine 
network. Recently, we found that proven blockade of the IL-2I1L-2R signalling 
pathway by CsA and an anti-IL-2R monoclonal antibody is not sufficient to prevent 
allograft rejection in cardiac allograft recipients (96). Other cytokines may adopt the 
function of IL-2. For instance, intragraft IL-7 and IL-15 (a T cell growth factor 
secreted by macrophages) mRNA expression are present in the IL-2 negative renal 
and liver allograft rejections and may well serve as initiators of the allogeneic 
process (6,67,86). 
chronic rejection 
Chronic allograft rejection is characterized by ongoing inflammation and diffuse 
concentric intimal proliferation in the arterial system (12,83). This chronic process is 
thought to derive from an interaction between non-specific and allogeneic factors, 
leading to smooth cell proliferation. The role of cytokines in the pathogenesis of 
transplant arteriosclerosis has been recognized for many years. The relationship 
between ischemia/reperfusion injury and development of chronic rejection is well-
known although the underlying mechanism is poorly defined. Recently, Adams et al. 
showed that perfusionlischemia leads to secretion of the chemokines macrophage 
inflammatory protein-1a and macrophage inflammatory factor-1B by endothelial cells 
of the transplanted liver (1). Chemokines produced by activated T cells and 
macrophages may also mediate the development of arteriosclerotic lesions. In 
comparison to non-transplanted controls, the chemokine RANTES (regUlated on 
activation normal T cell expressed and secreted) mRNA and protein production has 
been shown to be upregulated in coronary arteries obtained from patients with 
endstage chronic rejection after clinical heart transplantation (66). Using in situ 
hybridization and immunohistochemistry, RANTES was localized in the infiltrating 
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mononuclear cells and endothelial cells. In vitro stUdies showed that RANTES is 
produced by endothelial cells after exposure to TNF-a, IL-1j3, or IFN-y (27). 
Therefore, routine intragraft chemokine measurements of time-zero -and the first 
posttransplant biopsies may provide insight into how early chemokine production by 
endothelial cells or macro phages mediate mechanisms leading to acute and chronic 
rejection. 
Apart from ischemia-reperfusion injury, the typical non-specific factors, specific 
immune responses to the allograft can induce chronic inflammatory processes. This 
is based on the observation that a high incidence of acute rejection episodes is 
associated with the occurrence of chronic rejection. T cell derived cytokines such as 
IFN-y may not only mediate the acute allograft response but increase the expression 
of HLA and adhesion molecules and stimulate smooth muscle cell proliferation. 
However, evidence that graft arteriosclerosis is mediated by type 1 or type 2 
cytokines is limited (table 2). We found that production of type 1 cytokines preceded 
the diagnosis of chronic rejection after heart transplantation. Intragraft IL-2 mRNA 
expression during the first acute rejection episode and IFN-y production by graft 
infiltrating lymphocytes in the first 6 months posttransplant was associated with early 
development of chronic rejection (10,94). In long-term transplanted grafts 
endomyocardial lymphoid infiltration is common but these cells do not transcribe 
detectable IL-2 nor IL-4 mRNA, although mRNA expression of various grow1h factors 
was present (10). This observation suggests that cells producing type 1 cytokines 
are mainly involved in the initiation and not in the maintenance of transplant 
arteriosclerosis after heart transplantation. In liver grafts an association between 
type 1 cytokines and end-stage chronic rejection was reported by Hayashi et al (37). 
However, intragraft analysis in renal biopsies showed that not type 1 cytokines are 
involved but that type 2 cytokines are associated with graft arteriosclerosis 
(52,55,64). These stUdies show that T cells producing type 1 and type 2 cytokines 
are both involved in the pathogenesis of chronic rejection. PDGF, basicFGF, insulin 
grow1h factor-1, TNF-a, TGF-j3, are well characterized growth regulators for 
endothelial cells and smooth muscle cells. An association between chronic rejection 
and the presence of one or more of the above mentioned grow1h factors in the graft 
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was reported by several groups (table 2). Messenger RNA expression of acidicFGF 
and basicFGF is upregulated in most of the transplanted hearts, irrespective of their 
chronic rejection state, implying that these mediators playa role in processes after 
transplantation but their specific involvement in the development of transplant 
arteriosclerosis still is not totally elucidated (3,105). The role of TGF-~, TNF-a, and 
PDGF in chronic rejection appears more clear. In biopsies and specimens from 
grafts of patients who died from graft failure due to chronic rejection the expression 
of TGF-~, TNF-a, PDGF was related to this chronic complications 
(2,26,37,52,80,81,104). However, interpretation of most of these data is limited, 
findings were compared to non-transplanted tissue instead of transplanted organs 
without signs of chronic rejection. Moreover, cytokine production may be affected by 
the hypotensive period with warm ischemia during the terminal phase of life. Despite 
these remarks, it is assumable that increased production of TGF-~, TNF-a, PDGF 
may be of importance in the mediation of growlh and repair mechanisms of smooth 
muscle cells and injured endothelial cells. 
CYTOKINES AND GRAFT ACCEPTANCE 
Tolerance by donor specific blood transfusion, a brief course of GsA, anti-GD4 mAb 
pretreatment, blockade of co-stimulatory signals, is often associated by diminished 
type 1 cytokines and enhanced type 2 cytokines (16,19,77,88). These findings has 
led to hope that induction of a type 2 response to antigen might achieve donor-
specific tolerance. But the redundant and pleiotropic nature of the cytokine network 
suggests that induction and maintenance of transplant tolerance depends on 
complex mechanisms and can not entirely explained by the dichotomy into type 
1/type 2 (69). Recently Strom et al. published "the traffic light" hypothesis for 
tolerance (87). These authors postulate that tolerance induction can take place in 
the presence of autocrine IL-2 and IL-4 (green light), while in the presence of 
-paracrine IL-2, IL-7 and IL-15 induction can not be established (red light). Thus not 
the nature of cytokines as an answer to tolerance but the hierarchy of T cell growth 
factors and their ability to mediate tolerance and rejection determines in their view 
19 
the result of cytokine production. After clinical transplantation, IL-4 mRNA 
expression is frequenlly measured during histopathologic rejection and occasionally 
during immunological quiescence (table 1 and table 3; 8,9,20,29,32,46,53). An 
indication that IL-4 may down-regulate the immune response in patients was 
recently published. We found that spontaneously resolving liver graft rejection is 
associated with intragraft IL-4 mRNA expression in the absence of IL-2 mRNA (8). In 
line wilh this observation are the data published by Gorczynski and colleagues (32). 
In a high proportion of liver biopsies obtained from patients without clinical evidence 
of rejection IL-4 mRNA expression was present in the absence of IL-2 mRNA 
expression. After kidney transplantation, Kusaka et al. showed that peripheral blood 
cells from a patient who discontinued all immunosuppressive drugs produced high 
amounts of ILA (47). IL-10 is supposed to down-regulate the donor-specific immune 
response too. However, only occasionally intragraft IL-10 mRNA expression was 
associated with immunological quiescence. IL-10 mRNA was present in hearts and 
livers with stable graft function and absent in rejecting grafts (20,34). However, most 
of the in vivo studies analyzing intragraft IL-10 mRNA expression did not find any 
evidence for an immunosuppressive function. Instead, a positive correlatation with 
acute rejection was observed in many cases (5,86,95,102). The presence of type 2 
cytokines during acute rejection within the graft can mean two things. They are also 
involved in the acute allograft response or, which is more interesting, they may 
create an environment of immunologic non-responsiveness to the allograft. In this 
view, production of type 2 cytokines may be the response of the immune system to 
type 1 cytokine induced inflammatory responses, thereby restoring the balance of 
the cytokine network. In order to further elucidate the role of type 2 cytokines in the 
clinical transplant setting further conti'Olied studies need to be done. Especially 
analysis in serial biopsies of IL-4 and IL-10 mRNA expression may provide 
information about the role of cells producing type 2 cytokines as down-regulators of 
specific immune responses. Another interesting feature for intragraft type 2 cytokine 
measurements are its applications to monitor immunosuppression weaning 
protocols. From such trials much can be learned about the role of type 2 cytokines 
regarding active mechanisms involved in acceptance of an allograft. 
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DISCUSSION 
The current literature on cytokine production in clinical transplant settings is 
complex. It shows no consensus about the type 1/type 2 (Th1ITh2) paradigm in 
transplantation (tables). This is not entirely surprisingly given that data are generated 
from divers clinical situations. Besides, methodologically, most of the studies differ 
from another which makes not always possible to compare data. The lack of 
association in the type 1/type 2 paradigm in allograft responses in man is likely 
caused by the tremendous heterogeneity between allograft recipients and the 
complexity of the cytokine network. Most of the biopsies after liver and kidney 
transplantation are taken in case of deteriorating graft function whereas after· heart 
transplantation biopsies are obtained at a routine basis. Undeniably, definitions in 
diagnosis have vast consequences on the interpretation of data concerning intragraft 
cytokine measurements. Accordingly, it is difficult to find clear differentiating 
cytokines in processes like rejection and graft acceptance. However, these typically 
clinical complications do not rule out the possibility that type 1 cytokines, IL-2 and 
IFN-y, control the alloresponse to solid organ allografts and that type 2 cytokines, IL-
4 and IL-10, mediate responses committed with immunological quiescence or even 
tolerance. Nevertheless, it has become evident that the type 1/type 2 paradigm is an 
oversimplified model which represent extremes of many possible outcomes (63). It 
was found that clones, at the same time, can make both type 1 and type 2 cytokines 
(58). Therefore, we assume that graft infiltrating cells but also cells from the graft 
itself can produce type 1 and type 2 cytokines during an immune response. 
Nowadays we are aware of pleiotropism and redundancy of the cytokine network. In 
IL-2 negative rejections, potent cyclosporin resistant T cell growth factors such as IL-
7 and IL-15 mRNA are present which suggests that these mediators participate in 
the rejection process (6,13,86). Redundancy of the cytokine network also implies 
that elimination of a single mediator of the cytokine cascade may not be enough to 
inhibit an allogeneic response. In addition, clinical data can only be interpretated in 
the context of the specific immunosuppressive drugs used as those agents may 
interfere with local cytokine production. Several reports suggest that agents that 
block the calcineurin pathway selectively inhibit type 1 cytokines while sparing type 2 
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cytokine production (28,71). This may have a great clinical implications. However, 
there are no clinical studies available supporting these data. The association 
between type 1 cytokines and acute rejection is often based on timing. In both 
animal and human studies intragraft IL-2 mRNA expression may precede the 
rejection episode (23,24,54). However, this early T cell activation marker is not 
specifically associated with clinically significant rejection. Type 1 cytokines are 
measured in early serial fine needle aspirates obtained from rejecting as well as 
from non-rejecting infiltrates probably reflecting a common inflammatory responses 
due to surgical trauma, ischemia and reperfusion injury (54). Moreover, presence of 
a particular cytokine at the graft site is not direct evidence of its participation in the 
rejection response. The fact that local production of type 1 cytokines alone is not 
sufficient for the development of acute rejection may suggest that not all elements 
are available for an effective immune response. Unknown cytokines or other 
components of the immune system may be involved. Even cytokines produced by 
the graft itself may control the specific immune response. 
For chronic rejection the situation is even more complicated. The etiology of chronic 
rejection is multifactorial and can be distinguished into immunological and non-
immunological factors. For instance, oxidatively modified low-density lipoproteins 
may stimulate secretion of MCP-1 and colony stimulating factors by cultured 
endothelial cells resulting in enhanced monocyte adherence to these cells (50). This 
non-specific trigger of cytokine production may also have consequences for acute 
allogeneic responses, thereby accelerating the development of transplant 
arteriosclerosis. Despite the overwhelming literature on cytokine measurements in 
clinical transplant settings, almost none of the research groups has analyzed 
cytokine mRNA expression in biopsies taken 5-10 years after transplantation. This 
type of analysis may enlighten some of the mechanisms involved not only in chronic 
allograft rejection but also in graft acceptance. 
Recently, a new approach using PCR applications for cytokine analysis was 
reported by the group of Hutchinson. They correlated presence of polymorphic 
microsatellite markers in the TNF-a gene with cytokine production in vitro (90). It 
was found that heart transplant recipients with the microsatellite TNFd3 produced 
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significantly more TNF-a than TNFd3 negative patients. A mutation at position -308 
in the promotor region of the TNF-a gene is also associated with increased TNF-a 
production while presence of an A at position -1082 in the IL-10 gene is correlated 
with decreased IL-10 production (91,100). Analysis of these cytokine genotypes 
showed that heart transplant recipients typed as high TNF-a and low IL-10 
producers had significantly more severe acute rejection episodes (91). Fascinating 
from this type of analysis is the possibility to use cytokine genotypes as a marker to 
identify patients at risk for rejection or who will accept their allograft already pre-
transplant. In this perspective, both donor and recipient genotype are important. 
CONCLUSIONS 
This review shows that data on the cytokine network gained in experimental studies 
are, at the most, only an indication for these processes in transplant patients. The 
many reports on cytokine measurements in patients have resulted in a tremendous 
heterogeneity of data. Nevertheless, it is possible to characterise specific cytokine 
patterns within the graft during, acute and chronic rejection and graft acceptance. 
Allhough, cytokine profiles may vary between heart, kidney and liver allograft 
recipients, it was shown that cytokine measurements are extremely useful to monitor 
the efficacy of immunosuppressive drugs and to characterise changes in cytokine 
profiles in individual patients. Such an approach may point out specific patients who 
require more or less or no immunosuppressive therapy. Especially the link between 
cytokine polymorphisms and cytokine production, a new and promising approach, 
could be the opening in prospective immunological typing in clinical transplantation. 
Until the mechanisms responsible for control of cytokine biologic activities are 
clarified, we have to be cautious concerning the clinical significance of intragraft 
cytokine gene expression in transplantation. To elucidate the precise function of 
cytokines in patients further controlled studies are needed. Monitoring of therapeutic 
and cytokine intervention trials will help us to unravel the complex cytokine network 
which eventualy should lead to better care and treatment of transplant patients. 
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Table 1: Intragraft cytokine mRNA profiles by RT-PCR associated with acute rejection after clinical organ transplantation 
organ cytoklne profile associated cytoKme profile!1Q! associated refs comments 
K IL-2 23 IL~2 mRNA expression preceded clinical rejection 
K IFN-y 61 IFN-y mRNA expression preceded clinical rejection 
K IL-4, IL-5, IL-6, TNF-a IL-2, IFN-y, IL-7 46 no comparison against either normal kidney tissue or 
biopsies without signs of rejection was made 
K IL-2 IFN-y, IL-4, IL-6, IL-10, TNF-a 41 early rejections « day 100 pTX) 
IL-2, IFN-y, IL-4, IL-6 
TNF-a,IL-6 late rejections (> day 100 pTX) 
K IL-6 IFN-y 98 technique used: in situ hybridization 
K IL-2, IL-10 IFN-y, IL-4, IL-7, TGF-~ 102 compared to chronic allograft nephropathy samples 
• 
K IL-7, IL-10, IL-15 IL-2, IFN-y, IL-4 86 review article I 
L IL-2, IFN-y, IL-6", IL-1~" 13 compared to "normal" non-transplanted liver tissue, 
"reduced levels 
L IL-1 G, IL-2, IFN-y, IL-6, IL-4, TNF-a 20 IL-2 only in early rejections 
L IL-2, IL-4, IL-5 IL-6, TNF-a 29 IL-5 only in the tracolimuslFK506 group 
L IL-2 IL-4,IL-15 6,8 compared to both biopsies without evidence of rejection or 
with histological signs of rejection 
L IL-2,IFN-y IL-4, IL-6, TGF-~ 32 compared to biopsies without evidence of rejection 
. 
L IL-5 IL-2, IL-4, IL-6, 53 compared to biopsies without evidence of rejection 
IL-1~, TNF-a 
H IL-2 IL-4, IL-10, IL-1~, TNF-<x, TNF-~ 22 in severe rejection biopsies, requiring anti-rejection therapy 
H IL-2, IL-6, IL-4, IL-10 7,9,10 in severe rejection biopsies, requiring anti-rejection therapy 
which inhibited the cytokine mRNA expression 
H IL-2 IFN-y, IL-4, IL-6, IL-10, TNF-a 34 IL-2 only in early rejections 
H IL-6, TGF-~ IFN-y, IL-4, IL-5, IL-1~, TNF-a 105 only a trend for these cytokines was found 
H none IL-1~, IL-2, IFN-y, IL-4, IL-6, 48 no elevated cytokine mRNA levels were measured during a 
IL-10, TNF-a rejection period within the first 8 weeks posttransplant 
H IL-2, IL-4, IL-5, IL-8, IFN-y, IL-3, IL-6, IL-9, 95 technique used: in situ hybridization 
IL-10, TNF-a IL-1~, TNF-~ 
H IL-10 5 technique used: in situ hybridization 
K, kidney; L, liver. H, heart 
Table 2: Intragraft cytokine mRNA profiles by RT-PCR associated with chronic rejection after clinical organ transplantation 
organ cytokine profile associated cytokine profile DQ1; associated refs comments 
K TGF-~ 81 compared to specimens with signs of acute rejection 
K IL-15 IL-2, IL-7 86 review article; only in 2 out of 4 samples 
L IL-1~, IL-10 IL-2, IFN-y, IL-6 13 decreased cytokine mRNA expression compared to "normal" 
non-transplanted liver tissue 
L IL-2, IFN-y, IL-5, PDGF IL-4, IL-6, IL-8, IL-10, IL-1~, 37 compared to stable grafts 
! 
TNF-a 
L TGF-~ 26 technique used: in situ hybridization 
compared to "normal" non¥transplanted,tissue 
H acidic FGF, PDGF 104, compared to "normal" non-transplanted tissue 
105 
H RANTES 66 technique used: in situ hybridization 
compared to "norma]" non¥transplanted tissue 
H IL-2 IL-4,IL-6 10 the characteristics of the first acute rejection are assocated 
with the diagnosis of chronic rejecton at 1-year 
IL-2, IFN- y, IL-4, IL-6, at time of diagnosis of chronic rejection at 1-year 
IL-10, TGF-~, PDGF 
H basic FGF 3 technique used: Northern blotting 
compared to "normal" non-transplanted tissue 
K, kidney; L, liver, H, heart 
Table 3. Intragraft cytokine mRNA profiles by RT-PCR associated with graft acceptance after clinical organ transplantation 
organ cytokine profile associated cytokine profile!lQ! associated refs comments 
L IL-10 IL-2. IFN-y. IL-4. IL-6. IL-1~. 20 in stable grafts; IL~10 was absent during acute rejection 
IFN-y 
L IL-4 IL-2.IL-15 8 in spontaneously resolving rejections 
L IL-4 IL-2. IFN-y. IL-6. TGF-~ 32 in the absence of histological and clinical signs of rejection 
H IL-10 IL-2. IFN-y. IL-4. IL-6. 34 compared to biopsies with severe rejection 
TNF-a , , 
-- -- -
-_ .. -
- - -- - - - -
K, kidney; L. liver, H. heart 
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Chapter 2 
AIMS OF THIS THESIS 
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This thesis describes the use of intragraft cytokine mRNA measurements as a tool to 
unravel immune responses towards transplanted organs. 
With respect to histology, most of the immune responses after transplantation are 
characterized by cellular infiltration. One of the problems with histologic examination 
of allogeneic tissue is that these infiltrates do not always correlate with a decline in 
graft function. The immunologic events responsible for these infiltrates and for 
triggering (or sometimes preventing) organ dysfunction are not understood 
sufficiently, although they do clearly influence the interpretation of histologic findings. 
Interactions between immunocompetent cells of the recipient and the transplanted 
tissue trigger a number of intracellular events that, in cascade fashion, lead to 
release of cytokines and cytokine receptors. These mediators control the common 
inflammatory response and consequently also the donor-directed immune response. 
The intracellular molecular pathways that allow cells to make specific responses can 
be monitored by measuring cytokine mRNA expression using the reverse 
transcriptase polymerase chain reaction (RT-PCR) method. We used this technique 
to determine whether specific cytokine mRNA patterns within the allograft are 
associated with acute and chronic rejection, with immunological quiescence, or 
reflect the efficacy of rejection therapy. Analysis of messenger RNA expression of 
various cytokines and their cytokine receptors by RT-PCR may clarify some of the 
mechanisms involved in allogeneic immune responses. 
In order to correlate intragraft cytokine measurements with immune phenomena, we 
have to gain insight in the kinetics of cytokine mRNA and protein production by 
which the immune competent cells control the allogeneic immune response. 
Chapter 3: describes such an analysis in which we tried to determine the kinetics of 
IL-2 and IL-4 mRNA expression and protein production by graft infiltrating 
lymphocytes and peripheral blood mononuclear cells at the time of acute cardiac 
allograft rejection. 
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Rejection in heart transplant recipients is routinely monitored by histological 
examination of sequentially taken endomyocardial biopsies. This provided us with 
the opportunity to study the process of rejection at the molecular level. 
Chapter 4: describes our attempts to associate intragraft cytokine mRNA patterns 
with the "gold-standard" for the diagnosis of rejection: histology. 
To prevent early allograft rejection after heart transplantation, patients may receive 
induction therapy with mouse monoclonal antibodies. In view of the importance of 
cytokines in the rejection process, their receptors may be good targets for immune 
therapy strategies. 
Chapter 5: specifically characterizes the in vivo effects of anti-rejection prophylaxis 
with the anti-IL-2Receptor monoclonal antibody 8T563. 
Following the diagnosis of rejection, patients are treated with high doses of 
glucocorticosteroids. We have evaluated whether intragraft cytokine mRNA patterns 
can be used as a parameter that will predict the efficacy of methylprednisolone anti-
rejection therapy and also studied the effect of this therapy on these molecular 
parameters. 
Chapter 6: deals with both these subjects: a study in heart transplant patients 
treated with steroid anti-rejection therapy is presented in this chapter. 
Chronic complications such as graft vascular disease Significantly influence the graft 
and patient survival. Knowledge about the pathogenesis of chronic rejection after 
heart transplantation is limited. The cause of this complication is probably multi-
factorial. 80th non-immune and immune factors may trigger the development of graft 
vascular disease. 
Chapter 7: In this chapter we wondered which of non-immune and immune risk 
factors might trigger, individually or in combination, early development of graft 
vascular disease in heart transplant patients. 
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Tolerance of foreign tissue in the absence of immunosuppression is the "holy-grail" 
in transplantation immunology. Central for this phenomenon is the question: how is 
tolerance initiated, regulated and maintained? Do cytokines playa role at any level 
in this process? The so-called self-limited graft rejection seen in liver allografts 
provided an ideal clinical model to assess these questions. 
Chapter 8: In an attempt to answer these questions, we compared intragraft 
cytokine mRNA expression patterns in liver biopsies without any evidence of 
rejection, in biopsies with spontaneously resolving rejections, and in biopsies with 
histological rejection that were accompanied with clinical rejection. 
During an immune response, lack of a single cytokine is compensated by other 
cytokines. No single cytokine is indispensable in immune responses. Redundancy is 
a phenomenon which complicates the interpretation of cytokine profiles. Since the 
transcription of some cytokines is blocked by immunosuppressive agents, other 
cytokines which are resistant for these agents may take over these functions. 
Chapter 9: tries to unveil the roles of IL-2 and IL-15 in liver allograft rejection and to 
find evidence for redundancy phenomena in the cytokine network. 
Chapter 10: summarizes all these studies and gives a general discussion on the 
relevance of intragraft cytokine measurements for the clinic. 
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Chapter 3 
PATTERNS IN DONOR SPECIFIC mRNA AND PROTEIN 
PRODUCTION OF Th1 AND Th2 CYTOKINES BY GRAFT 
INFILTRATING LYMPHOCYTES AND PBMC AFTER HEART 
TRANSPLANTATION 
This chapter is based on articles published in: 
Transplant IntemationaI1996;9(S1):S237-S240 
Carla C. Baan, Nicole M. van Besouw, Comelis R. Daane, 
Aggie H.M.M. Balk, Bas Mochtar, Hubert G.M. Niesters, and Willem Weimar 
Transplant Immunology 1997;5:97-103 
Carla C. Baan, Nicole M. van Besouw, Comelis R. Daane, 
Aggie H. M. M. Balk, Bas Mochtar, Hubert G.M. Niesters, and Willem Weimar 
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ABSTRACT 
During cardiac rejection, we studied the kinetics of IL-2 and IL-4 mRNA and 
subsequent protein production by in vivo "primed" graft infiltrating lymphocytes (GIL) 
and by "naive" peripheral blood mononuclear cells (PBMC), using semi-quantitative 
RT-PCR and ELISA. For this purpose, these cells were stimulated for 1 to 72 h with 
donor and control third party antigens. Only stimulation of GIL with donor-specific 
antigen resulted in early detectable IL-2 and IL-4 mRNA and protein levels. Maximal 
relative IL-2 mRNA levels were significantly higher than maximal relative IL-4 mRNA 
levels (10 to 100-fold) in both GIL and PBMC after donor-specific stimulation. This 
was accompanied by a maximum protein production of 849 pg/ml IL-2 and 16 pg/ml 
IL-4 by GIL and of 17 pg/mllL-2 and undetectable IL-4 production by PBMC. 
These results suggest that, after stimulation donor-specific "primed" GIL, and not 
"naive" PBMC, rapidly produce abundant levels of IL-2 and IL-4 at both the 
transcriptional and protein level. 
INTRODUCTION 
After clinical heart transplantation, acute rejection usually occurs within the first three 
months and is characterized by high levels of inflammation in the graft (1-3). The 
immune mechanisms responsible for cellular allograft rejection are dependent on the 
activities of primed allospecific T lymphocytes. Interaction of these 
immunocompetent CD4' T helper cells (Th) and CD8' cytotoxic T lymphocytes (Tc) 
with donor antigens results in activation of the transcription of cytokine messenger 
RNAs (mRNA) followed by the subsequent cytokine protein release. These soluble 
mediators regulate the immune response against the transplanted graft. Human T-
cells, although not so tightly restricted as described for mouse T-cells, can be 
divided into functionally different subsets on basis of their cytokine production 
pattern. ThO cells produce cytokines such as IL-2 and IL-4, while Th1lTc1 cells 
secrete IL-2, IFN-y, TNF-B and Th2ITc2 cells produce IL-4, IL-5, IL-6, IL-10 (4,5). 
Allograft rejection is associated with an upregulation of several cytokines within the 
graft implying that ThO cells or a mixture of both Th1lTc1 and Th2ITc2 cells have 
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infiltrated the allograft (6,7). The production of cytokines within the graft can be 
analyzed directly in biopsies on the transcriptional level and on the protein level 
using techniques such as RT-PCR and immunohistochemistry. It was shown that, in 
man, cardiac allograft rejection is associated with intragraft production of IL-2 and 
IFN-y at both the transcriptional and protein level (8-10). Also the frequency of IL-2 
producing helper T-cells with specificity for donor-antigens in peripheral blood of 
heart transplant recipients was associated with rejection (11). In contrast, for the Th2 
cytokines IL-4 and IL-10 the data are less clear. Also at the transcriptional level, we 
and others found that both during acute cardiac allograft rejection and during 
immunological quiescence IL-4 and IL-10 mRNA expression can be found within the 
graft (8,9). This suggests that while these cytokines may be present during allograft 
rejection they actually may be involved in the down-regulation of the allogeneic 
immune response. Indeed, a role for IL-4 in the process of spontaneously resolving 
rejection and even in tolerance has already been reported after clinical liver and 
renal transplantation (12,13). Although it is thus clear that both IL-2 and IL-4 are 
important determinants of outcome of the immune process in human transplants, the 
kinetics of Th1 and Th2 cytokine production by graft infiltrating lymphocytes (GIL) 
and by peripheral blood mononuclear cells (PBMC) at the mRNA and at the protein 
level in the graft is unknown. We have shown that in vivo maturated, primed, T-cells 
with specificity for donor antigens home in the allograft, while naive, precursor T-
cells are primarily found in the peripheral blood (14). The capacity of in vivo "primed" 
GIL and of "naive" PBMC to produce cytokines can be determined after in vitro 
challenge with donor antigens (15). In order to study the regulation of cytokine 
production by GIL and by PBMC it is essential to measure cytokine mRNA 
expression since cytokine production is predominantly controlled at the 
transcriptional level (16). An important advantage of our in vitro system is that mRNA 
expression by these cells can be compared directly with the cytokine protein 
production. Therefore, we have analyzed the kinetic pattern of IL-2 and IL-4 mRNA 
synthesis by in vivo "primed" GIL, grown from rejection biopsies, and by 
simultaneously obtained "naive" PBMC after in vitro stimulation with donor and third 
party antigens using semi-quantitative RT-PCR analysis. These findings are 
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compared directly with levels of these cytokines measured in cell culture 
supernatants by ELISA. 
MATERIALS AND METHODS 
Patients 
Endomyocardial biopsies (n=3) and simultaneously taken PBMC (n=1) were obtained heart transplant 
recipients during their first acute clinical rejection episode (14-84 days posttransplant). Maintenance 
immunosuppressive therapy consisted of cyclosporin A and low-dose steroids, No additional therapy 
was given. Rejection was histologically diagnosed according to the criteria of the International Society 
for Heart and Lung Transplantation (3). For the diagnosis of clinical significant rejection, the co-
existence of myocyte damage and mononuclear infiltrates was required (grade 3A). In that case, anti-
rejection therapy was instituted. 
GIL culture method 
GIL cultures were grown from endomyocardial biopsies in 96 wells U bottom tissue culture plates 
(Costar, Cambridge, MA) as described before (17). GIL were expanded in culture medium (RPMI-1640 
Dutch Modification Gibeo, Paisley, Scotland) supplemented with 10% pooled human heat-inactivated 
serum, 4 mM L-glutamine, 100 IU penicillin and 100 ~glml streptomycin) in the presence of 30 U/ml 
exogenous IL-2 (lectin-free Iymphocult T-LF, Biotest AG, Dreieich, Germany) and 105 irradiated (30 
Gy) autologous peripheral blood mononuclear cells. GIL cultures were grown at 37 °C in a humidified 
CO2 incubator for two to three weeks. Half of the medium was refreshed every two to three days, 
Phenotypic analysis of GIL cultures 
Surface antigens were analyzed by two color flow cytometry after staining with monoclonal antibodies 
directed against CD3 (anti-leu 4) as pan mature T-cell marker, Wf31 as a marker for the alB chain 
and 11 F2 as a marker for y/5 chain of the T cell receptor. CD4 (anti-leu 3) and CD8 (anti-leu 2) were 
used as T cell subset markers. CD16 (anti-leu 11) was used as a marker for natural killer cells, The 
antibodies were directly conjugated to fluorescein or phycoerythrin (Becton and Dickinson, Maintain 
View, CAl. GIL cultures were analyzed using a flow cytometer (FACscan, Becton and Dickinson). 
Allogeneic stimulator cells 
B Iymphoblastoid cell lines (B-LCL) originated from infection of donor and third party spleen cells with 
EBV obtained from the marmoset cell line B95-8 (18). 
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Study design 
Before testing, GIL were washed and 5 x 104 cells/well were incubated in IL-2 free culture medium for 
24 h. Thereafter, 5 x 10' irradiated (60 Gy) and washed B-LCL of donor or third party controt origin 
were added. Third-party control 8-LCL shared Human Leucocyte Antigens neither with the donor nor 
with the recipient. At each time-point, the GIL were stimulated in duplo. After stimulation, these cell 
pellets and supernatants were pooled. Supernatants (180 ~I) and cell pellets (10' GIL + 10' Irradiated 
stimulator cells) were harvested between 1 and 72 h of coculture and stored at -80°C before analysis 
of cytokine production. Washed unstimulated GIL and irradiated stimulator B-LCL alone served as 
control. 
Total RNA preparation 
Total RNA was isolated from the stimulated GIL and their controls by a modification of the 
Chomczynski and Sacchi method as described before (9,19,20). Briefly, cells were homogenized in 
500 ~I 4 M guanidinium-isothlocyanate in the presence of 20 I-Ig poly A (Boehringer Mannheim, 
Germany). The solution was extracted once with phenol, phenol-chloroform-isoamyl alcohol [25:24:1) 
and chloroform-isoamyl alcohol [24:1], respectively. Total RNA was precipitated with 600 ~12-propanol 
and 35 ~13 M sodium acetate (pH 5.2) at -20°C for 18 hours. Precipitates were pelleted at 10.000 x 9 
at 4 "C and washed once with 500 ~I ice-cold 80% ethanol. AIr-dried pellets were resuspended in 50 111 
diethylpyrocarbonate treated-H,o. Total RNA was denaturated for 5 min at eo°c and then chilled on 
ice. 
eDNA synthesis 
First strand cDNA synthesis was performed from 25 ~I of the isolated RNA with 0.25 ~g 
hexanucleotides (Promega Corporation, Madison, WI) and transcribed with 500 U Moloney murine 
leukemia virus (MMLV) reverse transcriptase (Gibco-BRL, Gaithersburg, MD) at 42°C for 90 min in a 
total volume of 50 ~I. The reaction mixture contained 10 ~15x MMLV-RT buffer (250 mM Tris-HCI pH 
8.3, 15 mM MgCI" 375 mM KCI), 2.5 ~I dNTP (10 mM), 200 U of RNAsin (Promega) and 5 ~I (0.1M) 
on. 
peR amplification and Southern blot analysis 
Sequence specific primers were used for amplification of the human cytokine genes (table 1). PCR 
primers detecting transcripts for the human house keeping gene keratin, which is expressed by 
hematopoietic cell (21), were used as an internal control to monitor mRNA extraction and cDNA 
amplification (table 1). For qualitative analysis, 5 ~I cDNA sample was added to 95 ~I PCR mixture 
containing 10 mM Tris-HCI pH 8.3,50 mM KCI, 1.5 mM MgCI" 0.2 mM of each dATP, dCTP, dnp, 
dGTP, 2 U Taq DNA polymerase (Promega) and 50 pmol of 5' and 3' sequence specific primers. Each 
reaction mixture was overlaid wilh 50 IJI mineral oil (Sigma, St. louis, MO) prior to PCR reaction In a 
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DNA thermat cycler (Biomed-60, Germany) under the following conditions. After a 5 min 94"C 
denaturation step, samples were subjected to 40 cycles of denaturation at 94°e for 1 min, annealing 
at 60°C for 2 min, and extension at 72°C for 3 min, The last cycle was extended with 7 min at 72°C. 
Positive control samples were produced by stimulating 106 human spleen cells with 1% 
phytohemagglutinin (PHA)-M (Difeo, Detroit, MI) for 4 h at 37"C. Messenger RNA from this positive 
control was extracted as described above, Negative controls consisted of omission of reverse 
transcriptase from the eDNA synthesis reaction for each EMS followed by amplification In peR with 
the IL-2, IL-4 and keratin primers, and the use of and diethylpyrocarbonate-treated H20 as no-template 
reaction. After amplification, 1 j.Jl peR product was electrophoresed through 2% agarose gel, 
transferred to a Hybond-N+ membrane (Amersham, Aylesbury, UK) by alectroblotting and hybridized 
with y"P labelled specific probes. Hybridization was detected by autoradiography. 
Table 1. Oligonucleotides used to amplify target eDNA Product sizes predicted, and the sequences of 
the internal oligonuleolides used for Southern blot analysis of the products. 
Target 
IL-2 sense 
IL-2 anti-sense 
IL-2 probe 
IL-4 sense 
IL-4 anti-sense 
IL-4 probe 
Keratin sense 
Sequence 
5'ATG TAC AGG ATG CM CTC CTG TCT T3' 
5'GTC AGT Gn GAG ATG ATG cn TGA C3' 
5'nc nc TAG ACA CTG MG ATG TIT CAG nC3' 
5'ATG GGT CTC ACC TCC CM CTG3' 
5'TCA GCT CGA ACA cn TGA ATA TIT CTC TCT CAT3' 
5'GTC cn CTC ATG GTG GCT GTA GM CTG CCG3' 
5'TGA AGA TCC GTG ACT GGT AC3' 
Keratin anti-sense 5'ATG TCG GCT TCCACA CTC AT3' 
Keratin probe 5'TCT CCT TCT GCA GAT TGA CM TGC CCG TCT3' 
Semi-quantitative RT-PCR 
Product 
size (bp) 
458 
462 
218 
For semi-quantitative analysis, eDNA samples were titrated (10-fold dilutions) and aliquots of each 
dilution were amplified using the conditions as described above, The amount of target eDNA present 
was expressed as end-point of the titration. Corrections were made for the integrity of the mRNA 
isolated and the efficiency of eDNA synthesis, which both may vary from isolation to isolation by 
standardization with keratin. It was expressed as arbitrary mRNA equivalents, defined as the highest 
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dilution showing positive signal. To estimate the relative initial amount of functional mRNA in the GIL 
cultures, aliquots of titrated cDNA samples were amplified using specific primers for keratin to correct 
for the above mentioned variables. The results were expressed as a ratio calculated from the titre of 
IL·2 or IL·4 gene PCR product over the titre of amplified keratin product. To exclude inter· and intra· 
assay variability, amplification of titrated eDNA of PHA·M activated spleen cells were included in each 
assay. These control cells expressed keratin, IL-2 and ILA. 
Enzyme linked Immunosorbant assay (ELISA) 
The concentration of cytokines in the supernatants of the GIL cultures was measured with the 
following ELISA kits: IL-2 (Immunotech, Marseille, France) detection range 15-1000 pg/ml IL-2; IL-4 
(Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The 
Netherlands) detection range 10·450 pg/mIIL·4. 
Statistics 
As data regarding relative levels of mRNA expression and secreted IL·2 and IL·4 in supernatants were 
nonparametric, pairwise comparisons between groups were carried out using the Wilcoxon signed 
rank test. P·values ~ 0.05 were considered to be statistically significant. 
RESULTS 
Phenotypic analysis of GIL cultures 
Phenotypic characterization of the three GIL cultures,showed that the majority of the 
cells of the GIL cultures were CD3' (95%, 100%, 100%) and expressed the aB T-
cell receptor. In these cultures 29%, 52%, 61 % of the cells expressed CD4 and 
39%,40%,70% CDB, In culture I CD16 (5%) positive cells were present. 
mRNA expression of the housekeeping gene keratin 
This transcript was chosen as a marker for the total number of cells and for the total 
quantity of mRNA extracted, Keratin mRNA expression is found to be in the range of 
mRNA expression of the cytokines tested, which is an advantage above the 
frequently used house keeping genes B-actin and glyceraldehyde 3-phosphate 
dehydrogenase (20,22), Especially in muscle tissue glyceraldehyde 3-phosphate 
dehydrogenase levels are abundant and therefore not suitable for analysis in heart 
samples (23), All samples obtained from one culture were isolated at the same time. 
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After activation with either donor or third party antigens, the keratin mRNA levels 
gradually increased (figure 1). Semi-quantitative analysis showed a maximum 
increase of the keratin mRNA levels of one-dilution step primary between 1 hand 72 
h after stimulation. However, there was no statistically significant difference in the 
amount of mRNA for keratin after donor or third party stimulation (p=0.50). 
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Figure 1. Time course of keratin mRNA expression in GIL cultures (0=3) after stimulation with either 
donor (black bars) or third party antigens (hatched bars). To estimate the relative initial amount of 
target cDNA, aliquots of ten-fold diluted eDNA samples were amplified using specific primers for 
keratin. After amplification the amount of target eDNA was determined by the highest dilution showing 
a positive signal after hybridization. Each bar represents the relative mean value for three GIL 
cultures. 
Relative IL-2 and IL4 mRNA levels by GIL cultures 
In the present study, IL-2 and IL-4 mRNA expression was analyzed only in GIL 
cultures and irradiated stimulator B-LCL with keratin mRNA expression. Figure 2 
depicts the time course of keratin, IL-2 and IL-4 mRNA expression in culture III after 
stimulation with donor and third party cells. Table 2 shows the kinetics of IL-2 and IL-
4 mRNA expression of each individual GIL culture after stimulation with donor and 
third party antigens respectively. Unstimulated GIL cultures (0 h), and irradiated 
stimulator B-LCL alone neither expressed mRNA nor secreted protein of IL-2 and IL-
4 at detectable levels (table 2 and 3). Upon stimulation by cells of donor or third 
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party origin an upregulation of cytokine mRNA production was observed. In general, 
IL-2 and IL-4 mRNA was apparent as early as 1 h after stimulation and reached 
maximal levels within 2 - 48 h after which it gradually decreased to prechallange 
base-line levels (20 -72 h). This pattern was seen after stimulation with both donor 
and third party antigens. However, the relative amount of IL-2 and IL-4 mRNA 
produced by GIL was higher after donor specific stimulation than after stimulation 
with third party cells (p=0.02). Moreover, the relative amount of donor specific IL-2 or 
IL-4 mRNA by these GIL cultures was clearly different. GIL cultures grown from 
endomyocardial biopsies taken during acute rejection synthesized significantly more 
donor specific IL-2 mRNA than IL-4 mRNA (p=0.002). In 2 out of 3 cultures, we 
measured a 100-fold IL-2I1L-4 mRNA ratio of the maximum mRNA levels. 
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Figur. 2. Semiquantitative RT-PCR analysis of keratin, IL-2 and IL-4 mRNA expression by Southern 
blotting and hybridization. 
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Table 2. Ratio of IL-2 or IL-4/keratin mRNA expression in GIL cultures after 
stimulation with donor 8-LCL and third party control 8-LCL 
donor stimulation third party stimulation 
I' 
time (h) IL-2 IL-4 
° 
-' 
l' 0,1 
2 
4 
8 
12 0,1 
20 100 0,1 
48 100 
72 0,1 
1 GIL culture number 
2 not detectable 
I! III 
IL-2 IL-4 IL-2 
10 
10 1 10 
10 10 1000 
10 
10 
10 0,1 
10 1 
I! III 
IL-4 IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 
10 0,1 1 
1 10 0,1 
10 0,1 1 0,1 
10 1 0,1 0,1 1 
10 1 1 0,1 0,1 
0,1 0,1 10 0,1 0.1 
1 1 
0,1 
'IL-2 and IL-4 are expressed as a ratio calculated from the titre of IL-2 or IL-4 mRNA product over the 
titre of amplified keratin mRNA product. 
The amount of IL-2 mRNA'and IL-4 mRNA were significantly higher after donor stimulation than after 
third party stimulation (p=0,007 and p=0,02 respectively, Wilcoxon signed rank test), Donor specific IL-
2 mRNA titres were significantly higher than specific IL-4 mRNA titres (p<0,001), 
IL-2 and IL-4 protein levels by GIL cultures 
After donor specific stimulation, the upregulated IL-2 mRNA expression resulted in 
measurable IL-2 protein levels from 4-8 h and accumulating at least 20-48 h (table 
3), In contrast, after challenge by third party antigens the significant levels of IL-2 
mRNA did not, or only at very low levels, result in subsequent IL-2 protein release by 
GIL (p<0,001, table 3), After antigen specific stimUlation the maximum IL-2 protein 
production ranged between 28-849 pg/ml versus 0-55 pg/ml after third party 
stimUlation, IL-4 protein levels were only measured in GIL culture I. In the 
supernatant of this culture we found comparable IL-4 protein levels within 20-48 h 
after stimulation with donor or third party antigens (table 3), 
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Table 3. IL-2 and IL-4 protein production by GIL cultures after stimulation with donor 
B-LCL and third party control B-LCL 
donor stimulation third party stimulation 
I' II III II III 
tome (h) IL-2' IL-4 IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 
0 <153 <10 <15 NA <15 NA <15 <10 <15 NA <15 NA 
<154 <10 <15 <15 <15 <10 <15 <15 
2 <15 <10 <15 <15 <15 <10 <15 <15 
4 62 <10 <15 70 48 <10 <15 <15 
8 115 <10 28 117 35 <10 <15 <15 
12 161 <10 35 136 43 <10 <15 <15 
20 849 16 24 131 50 <10 <15 <15 
48 524 15 29 224 55 21 <15 <15 
72 164 <10 20 125 35 <10 <15 <15 
1 GIL culture number 
, pgfml 
3 detection limit 
4 N.A, not avallable 
The overall IL-2 protein was significantly higher after stimulation with donor than after third party 
stimulation (p=0.002. Wilcoxon signed rank test). 
Relative IL-2 mRNA and protein levels by PBMC 
In PBMC, messengers coding for IL-2 were detectable 2 h, and for IL-4 28 h after 
stimulation with donor antigens and 20 hand 1 h, respectively. after stimulation with 
third party antigens (table 4). Neither the relative IL-2 mRNA level nor the relative IL-
4 mRNA level was significantly different between donor and third party stimulation, 
but only donor-specific stimulation resulted in measurable IL-2 protein levels at 48 h. 
Similarly to GIL, also in the PBMC. the relative maximum donor-specific IL-2 mRNA 
level was significantly higher compared to the relative donor-specific maximum IL-4 
mRNA level (1 DO-fold). 
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Table 4. IL-2 and IL-4 mRNA and protein production by PBMC' after stimulation with 
donor B-LCL and third party control B-LCL 
donor stimulation third party stimulation 
mRNA' protein3 mRNA protein 
IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 IL-2 IL-4 
time (h) 
0 -4 <155 <10 <15 <10 
1 <15 <10 <15 <10 
2 <15 <10 <15 <10 
4 1 <15 <10 <15 <10 
20 <15 <10 100 <15 <10 
28 10 <15 <1U 100 1 <15 <10 
48 100 10 82 <10 100 1 <15 <10 
, PBMC of patient I 
21L-2 and IL-4 are expressed as a ratio calculated from the titre of IL-2 or IL-4 mRNA product over the 
titre of amplified keratin mRNA product. 
3 pglml 
4 not detectable 
6 detection limit 
DISCUSSION 
After transplantation, it is thought that allogeneic primed T-cells are responsible for 
the process leading to graft destruction. After allogeneic stimulation these cells 
produce cytokines. However, the kinetics of donor-specific IL-2 and IL-4 mRNA and 
subsequent protein production by these "primed" and also by "naive" T lymphocytes 
is not known. Therefore, we have analyzed the kinetics of IL-2 and IL-4 mRNA and 
subsequent protein production by in vivo "primed" GIL, grown from rejection 
biopsies, and by "naive" PBMC after in vitro stimulation with donor and third party 
cells. In time, the induction of both mRNA and protein was quicker by GIL than by 
PBMC. Especially in GIL cultures, the relative level of IL-2 mRNA transcription and 
subsequent IL-2 protein production was significantly higher after stimulation with 
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donor antigens. This relative high level of IL-2 production by GIL cultures may reflect 
increased transcription in each cell or is the result of a higher frequency of donor 
specific IL-2 producing T-cells in the graft during rejection. This explanation is in line 
with the results of Bishop et al. who showed a high frequency of IL-2 producing T-
cells in sponge matrix allografts (24). The results for IL-4 mRNA expression are in 
agreement with that of IL-2 mRNA. Also, at the mRNA level a donor-specific IL-4 
signal was measured. However, during rejection, GIL cultures synthesized 
significantly more donor specific IL-2 mRNA than IL-4 mRNA. We could not detect 
these primed T-cells in PBMC on basis of significant early donor-specific mRNA 
transcription and subsequent protein production by the highly sensitive RT-PCR and 
ELISA, respectively. Probably the alloantigen primed T-cells are not or below the 
detection level present in the peripheral blood. These findings suggest that in vivo, 
"primed" T-cells with donor specificity mediated early events of the immune 
response within the transplanted organ. 
Cells cultured from the transplanted graft are stimulated in vivo by donor antigen on 
antigen presenting cells and as a consequence they are differentiated into either 
Th1 or Th2 cells and can not be influenced by addition of cytokines as is the case for 
naive T-cells (25). Upon restimulation in vitro these cells maintain a similar pattern of 
cytokine production. Moreover, both IL-2 (Th1) and IL-4 (Th2) producing cells 
proliferate in response to the added IL-2 in vitro (26). Accordingly, it is likely that 
most of the in vitro cytokine production is released by GIL that differentiated in vivo 
into either Th1 (IL-2) or Th2 (IL-4) producing lymphocytes. Also after transplantation, 
the Th1ITh2 paradigm is frequently used to explain different immunological 
phenomena. Abundant production of Th1 cytokines is often accompanied with low 
secretion of Th2 cytokines and visa versa (6,7). Our results obtained in human 
lymphocytes at time of cardiac rejection are consistent with the hypothesis of the 
balance between IL-2 and IL-4 in allogeneic processes. Much of today knowledge 
about the kinetics of cytokine production by lymphocytes is based on studies of 
clonal cells and peripheral blood cells after stimulation with either mitogens or 
alloantigens (27-31). These studies show that IL-2 and IL-4 mRNA expression is 
rapidly but transiently induced after stimulation in T-cells. Also, in our bulk GIL 
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cultures IL-2 and ILA mRNA transcription was detectable as early as 1-2 h after 
stimulation reached maximum levels between 2 - 48 h and base-line levels were 
approached by 20 - 72 h. Subsequent IL-2 protein release was detectable from 4 h 
with cytokines accumulating at least 20 - 48 h. In contrast to the IL-2 mRNA 
expression by mitogen activated human T-cells as described by Shaw and 
colleagues (27) our mRNA profiles were definitely less spiking, which might be due 
to the composition of our bulk cultures. Phenotypic analysis showed that both CD4+ 
and CD8+ T-cells were present in the bulk GIL cultures. However, the time-course 
patterns of IL-2 and IL-4 production on the mRNA and protein level by CD4+ and 
CD8+ T-cells are only marginally different (28). In contrast, the kinetics of cytokine 
mRNA production by lymphocytes is dependent on their activation level (32). 
Accordingly, we assume that in the graft, during acute rejection, cytokines are 
produced by allospecific T-cells with different stages of activation. After the initial 
priming, alloreactive T-cells home in the graft but nevertheless, represent, less than 
1 % of the total infiltrate (14,33). Severe local inflammation, perhaps triggered by 
cytokine release might not only recruit T-cells with allospecificity to the graft but also 
T-cells with broader or irrelevant specificity. This mechanism might also explain why 
considerable levels of IL-2 and ILA mRNA expression were also found after 
stimulation with third party cells. In the present study, the time course patterns of 
mRNA expression of IL-2 and IL-4 were comparable between GIL stimulated with 
donor cells and those activated third party cells, suggesting that also infiltrating T-
cells with more public specificities underwent some level of activation. Nevertheless, 
these third party cytokine mRNA levels, in contrast to donor specific cytokine mRNA 
levels, did not regularly result in measurable protein levels. A strong correlation has 
been shown between mRNA expression and protein production of various cytokines 
in GIL cultures isolated from rejected kidneys after activation with anti-CD3 (35). 
Anti-CD3 antibodies will activate all infiltrated T-cells including the donor-specific 
subpopulation. However, in vivo T-cell activation requires the interaction of antigen 
presenting cells, peptide and a specific T-cell receptor. Therefore, the results after in 
vitro stimulation with alloantigens is a better reflection of events within the allograft 
during acute rejection. The discrepancy we found between mRNA and protein 
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production after third party but not donor-specific stimulation could of course be a 
detection phenomenon. Another explanation is that donor-specific signals are 
involved at the post-transcriptional level. GIL have T-cell receptors with low affinity 
for third party antigens and activation of these low affinity T-cell receptors might not 
lead to all the necessary signals required for translation of mRNA (35). 
In conclusion, the kinetics of cytokine mRNA and protein production was significantly 
different between "naive" PBMC and "primed" GIL. In addition, analysis showed that 
each individual GIL culture had its own characteristic mRNA and protein profile 
presumably due to differences in activation level of the alloreactive T-cells. Only 
these in vivo maturated primed T-cells are capable of secreting IL-2 (Th1) and IL-4 
(Th2) immediately upon antigen stimulation. 
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Chapter 4 
CYTOKINE mRNA EXPRESSION IN ENDOMYOCARDIAL BIOPSIES 
DURING ACUTE REJECTION FROM HUMAN HEART 
TRANSPLANTS 
This chapter is based on the article published in: 
Clin Exp ImmunoI1994;97:293·298 
Carla C. Baan, Nancy E.M. van Emmerik, Aggie H.M.M. Balk, 
Wim G. V. Quint, Bas Mochtar, Nicolet H.P.M. Jutte, Hubert G.M. Niesters, 
and Wil/em Weimar 
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ABSTRACT 
The immune response to an allograft is regulated by cytokines produced by cells 
infiltrating the allograft. However, the immunopathogenesis of allograft rejection is 
not completely understood. To investigate the role of cytokines after clinical heart 
transplantation, we analyzed the expression of cytokine genes in sequentially taken 
endomyocardial biopsies (EMB) by using the reverse transcriptase-polymerase 
chain reaction (RT-PCR). We analysed 44 EMS from 11 recipients: 21 EMS before 
or during rejection, and 23 EMS without histological evidence of acute rejection. A 
strong correlation was found between IL-2 gene expression and histologically 
proved rejection (16/21 versus 1/23 without rejection; p<0.001; X'-test). Also, 
expression of IL-4 and IL-6 genes was more often found in EMS during rejection 
than in EMS without signs of rejection (lL-4, 62% versus 35%; and IL-6, 81% versus 
39%, respectively). No relation with rejection or with immunological quiescence was 
observed for the presence of IL-10 gene transcripts. IL-10, but also IL-6 mRNA were 
detectable in donor heart tissue before transplantation (9/10). In contrast, IL-2 and 
ILA gene transcripts were absent in these samples. These differences could not be 
explained by the presence or absence of T-cells, since the gene for the constant 
region of the l1-chain (CI1) of the T-cell receptor (TCR) not only was expressed in 
post-transplant EMS but also in pre-transplant donor heart tissue. 
Our results provide strong evidence that the immunoregulatory cytokines IL-2, IL-4 
and IL-6 are important local regulators in the graft during acute rejection. The role of 
IL-10 in the immunologic response to the transplanted organ needs further 
investigation. 
INTRODUCTION 
The interaction of immunocompetent cells with their targets causes changes in the 
steady-state expression of different cytokine genes. Cytokines are soluble mediators 
of communication and it has become clear that these regulators can be secreted 
both by graft infiltrating cells and by cells from graft tissue. Evidence is increasing 
that different immunologic situations after organ transplantation may be associated 
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with specific patterns of cytokine gene expression, although discrepancies in the 
detection between mRNA for certain cytokines and the specific cytokine protein have 
been reported (1). In case of rejection, cytokine gene expression is observed even 
before tissue damage as reflected by histology or functional impairment of the graft 
is detected. Intragraft studies using Northern blotting and in situ hybridization 
following experimental and clinical transplantation showed that allogeneic reactions 
may be associated not only with expression of IL-2, IL-4 and interferon-y (IFN-y) 
(2,3) but also with gene expression of proinflammatory cytokines such as IL-1B, 
tumour necrosis factor-a and IL-6 (4,5,6). In contrast, IL-10 and probably IL-4 might 
playa major role in suppressing rejection and inflammatory responses (7,8). Al-
though useful, both Northern blotting and in situ hybridization require relatively large 
amounts of mRNA and are technically difficult. In contrast, the reverse transcriptase-
polymerase chain reaction (RT-PCR) provides a sensitive and reproducible method 
for the analysis of expression of several cytokine genes in a small number of cells. 
Using this technique, local transcription of various interleukin mRNAs was found 
during clinically relevant rejection episodes. In human kidney transplants an 
association was found with IL-2 expression while in liver transplants IL-5 seemed to 
be more important (9,10,11). After clinical lung transplantation, cytokine gene an-
alysis on broncho alveolair lavage material showed that the ILA gene expression is 
more prominent at the time of a cellular rejection period (12). The situation after 
heart transplantation is less obvious. Studies in experimental animals, cynomolgus 
monkeys and mice demonstrated that IL-2, IFN-y, IL-4 and IL-6 gene transcription 
was induced within the transplanted heart during the processes of rejection (13,14). 
In contrast, in human cardiac allografts a correlation was found between histological 
rejection and expression of IL-6 and transforming growth factor-beta (TGF-B) genes 
(15,16) which could be the result of non-specific inflammation rather than a T-cell 
mediated specific allogeneic reaction. 
In order to assess cytokine transcription patterns that might be related with cell 
mediated acute rejection or immunological quiescence after clinical heart 
transplantation, we determined the presence of IL-2, IL-4, IL-6 and IL-10 gene 
transcripts in donor heart tissue and in endomyocardial biopsies (EMB) post-
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transplantation by RT-PCR. By the same methodology, expression of the constant 
region of the B chain (CB) gene of the T-cell receptor (TCR) was performed to 
analyse the expression of cytokine genes in relation with the presence of a T-cell 
infiltrate. The results were correlated with histological findings on simultaneously 
taken EMB. 
MATERIAL AND METHODS 
Patients 
We analysed 44 EMS from 11 heart transplant recipients who showed histological signs of rejection. 
All EMB were taken during the first year after transplantation before, during and after rejection. Donor 
heart tissue taken before transplantation served as control (n = 10). Patients received cyclosporin A 
and low-dose steroids only as maintenance Immunosuppressive therapy. Rejection was histologically 
diagnosed in EMS by the criteria of the International Society for Heart and Lung Transplantation (17). 
In brief: grade 0, no evidence for rejection; grade 1A, focal (perivascular or interstitial) infiltrate without 
necrosis; grade 1 Bf diffuse but sparse infiltrate without necrosis; grade 2, one focus only with 
aggressive infiltration andlor focal myocyte damage; grade 3A, diffuse inflammatory process with 
necrosis; grade 3B, diffuse inflammatory process with necrosis; grade 4, diffuse aggressive 
polymorphous ± infiltrate, ± edema, ± hemorrhage, ± vasculitis, with necrosis. For this study, EMB 
were grouped into those without myocyte damage (grade 0 and 1, n = 23), and those with myocyte 
damage (grade 2 and 3, n = 21). 
RNA extraction and transcription 
Donor heart tissue and post-transplant EMB for RT-PCR were snap-frozen In liquid nitrogen and 
stored at - 80°C until analysis. Total RNA was extracted from snapfrozen EMB samples by a 
modification of the guanidinium method as described by Chomczynski and Sacchl (18). EMB tissue 
was homogenized In 500 1J14 M guanidine thiocyanate In the presence of 104 mouse 3T3 cells (ATCC, 
Rockville, MD). These mouse cells act as a carrier to improve the yield of total RNA. The solution was 
extracted with phenol, phenol-chloroform-isomethylalcohol (25:24:1] and chloroform-isomethylalcohol 
[24:1J. Total RNA was precipilated wilh 600 ~12-propanol and 35 ~I 3 M sodium acetate (pH 5.2) at-
20°C for 18 hours. Precipitates were peileted at 10.000xg at 4"C and washed with 500 IJI cold 80% 
ethanol. Air-dried pellets were resuspended in 50 IJI dlethylpyrocarbonate treated-H20. Total RNA was 
denaturated for 5 min at 80"C and then chilled on Ice. First strand cDNA synthesis was performed 
from 25 ~I of the isolated RNA with 0.25 ~g hexanucleotides (0.5 ~g/~l; Promega Corporation, 
Madison, WI) and transcribed with 2.5 IJI Moloney murine leukemia virus (MML V) reverse 
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transcriptase (200 U/~t; Gibco-BRL, Gaithersburg, MD) at 42'C for 90 min in a totat volume of 50 ~I. 
The reaction mixture contained 10 ~15x MMLV-RT buffer (250 mM Tris-HCI pH B.3, 15 mM MgCI" 375 
mM KCI), 2.5 ~I dNTP (10 mM) 0.5 ~I of RNAsin (400 u/~I; Promega) and 5 ~I DTT (0.1M). 
peR amplification and Southern blot analysis 
Sequence specific primers (Clontech Laboratories, Palo Alto, CA) were used for amplification of the 
human cytokine genes. These primers were located next to splice sites, to be able to discriminate for 
RNA only. Five ~I cDNA sample was added to 45 ~I PCR mixture ccntaining 10 mM Tris-HCI pH B.3, 
50 mM KCI, 1.5 mM MgCI" 0.2 mM of each dATP, dCTP, dTTP, dGTP, 2 U Taq DNA polymerase 
(Promega) and 50 pmol of 5' and 3' sequence specific primers. Each reaction mixture was overlaid 
with 50 ~I mineral oil (Sigma, St. Louis, MO)prior to PCR reaction in a DNA thermal cycler (Biomed, 
thermocycler 60) under the following conditions. After a 5 min 94 "C denaturation step, samples were 
subjected to 40 cycles of denaturation at 94 "C for 1 min, annealing at 60°C for 2 min, and extension at 
72°C for 3 min. The last cycle was extended with 7 min. As positive controls for the cytokines we used 
cDNA isolated from HuT78 cells (ATCC, a human T-cell line derived from a patient with Sezary 
syndrome), and Epstein-Barr virus (EBV) immortalized B cells. The presence of T-cells was 
determined by amplification of the gene coding for the f1 chain constant region of the TCR as 
described by Hawes (19). PCR primers detecting transcripts for the human keratin gene (sense primer 
5'TGAAGATCCGTGACTGGTAC3' and anti-sense primer 5'ATGTCGGCTTCCACACTCAT3') were 
used as an internal control to confirm successful RNA extraction and cDNA amplification (20). After 
amplification, 8 IJI PCR product was electrophoresed through 2% agarose gel, transferred to a 
Hybond-N+ membrane (Amersham, Aylesbury, UK) by electro blotting and hybridized with y"P 
labelled probes which are located across the splice-site (cytokines, Clontech Labs; and keratin, 
5'TGTCCTTCTGCAGATTGACAATGCCCGTCT3'). Hybridization was detected by autoradiography. 
RESULTS 
We analysed 10 samples of pre-transplant donor graft tissue and 44 post-transplant 
EMS, obtained from 11 recipients for alterations in expression of IL-2, IL-4, IL-6 and 
IL-10 genes in relation to histological diagnosis. Transcripts from the human keratin 
gene were amplified in all tested samples. mRNA extracted from the mouse 3T3 
carrier cell line did not show expression of genes coding for human cytokines, nor for 
CB of the TCR or keratin. 
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Pre-transplant donor cardiac tissue 
Genes coding for IL-6 and IL-10 were expressed in the majority of the pre-transplant 
samples, whereas IL-4 mRNA was never detectable and IL-2 mRNA was present in 
one sample only (table 1). Also CB mRNA of the TCR was successfully amplified in 
8 of the 10 pre-transplant samples (table 1), reflecting the presence of the T-cells in 
donor cardiac tissue. 
Table 1. Cytokine and TCR-CB chain gene expression in pre-transplant donor heart 
tissue. Southern blot analysis of polymerase chain reaction (PCR)-amplified DNA 
Donor 
II 
III 
IV 
V 
VI 
VII 
VIII 
IX 
x 
+/total 
IL-2 IL-4 
-' 
+ 
1/10 0110 
a _, no signal; +, positive expression 
IL-6 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
9/10 
IL-10 TCR-CB chain 
+ 
+ + 
+ 
+ + 
+ + 
+ + 
+ + 
+ + 
+ 
+ + 
9/10 8/10 
Cytokine gene expression versus histologic evidence of rejection 
Typical results of the kinetics of cytokine gene expression in pre-transplant and post-
transplant EMB for one patient before, during and after acute cellular rejection are 
shown in figure 1. Results of sequential EMB from 11 patients are presented in 
tables 2 and 3 for EMB without and with histological evidence of rejection, 
respectively. The presence of IL-2 transcripts was characteristic for EMB taken at 
the time of rejection as 16/21 EMB (76%) showed transcription of the IL-2 gene, 
while only 1/23 (4%) EMB in which no myocyte damage was seen, expressed the IL-
2 gene (p<0.001; X'-test, tables 2 and 3). IL-2 mRNA transcripts were already 
64 
ongoIng reje<:Uon 
~ 9 16 23 37 121 187 days 
k~ratin 
IL-2 
IL-4 
--
IL-6 
IL-l0 ND 
Flgur. 1. Southern btot anatysis of RT-PCR-amplified keratin. IL-2. Il-4. Il-6 and IL-l0 transcripts 
from mRNA obtained from one patient (Me) of pre-transplant and post-transplant EMB, taken before, 
during and after rejection. Pre TX, pre·transplant EMB; day 9 post-transplant (pTX), no rejection; day 
16 pTX, one focus only with aggressive infiltration and/or focal myocyte damage; day 23 pTX, one 
focus only with aggressive infiltration and/or focal myocyte damage; day 37 pTX, diffuse inflammatory 
process with necrosis; day 121 pTX, focal infiltrate without necrosis; day 187 pTX, no rejection. 
detectable in EMS with histological rejection grade 2, preceding grade 3 EMS (table 
3). Prior to or during an acute rejection episode, IL-2 mRNA positive EMS frequently 
showed coexpression both of IL-4 and IL-6 mRNA (10/16). Nevertheless, the 
presence of ILA gene transcripts did not discriminate between EMS with and those 
without histological signs of rejection (13/21, 62% vs 8/23, 35%; p>0.05: tables 2 
and 3). Neither was the presence of IL-6 mRNA solely indicative for episodes of 
rejection, since in these cases 17/21 EMS (82%) expressed the IL-6 gene compared 
to 9/23 EMS (39%) taken at the time of immunological quiescence (table 2 and 3). 
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For IL-10 gene no difference in transcription was found between the two EMS 
groups since IL-10 mRNA was present in all EMS. The cytokine mRNA profiles of 
the subgroups of EMS without myocyte damage, i.e. rejection grades 0 and 1A, 
were comparable (table 4). The mild immune response reflected in EMS by the 
presence of cellular infiltration but without myocardial injury, apparently did not lead 
to expression of the IL-2 gene in the ten grade 1A EMS tested. 
TCR-CB gene expression versus histologic evidence of rejection 
The IL-2 gene expression seen in EMS with rejection, is supposed to be transcribed 
by activated T-cells only. Other cytokines may also be synthesized by cell types 
present concomitant in the graft. Therefore, we analysed the occurrence of T-cells in 
the EMS in an attempt to enhance the discriminatory capacity of the other cytokine 
RT-PCR results. Although the CB gene of the TCR appeared to be more prominently 
expressed in EMS wilh rejection than in those without, no significant correlation 
between the presence of T-cells and the cytokine gene expression pattern could be 
made. TCR-CB gene transcription was detectable in all 44 post-transplantation EMS, 
those with and those without rejection and even in pre-transplant donor heart tissue 
(fig 2). 
DISCUSSION 
After transplantation, cytokines are transcribed and produced both by cells from graft 
tissue and by lymphocytes infiltrating the allograft. Cytokines mediate and control the 
allogeneic response, and therefore monitoring of cytokine gene patterns might be 
helpful in understanding immunological processes in the transplanted heart. 
Therefore, we determined cytokine and TCR-Cj3 gene expression in pre-transplant 
donor heart tissue and in post-transplant EMS. 
We have shown that the intragraft cytokine gene pattern of post-transplant donor 
cardiac tissue differs from that of normal tissue. We found that pre-transplant heart 
tissue contained IL-6 and IL-10 transcripts. 
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Table 2, Cytokine gene expression in endomyocardial biopsies (EMB) without 
histological evidence of rejection', Southern blot analysis of PCR-amplified DNA 
EMBb Days IL-2 IL-4 IL-6 IL-10 
post-Iransplant 
BI1 16 -' + + 
BI4 155 + ND 
Bo1 28 + 
B03 230 + 
Dei 8 + + 
De4 100 + + 
Ge2 44 + + ND 
Ge3 51 + ND 
Ko1 31 ND 
K03 105 ND 
Me1 9 + 
Me5 121 + + + 
Me6 187 + + ND 
Mi1 22 ND 
Pe3 346 + 
Poi 22 + + + 
P03 58 + 
P05 126 + + + + 
Se1 19 + 
Se4 80 + 
Se5 111 + + + 
Se6 262 ND 
Wa4 135 ND 
+/total 1/23 8/23 9/23 14/14 
'No rejection: EMB grading 0 and 1 according to Billingham (17) 
b EMB description: composed of patient identification and EMB number analyzed 
eND = not done; ., no signal; +, positive cytokine expression 
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Table 3. Cytokine gene expression in endomyocardial biopsies (EMS) with 
histological evidence of rejection'. Southern blot analysis of PCR-amplified DNA 
EMB' days IL-2 IL-4 IL-6 IL-l0 
post-transplant 
Bi2 60 -' + + 
Bi3 67 + + 
B02 125 + + + NO 
Oe2 29 + + + + 
De3d 86 + + + + 
Gel 16 + + NO 
Ge4 72 + + NO 
Ge5 101 + + NO 
K02 99 + NO 
Me2d 16 + + + 
Me3d 23 + + + + 
Me4 37 + + + + 
Pel 59 + + + + 
Pe2 114 + 
P02 35 + + + + 
P04 96 + + + 
Se2d 26 + + + 
8e3 33 + + + + 
Wal 16 + + + NO 
Wa2 23 + NO 
Wa3 108 + + + NO 
+lIotal 16/21 13/21 17/21 13/13 
'Rejection: EMB grading, 2 according to Billingham (17) 
b EMS description: composed of patient identification and EMS number analyzed 
eND = not done; -, no signal; +, positive cytokine expression 
d Rejection grade 2 biopsies 
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In contrast, we hardly ever detected IL-2 and IL-4 gene expression in these 
samples. Therefore, the presence of these latter transcripts appeared to be 
characteristic for the immune response after transplantation. We found that locallL-2 
mRNA transcription was correlated with cellular rejection leading to myocyte 
damage, after clinical heart transplantation. Moreover, analysis showed that IL-2 
mRNA transcripts were already detectable in EMB histologically defined as rejection 
grade 2, in the period preceding rejection defined as rejection grade 3. Our results 
after clinical heart transplantation are in agreement with RT-PCR data after 
experimental heart transplantation (8,13,14,21). The discrepancy between these 
data and those published by Zhao et al (15,16) may be the result of differences in 
the amount of cardiac tissue from which the RNA was isolated or in sensitivity of the 
RNA extraction. In contrast to the studies by Zhao et ai, we added carrier cells at the 
beginning of the RNA exlraction which is necessary for optimal isolation from small 
amounts of tissue (22,23). Also their identification of a PCR product was solely 
based on the generation of a PCR product of predicted size while the identity must 
be verified by a y "p labeled internal probe which is significantly more specific and 
sensitive. At this point one has to keep in mind that detection of mRNA using 
sensitive RT-PCR techniques may not give a correct impression of relevant 
production of the biologically active cytosine proteins. One could for instance 
hypothesize a (post)-translational blockade due to the clinical use of 
immunosuppressants, although such an activity of cyclosporin or prednisone has not 
been described. It would nevertheless be important for our understanding of the 
cytokine network in transplantation medicine if we could correlate mRNA expression 
with protein production. This, however,. implies the introduction of an in vitro cell 
culturing phase with all it's adherent confounding variables. The prominent place for 
IL-2 in the clinical rejection process as suggested by our RT-PCR results has also 
been found by Ruan et al (24) in their immunohistochemical study. As in our present 
report they showed that IL-2 was absent or only occasionally expressed in EMB 
without signs of myocyte damage. In our study, some of the tested EMB taken 
during rejection did not express the IL-2 gene. 
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Table 4. Cylokine gene expression in the subgroups of endomyocardial biopsies 
(EMB) without myocyte damage 
Gene product 
IL·2 
IL·4 
IL·6 
/I number of positive EMB 
rejection grade 0 
n' (%') 
(n = 13) 
1 (7) 
4 (31) 
5 (38) 
1 Positive EMS as percentage of total EMB tested 
rejection grade 1A 
n (%) 
(n = 10) 
o (0) 
4 (40) 
4 (40) 
Apparently sampling timing is essential and might be explained by the transient 
expression of IL-2 (25). Besides, focal expression may cause discordance between 
EMB tested for cytokine gene expression and concurrently taken EMB obtained for 
histological evaluation. Activated lymphocytes not only release IL-2 but also other 
cytokines such as IL-4 (26). Like IL-2, IL-4 was also only expressed in post-
transplant EMB, but its presence had low predictive value for acute allograft 
rejection. Still the finding that IL-2 and IL-4 genes are concurrently expressed during 
acute rejection indicates that not only IL-2 but also IL-4 plays an important role in the 
regulation of the allogeneic response in vivo. This is in agreement with the 
observations by Dallman et al (14) and by Morgan et al (21) who reported that in 
non-immunosuppressed murine cardiac allografts genes for IL-2 and IL-4 are 
induced during rejection. The difference between the more clear-cut role for IL-4 in 
these experimental studies and our less uniform findings might be the result of 
immunosuppressive therapy in the clinic. Also recently published data of human lung 
transplant recipients demonstrated that induction of IL-4 gene transcription is far 
from uniformly in allograft rejection (12). In contrast to the mRNA for IL-2 and IL-4, 
the presence of the IL-6 and IL-10 mRNAwas not confined to post-transplant EMB. 
The proinflammatory cytokine IL-6 and the anti· inflammatory cytokine IL-10 are not 
produced by activated T-cells only (27,28) but are synthesized by a variety of cells, 
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including monocytes (29,30) and endothelial cells (31,32) which are normally 
present in cardiac tissue. The proinflammatory cytokine IL-6 and the anti-
inflammatory cytokine IL-10 are not produced by activated T-cells only (27,28) but 
are synthesized by a variety of cells, including monocytes (29,30) and endothelial 
cells (31,32) which are normally present in cardiac tissue. 
1A 3A o 
CI3 •........ "",. 
Figure 2. Southern blot analysis of RT~PCR~amplified r.,-chain transcripts of the constant region (Gil) 
of the T~cell receptor from mRNA obtained from one patient (Ko) of pre-transplant allograft tissue and 
post-transplant endomyocal biopsies (EMS). Histology: pre TX = donor heart tissue before 
transplantation; day 31 post-transplant (pTX), 1A: focal (perivascular or interstitial) infiltrate without 
necrosis; day 99 pTX, 3A: diffuse inflammatory process with necrosis; day 105 pTX, 0: no rejection. 
The inflammation that accompanies surgery would suffice to induce release of IL-6 
(33) and possibly other cytokines such as IL-10. In the current study, measurement 
of IL-6 mRNA directly in post-transplant EMB was associated with, but again had no 
predictive value for allograft rejection. IL-6 transcripts were present in 81 % of the 
EMB with clinically relevant rejection (myocyte damage) and in only 40% of those 
with irrelevant rejection (infiltrate only). It is likely that IL-6 is involved in the 
inflammation process occurring during acute rejection since the presence of IL-6 
transcripts in post-transplant EMB is associated with a massive infiltration of T-cells 
(fig 2) and monocytes (34) in the allograft which suggests that least some of the IL-6 
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gene expression is derived from cells invading the allograft. The positive correlation 
of IL-6 expression to acute renal graft rejection is supported by several studies 
(4,35,36). This relationship, however, was not found after clinical liver transplantation 
where intragraft IL-6 mRNA transcription was not associated with allograft rejection 
(10). Interestingly, in the present study, the IL-10 cytokine gene was persistently 
expressed both before and after transplantation. Recently published data from 
mouse studies showed that this cytokine is transcribed not only during 
immunological tolerance but also at the time of cellular rejection (8). Furthermore, 
Merville et al showed that a high proportion of cells derived from a human kidney 
with irreversible rejection secreted IL-10 (35). Since IL-10 can both suppress the 
immune response (37,38,39) and act as a cofactor to promote cell growth (40), a 
continuous presence of mRNA for IL-10 under different immunological conditions 
can be explained. To clarify the exact relationship between IL-10 gene expression 
and T-cell infiltration in the transplanted organ more precisely, a quantitative or semi-
quantitative analysis is required. 
In conclusion, rejection and immunological quiescence were correlated with distinct 
patterns of cytokine gene expression. We found a clear correlation of IL-2 and to a 
lesser extent of IL-4 and IL-6 gene expression with myocyte damage. These 
cytokine profiles might be of prognostic significance for rejection processes after 
clinical heart transplantation. However, the role of IL-10 in processes leading to 
rejection or immunological tolerance remains to be determined. 
REFERENCES 
1. Daane CR, van 8esouw NM, van Emmerik NEM, et al. Discrepancy between mRNA 
expression and production of IL2 and IL4 by cultured graft infiltrating cells propagated from 
endomyocardial biopsies. Transplant Int 1994;7(S1):627-628. 
2. Dallman MJ, Porter ACG, Larsen CP et al. Lymphokine production In allograffs-analysis of 
RNA by Northern blolling. Transplant Proc. 1989;21:296-298. 
3. Dallman MJ, Montgomery RA, larsen CP, et al. Cytokine gene analysis using Northern 
blolling, polymerase chain reaction and In situ hybrisation. Immunol Rev 1991;119:163-179. 
72 
4. Vandenbroecke C, Camat~Zucman S, Legendre C, et al. Differential in situ expression in 
renal allograft rejection. Transplantation 1991;51:602-609. 
5. Jordan SC, Kondo T, Prehn J, et al. Cytoklne gene activation in rat lung allografts: analysis by 
Northern Blotting. Transplant Proc. 1991 ;23:604-606. 
6. Norohna IL, Hartley B, Cameron JS et al. Detection of IL-1B and TNF-cx message and protein 
In renal allograft biopsies. Transplanlation 1993;56:1026-1029. 
7. Lowry RP, Wang K, Vernooij B, et al. Lymphokine transcription in vascularized mouse heart 
grafts: effects of tolerance Induction. Transplant Proc 1989;21:72-73. 
8. Takeuchi T, Lowry RP, Konieczny B. Heart allografts in murine systems: The differential 
activation ofTh2-like effector cells In peripheral tolerance. Transplantation 2;63:1281-1294. 
9. Dallman MJ, Roake J, Hughes 0, et al. Sequential analysis of IL~2 gene transcription in renal 
transplants. Transplantation 1992;53:683-685. 
10. Martinez OM, Krams SM, Sterneck M, et al. Inlragraft cytokine profile during human liver 
allograft rejection. Transplantation 1992;53:449-456. 
11. Martinez OM, Villanueva JL, Roberts JP, et al. IL-2 and IL-5 gene expression in response 
to alloantigen in liver allograft recipients and in vitro. Transplantation 1993;55:1159~1166. 
12. Whitehead BF, Stroehr C, Wu CJ, et al. Cylokine expression In human lung transplant 
recipients. Transplantation 1993;56:956-961. 
13. Wu CJ, Lovett M, Wong~Lee J, et al. Cytokine gene expression in rejecting cardiac allografts. 
Transplantation 1992;54:326-332. 
14. Dallman MJ, Larsen CP, and Morris PJ. Cytokine gene transplantation in vascularised organ 
grafts: analysis using semiquantitative polymerase chain reaction. J Exp Med 1991;174:493~ 
496. 
15. Zhao XM, First WH, Yeah TK, et al. Expression of cytokine genes in human cardiac allografts: 
correlation of IL-6 and transforming growth factor-beta (TGF-I1) with histological rejection. Clin 
Exp ImmunoI1993;93:448-451. 
16. Zhao XM, Yoeh TK, Hiebert M, et al. The expression of acidic fibroblast growth factor 
(heparin-binding growth factor~1) and cytokine genes In human cardiac allografts and T cells. 
Transplantation 1993;56:1177-1182. 
17. Billingham ME, Path FRC, Cary NRB, et al. A working formulation for the standardization of 
nomenclature in the diagnosis of heart and lung rejection: Heart rejection study group. J Heart 
Transplant 1990;9:587-593. 
18. Chomczynski P, Sacchi N. Single step melhod of RNA isolation by acid guanidinium 
thiocyanate-phenol-chloroform exlraction. Anal Biochem 1987;162:156-159. 
19. Hawes GE, Struijk L, van den Elzen PJ. Differential usage of cell receptor V-gene In CD4+ 
and CD8+ subsets of T lymphocytes In monozygotic twins. J ImmunoI1993;150:2033-2045. 
73 
20. Marchuk D, McCrohon S and Fuchs S. Complete sequence of a gene encoding a human type 
I keratin: Sequences homologous to enhancer elements in the regulatory region the gene. 
Proc Nail Acad Sci USA 1985;82:1609-1613. 
21. Morgan CJ, Pelletier RP, Hernandez CJ, et al. Alloantigen-dependent endothelial phenotype 
and Iymphokine mRNA expression In rejecting murine cardiac allografts. Transplantation 
1993;55:919-923. 
22. Brenner CA, Tam AW, Nelson PA, et al. Message amplificallon phenotyping (MAPPing): a 
technique to simultaneously measure multiple mRNAs from small number of cells, 
BioTechniques 1989;7:1096-1103. 
23. Winslow SG, and Henkart PA. Polyinosinic acid as a carrier in the mlcroscale purification of 
total RNA. Nucleic Acids Res 1991;19:3251-3253. 
24. Ruan X, Qlaa J, Trento A, et at Cytoklne expression and endothelial cell and lymphocyte 
activation in human cardiac allograft rejection: An immunohistochemical study of 
endomyocardial biopsy samples. J Heart Lung Transplant 1992;11:1110-1116. 
25. Cosman D. Control of messenger RNA stability. Immunol Today 1987;8:16-17. 
26. O'Garra A.lnterleukins and immune system 2. Lancet 1989;1:1003-1005. 
27. Kishimote T, Akira S, Taga T. Interleukln-6 and Its Receptor: a paradigm for cytoklnes. 
Science 1992;258:593-597. 
28. Vieira P, de Waal-Malefyt R, Dang MN, et at Isolation and expression of human cytoklne 
synthesis inhibitory factor (CSIFIIL-10) cDNA clones:homology to Epstein-Barr virus opre 
reading frame BCRF1. Proc Nail Acad Sci USA 1991;88:1172-1176. 
29. May LT, Grayeb J, Santhanam U, et al. Synthesis and secretion of multiple forms of 8-2 
interferon/S cell-differentiation factor 2/hepatocyte stimulating factor by human fibroblasts and 
monocytes. J Bioi Chern 1988;263:7760-7766. 
30. de Waal Maletyt R, Abrams J, Bennett B, et al. Interleukin 10 (IL-10) inhibits cytokine 
synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J 
Exp Med 1991;174:1209-220. 
31. Lansdorp PM, Aarden LA, Calafat J et al. A growth-factor-dependent B -cell hybridoma. In 
Mechanisms in B-cell Neoplasia (eds. F. Melchers & M Potter) vol 132, p.105, Springer-
verslag, Berlin/Heidelberg, and In Thesis, Amsterdam, 1985. 
32. Halloran P, Batiuk T, Goes N. An overview of the cytokines in transplantation. Transplantation 
Science 1993;3:69-76. 
33. Pham SM, Yoshida Y, Aeba R, et a!. Interleukln-6, a marker of preservation Injury in clinical 
lung transplantation. J Heart Lung Transplant 1992;11:1017-1024. 
34. Gassel AM, Hansmann ML, Radzun HJ, et al. Human cardiac allograft rejection. Am J elin 
PathoI1990;94:274-279. 
74 
35. MelVille P, Pouleii-Noble C, Wijdenes J, el al. Deleclion of single cells secreling IFN-gamma, 
IL-6 and IL-10 in irreversibly rejecled human kidney allografts, and their modulalion by IL-2 
and IL-4. Transplanlalion 1993;55:639-646. 
36. Oers MHJ, Van Der Heyden AAPAM, Aarden LA. Inlerleukln 6 (IL-6) in serum and urine of 
renallransplant recipients. Clin Exp ImmunoI1988;71:314-319. 
37. Lowry RP. The relationship of IL·4, IL-10 and other cytokines to transplantation tolerance. 
Transplanlalion Science 1993;3:104-112. 
38. Fiorentino OF, Zioinik A, Vieira P, el al. IL-10 acls on the anllgen-presenllng cell to Inhibit 
cylokine produclion by Th1 cells. J ImmunoI1991;146:3444-3451. 
39. Yssel H, De Waal Maletyt R, Roncarolo MG, et al. IL-10 Is produced by subsets of human 
CD4+ T cell clones and peripheral blood T cells. J ImmunoI1992;149:2378-384. 
40. Chen WF, and Zioinik A. IL-10: a novel cyloloxic T cell differenlialion factor. J Immunol 
1991 ;147:528-534. 
75 
76 
Chapter 5 
BLOCKADE OF THE IL-2I1L-2RECEPTOR SIGNALLING PATHWAY 
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ACUTE HEART ALLOGRAFT REJECTION IN HUMANS 
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ABSTRACT 
Anti-lnterleukin-2Receptor (IL-2R) antibodies have been used as rejection prophylaxis 
after organ transplantation. Despite this induction treatment acute rejections may occur. 
We wondered whether these rejections developed via the IL-2/IL-2R pathway. In a 
prospective trial using BT563, a murine IgG, anti IL-2Receptor antibody, for rejection 
prophylaxis after heart transplantation, 20 patients were treated in combination with 
cyclosporine from the day of transplantation (group A). As a control group served 31 
patients also treated with 8T563, but in these patients cyclosporine treatment was 
initiated on day 3 (group B). 
Three patients from group A and two patients from group B died in the first post-
operative month (of causes not related to acute rejection) and were left out from the 
analysis of rejection incidence. Freedom from acute rejection at 1 week after 
transplantation in group A (14/17; 82%) was lower than in group B (16/29; 55%), 
although the difference did not reach statistical significance. There was no difference 
in either the number of acute rejections at 12 weeks or the required rejection treatments 
between groups A and B. Infectious complications were evenly distributed in both 
groups. Immunohistochemistry showed that during acute rejection, in the presence of 
circulating BT563, IL-2R bearing cells were present in only 1/5 (20%) rejection biopsies, 
whereas these cells were often present (75%; 7/8) in rejections occurring in the 
absence of BT563. BT563 presence was associated with a similar difference in the 
mRNA expression of IL-2 (40% versus 75%). In contrast, no effect of BT563 was seen 
on intragraft mRNA transcription of the macrophage derived T-cell growth factor IL-15. 
Quantitative analysis in rejection biopsies showed comparable IL-15 mRNA levels 
during and after BT563 treatment. 
Despite adequate blockade of the IL-2I1L-2R signalling pathway patients may develop 
acute rejection, reflecting the redundancy of the cytokine network. The ever-present IL-
15 may well be a candidate for overtaking the role of IL-2. 
INTRODUCTION 
OKT3, an anti-pan-T-cell monoclonal antibody, is effective as anti-rejection therapy and 
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possibly as rejection prophylaxis in heart and kidney transplantation (1,2). However, the 
administration of OKT3 is accompanied by a cytokine release syndrome and a profound 
non-specific immunosuppression that may result in an increased incidence of infectious 
complications and development of malignancies (3-5). More specific 
immunosuppression may be obtained by use of monoclonal antibodies against the 
interleukin-2 Receptor (IL-2R MoAbs). Anti-IL-2R MoAbs administration is not 
complicated by a cytokine release syndrome. Clinical trials with several examples of this 
class of antibodies have been performed in the prevention of acute rejection after 
kidney, combined kidney and pancreas, heart and liver transplantation (6-13). 
Our earlier controlled trial comparing safety and efficacy of BT563, a murine IgG, anti-
IL-2R MoAb, with OKT3 as prophylaxis against acute rejection after heart 
transplantation showed no difference between the two groups with respect to freedom 
from rejection at 3 months or infectious complications (11). During BT563 treatment, 
however, a high incidence of early acute rejections was found. In contrast, a significant 
reduction of early acute rejection episodes was found in a trial with BT563 to prevent 
acute rejection in kidney transplant recipients (9). An important difference between our 
heart and kidney transplant trial is that in the renal allograft recipients cyclosporine 
treatment started on day 0, whereas in the heart transplant patients, cyclosporine was 
initiated on day 3 to prevent nephrotoxicity in the first post-operative days. In animal 
studies, a synergistic effect of the combination of cyclosporine and anti-IL-2R MoAbs 
has been demonstrated (14,15). The results of rejection-prophylaxis with BT563 in the 
heart recipients might have been better if cyclosporine had been initiated on the day of 
transplantation, making optimal use of the synergistic effect of combining BT563 and 
cyclosporine. The results of our renal study support this hypothesis (9). 
In this article, we present data of a study investigating the effect of combining 
cyclosporine and BT563 from the first day after heart transplantation on rejection 
incidence, renal function and adverse side effects. Apart from clinical data, 
immunological monitoring of the IL-2/IL-2R pathway in peripheral blood by flow 
cytometry, and within the graft by immunohistochemistry and by reverse transcriptase-
polymerase chain reaction (RT-PCR) is presented. 
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PATIENTS AND METHODS 
Patients 
Between February 1996 and November 1996, 20 consecutive recipients of a cardiac allograft (group A) 
were prophylactically treated with BT563 after returning from the operation theatre. BT563 (Biotest 
Pharma GmBH, Dreieich, Germany) was given in a dosage of 11 mg Lv. from day 0 to day 12 after 
transplantation. tn addition to BT563, patients were treated with prednisone 50 mg daily from day 0, 
gradually decreasing to 15 mg at 4 weeks after transplantation. Cyclosporine was started 6 hours after 
vascular anastomosis in a dosage of 2 mg/kg/day i.Y. After 2 days oral cyc!osporine administration was 
started, aiming at whole blood trough levels of 250 - 350 nglml (EMIT, Behring Diagnostics, Cupertino, 
CAl. Endomyocardial biopsies (EMBs) were performed weekly during the first 6 weeks, biweekly during 
the next month, and monthly for the next 4 months after transplantation. Biopsies were repeated more 
frequently after a rejection episode. 
As a control group (group B) we used the BT563-treated patients (n=31) of the earlier randomized trial, 
following an identical treatment and surveillance protocol, but receiving cyclosporine on day 3 after 
transplantation (11). These patients were transplanted between November 1991 and February 1994. The 
duration of BT563 administration for patients in group A was 12 days, and for group B, 7 days. 
Peripheral blood monitoring 
Before, during, and after BT563 treatment peripheral blood samples were collected at day 1, 3, 5, 7, 14, 
21,28,35 and 42 In EDTA containing tubes and monitored for the presence of T-cell subsets by two color 
flowcytometry using MoAb directly conjugated to fluorescein (FITC) or phycoerythrin (PE). Before 
incubation with MoAb, 100 1'1 whole blood was washed three times with 2 ml Hanks' Balanced Salt 
Solution (Gibco, Paisley, Scotland) supplemented with 1% Bovine Serum Albumin (BSA) (Sigma, St.Louis, 
MO) and 0.1% sodium azide (Merckx, Darmstadt, Germany) to remove BT563 and human-anti-mouse 
antibodies that might interfere with the staining procedures. Subsequently, 20 IJI of the following dual 
MoAb combinations were added to 1001'1 cell suspensions: CD45-FITCICD14-PE; IgG,-FITCllgG,,-PE 
as isotype control; CD3-FITCICD19-PE; and the combination Wf31-FITC (anti-T -cell receptor ITCR] alP) 
ICD25-PE (MoAb 2A3) all obtained from Becton & Dickinson (San Jose, CAl. After 30 min of incubation 
at room temperature, red blood cells were lysed with FACS lysing solution (Becton & Dickinson) during 
10 min. Afterwashlng, cells were analysed on a FACScan (B&D) f1ow-cytometer using SimulSet software 
(B&D) for data analysis. To establish an analysis gate that included at least 90% of the lymphocytes, the 
CD45/CD14 reagent was used. One thousand to 2000 gated lymphocyte events were acquired from each 
tube. The CD25 MoAb 2A31s also directed against the IL-2R a-chain, but is not competitive with BT563 
(16). In all patients, we also analysed for the presence of CD122 (IL-2R fl-chain (p75)] on the T-
lymphocytes by the MoAb combination TCR alB-FITC (WT31) and CD122 (anti IL-2R p75)-PE (B&D). A 
PE-conjugated monoclonal rat-anti-mouse antibody (RAM, B&O) was used to determine whether CD25-
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positive cells in peripheral blood were coated with BT563 during treatment ("bound BT563"). 
Plasma BT563 levels 
8T563 trough levels were measured daily during treatment. Plasma levels were determined with an ELISA 
sandwich method using goat anti-mouse-lgG (Southern Biological Associates, Birmingham, AL) and 
alkaline-phosphatase-(AP)-conjugated goat anti-mouse-lgG (H+L) antibodies (Jackson Immuno Research, 
West Grove, PAl. Samples were diluted 1:450 and 1:2000 with Tris buffered salinefTween 20/Bovine 
Serum Albumine (TBSfTw/BSA). The concentration of BT563 was estimated by interpolation of obtained 
values on a standard curve of parental grade 8T563 diluted in this solution. 
ReJection: monitoring and treatment 
A pathologist, unaware of the Immunosuppressive protocol, examined EMS-specImens stained with 
hematoxylin-eosin using light microscopy. Biopsies were graded according to the guidelines of the 
InternaUonat Sociely for Heart and Lung Transplantation (17). Biopsies graded 3A or higher were regarded 
to represent rejection episodes necessitating anti-rejection treatment. In the majority of cases rejection 
was treated with 1 gram methylprednisolone Lv. on three consecutive days. Frequently recurring Of 
refractory rejection episodes were treated with rabblt·ATG (Imtix, Amstelveen, The Netherlands). 
Recurrent episodes of steroid·unresponsive rejection after treatment with r-ATG were treated with a 
course of OKT3. 
Immunohistochemistry 
From all patients in group A, immunohistochemistry was performed on all EMBs taken weekly until the first 
acute rejection episode or until week 6 for non-rejectors (n=48). From 11 patients, a peroperative time=O 
EMB Was obtained. Snap-frozen EMB specimens were cut in 5.um sections, air dried, and fixed in 4% 
formalin. The slides were subsequentiy Incubated with the appropriately diluted MoAb (C03 = RIV9 (RIVM, 
Bilthoven, Netherlands); C04 = antl-Leu3 (B&O); CD8 = anti-Leu2 (B&O); C025 = 2A3(B&0); C068 = 
mouse anti-human macrophage clone PK1 (DAKO, Denmark»). The slides were rinsed in phosphate-
buffered saline (PBS) and incubated with biotinylated antimouse-Immunoglobulins (1:50 In PBS; Biogenex, 
San Ramon, CAl, rinsed, and labeled with AP-Iabeled streptavidin (Biogenex, 1 :50 in PBS). The enzym 
was finally detected with new fUchsin as a substrate as described by the manufacturer. Slides were 
counterstained with Mayer's haematoxylin, examined and the number of positive staining cells was 
counted. The results are expressed per half field at 100x magnification (ob). 10x). A total field at this 
magnification measures 2.54 mm2. After staining the biopsies were scored on a scale from 0 to 4. Score 
0: no positive cells; score 1: 1-10 positive cells; score 2: 11-30 positive cells; score 3: 31-100 positive 
cells; score 4: > 100 positive cells. "Bound" BT563 was measured using the above mentioned procedure, 
omitting the first step. 
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mRNA isolation and cDNA reaction 
For RT-PCR analysis, specimens were snap·frozen in liquid nitrogen and stored at _80°C. mRNA 
extraction and transcription was performed as described previously (18). Briefly, total RNA was extracted 
from snap· frozen samples by a modification of the guanidinium method, as described by Chomczynski 
and Sacchi (19). Specimens were homogenized in 500 /AI 4M guanidinium·isothiocyanate in the presence 
of 20 pg/ml poly A (Boehringer, Mannheim, Germany). The solution was extracted once with phenol, 
phenol-chloroform-isoamylalcohol [25:24:1) and chloroform-isoamylalcohol 124:1). Total RNA was 
precipitated with 600 /l12-propanol and 35/113M sodium acetate (pH 5.2) at -20'C for 18 hr. Precipitates 
were pe1Jeted at 10.00Oxg at 4t1 C during 20 min and washed once with 500 pI ice·cold 80% ethanol. Air-
dried pellets were resuspended in 50 1'1 diethylpyrocarbonate (OEPC) treated-H,O. Total RNA was 
denaturated for 5 min at BOtlC and then chilled on ice. First strand cDNA synthesis was performed from 
the isolated RNA with 0.5.11g hexanuc!eotides (Promega Corporation, Madison, WI) and transcribed with 
1000 U Moloney murine leukemia virus (MMLV) reverse transcriptase (Gibco-BRL, Gaithersburg, MO) at 
42°C for 90 min in a total volume of 100 til. The reaction mixture consisted of 20 .u15x MMLV·RT buffer 
(250 mM Tris-HCI pH 8.3,15 mM MgCI" 375 mM KCI), 5/l1 dNTP (10 mM), 400 U of RNAsin (Promega) 
and 101'1 (0.1M) OTT. 
Polymerase Chain Reaction (PCR) 
Sequence-specific primers were used for amplification of the human Il-2, IL·2R (a-chain), IL-4, IL·15 and 
TCR·Cr.. genes. PCR primers detecting transcripts for the human house·keeping gene r..-actin (Clontech 
Laboratories, Palo Alto, CAl were used as an internal control to monitor mRNA extraction and cDNA 
amplification. For qualitative analYSiS, 5.111 cDNA sample was added to 95 pi PCR mixture containing 10 
mM Tris-HCI pH 8.3, 50 mM KCI, 1.5 mM MgCI" 0.2 mM of each dATP, dCTP, dTTP, dGTP, 2 U Taq 
DNA polymerase (Promega) and 50 pmol of 5' and 3' sequence·specific primers. Each reaction mixture 
was overlaid with 75 til mineral oil (Sigma, St. Louis, MO) prior to PCR reaction in a DNA thermal cycler 
(model 480, Perkin·Elmer, Norwalk, CT) using the following conditions. After a 5 min 94 t1 C denaturation 
step, samples were subjected to 40 cycles of denaturation at 94°C for 1 min, annealing at 60"'C for 2 min, 
and extension at 72 t1C for 3 min. The last cycle was extended with 7 min at 72t1C. Positive control samples 
were produced by stimulating 10" human spleen cells with 1% phytohemagglutinin (PHA}·M (Ditco, Detroit, 
MI) for 4 h at 3rC. mRNA from this positive control was extracted as described above. Negative controls 
consisted of omission of template from the cDNA synthesis reaction for each biopsy followed by 
amplification in PCR with the IL-2, IL-2R (<<-chain), IL-4, IL-15, TCR-C~, and ~-actin primers, and the use 
of DEPC-treated·H20 as no-template reaction. After amplification, 16 pI PCR product was 
electrophoresed through 2% agarose gel, transferred to a Hybond·N+ membrane (Amersham, UK) by 
electroblotting, and hybridized with ynp labelled specifiC probes which are located across the splice·site. 
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Hybridization was detected by autoradiography and Indicated the presence of IL-2, IL-2R (a-chain), IL-4, 
IL-15, TCR-CB and B-actin mRNA expression In the original biopsy. 
Competitive template RT-PCR 
To determine the relative amount of functionallL-2R (a-chain), IL-15, and TCR-CB mRNA in EMB, a 
competitive RT-PCR assay was used and comparison was made against the house-keeping B-actin gene. 
This gene is assumed to be expressed at a constant level in EMS. To obtain a standard curve for IL-2R 
(a-chain), IL-15, TCR-CB and B-actin, known amounts of internal control fragment were added in different 
dilutions to constant amounts of sample eDNA for competitive amplification with specific primers. The 
internal control was designed to generate a peR product of a different size to allow differentiation between 
the amplified target and internal standard. Dilutions of the competitor template, ranging from 0.1 f9 to 5 
pg in 5 tll, were coampHfied with constant amounts of sample eDNA. After peR, under conditions identical 
to those described above, the amplification products were analyzed by gel electrophoresis, and the 
amount of products by the internal control and targets are determIned for each Individual reaction. The 
relative ethidium bromide intensity on gel was measured by lumInescence with a DC-40 camera in 
combInation with analysis software (Kodak, Rochester, NY). The logarithm of the ratio targeUinternal 
control is plotted as a function of the logarithm of the internal amount of the standard. At ratio 1, the 
starting concentration of IL-2R (a-chain), IL-15, TCR-CB and B-actin cDNA before PCR is assumed to be 
equal to the known starting concentration the competing internal control. The relative concentration of 
inlragraft IL-2R (a-chain), IL-15, and TCR-CB gene transcripts were divided by the relative concentration 
of B·actin. This represents the amount of Il-2R (a--chain), ll-15, and TCR-CB mRNA transcripts corrected 
for the amount of mRNA used for reverse transcription and the efficacy of each reaction. 
Statistics 
For the determination of levels of statistical significance, two-sided probability values according to Fisher's 
exact test or, If appropriate, the Mann Whitney U test were calculated. 
RESULTS 
Clinical data 
The baseline characteristics of the patients that entered this study are shown in table 
1. The BT563-treated patients from this study (group A) were similar to the patients in 
the control group (group B) in respect to all of these characteristics. 
The majority of recipients were male (82%), > 40 years of age (85%), and suffered from 
ischemic heart disease (65%). Most donors were < 40 years of age (83%). Donors and 
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recipients were not matched for cytomegalovirus (CMV) serology. CMV-positive donor 
I CMV-negative recipient combinations were equally distributed among the two groups. 
Table 1. Baseline characteristics of heart transplant recipients 
Group A (n-20) Group 8 (n=31) 
Age (median;range) 55 (36·64) 53 (14-65) 
Weight kg (median;range) 72 (58-91) 69 (34-114) 
Gender (M/F) 17/3 2516 
Etio!ogy heart disease: 
ischemic 12 20 
cardiomyopathy 7 7 
other 4 
Donor age yrs (median;range) 33 (13·43) 27 (14-45) 
Cold Ischemia lime (min.) 163 (119-240) 155 (107-260) 
Peripheral blood monitoring 
Within hours after the first dose of BT563, the IL-2R-bearing cells (CD25) in peripheral 
blood were covered by the antibody (figure 1). Peripheral blood lymphocytes remained 
negative for CD25 for the duration of BT563 adminstration and for a period of 3 to 21 
days (median, 7 days) thereafter. During this period CD122 (B-chain) remained 
present, showing continued presence of IL-2R positive cells, but with a coated <x-chain. 
BT563 trough levels reached a plateau phase after day 5, with mean trough levels of 
6144 (± 445) nglml. The half life of BT563 in blood, calculated from the descending 
part of the curves, using a one-compartment model, was 39 ± 3 hr. 
Clinical complications 
As a result of starting cyclosporine 6 hr after transplantation, we observed cyclosporine 
nephrotoxicity in 7/19 (37%) of patients. In all cases this was reversible, but temporary 
interruption (in most patients 12-36 hr) or reduction in cyclosporine administration was 
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necessary. No patient required renal replacement therapy for cyclosporine 
nephrotoxicity. Mortality in group A was 3/20 in the first 3 months. One patient died on 
postoperative day 1 as a result of severe hemorrhage from a ruptured suture. One 
patient suddenly died in the postoperative week 4 after having had a fever for more 
than a week, for which no clear cause could be found and for which broad-spectrum 
antibiotic treatment had been initiated. A third patient died 26 days post-transplantation, 
after having developed renal and hepatic failure in a situation of primary donor-organ 
failure from the first day after transplantation. In group B, 2/31 patients died, 1 as a 
result of hemorrhagic stroke on day 4, the other due to sepsis after several 
thoracotomies for tamponade on day 17. These 5 patients were excluded from the 
analysis of rejection-incidence. Infectious complications were evenly distributed 
between the two groups. Urinary tract infections (7/29 versus 5117), herpes 
hominis/zoster infections (7/29 versus 5117) and CMV disease (3/29 versus 2117) were 
most frequent. 
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Figure 1. Peripheral blood monitoring during 
the first 6 weeks after heart transplantation. 
The first dose of 8T563, given at day 0, results 
in a complete coverage of all CD25+ cells. The 
cells remain coated for the duration of 8T563 
treatment. The CD122 signal (IL-2R II-chain) 
is proof of the fact that BT563 does coat the 
IL-2R cx-chain (CD25) and not the II-chain. 
After BT563 levels drop to 0 uncoated «-
chains reappear. The strong decrease in the 
number of CD3+ cells reflects the effect of 
steroid treatment 
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Rejection 
Figure 2 shows the numbers of patients free from rejection at several intervals after 
transplantation. The number of patients with two or more acute rejection episodes in 
group A and B were 8/17 (47%) and 17/29 (59%), respectively. Anti-rejection treatment 
given in group A (n=17) included 23 courses of steroids and 7 courses of anti T-cel 
antibodies (all rATG). In group B (n=29) 30 steroid-courses and 19 anti-T eel antibody 
courses (15 rATG, 4 OKT3) were used. 
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Figure 2. Freedom from acute rejection 
after heart transplantation. All patients 
received prophylactic treatment with an 
anti-IL-2Receptor antibody (BT563). 
Group A was treated with cyclosporin 
from day 0, in group B cyclosporine 
treatment was started on day 3. 
From 15/17 patients of group A, serial EMB were analysed immunohistochemically 
(n=59 EMBs). In 13/59 EMBs, acute rejection was present; in 36/59 EMBs represented 
non-rejection (lSHLT grade 0, 1A, 1B, or 2). In the rejection biopsies, CD25+ cells were 
present in 7/13 (54%). However, CD25+ cells could also be found in 13/36 (36%) of 
non-rejection biopsies. Among the rejection biopsies, the presence of CD25+ cells was 
clearly influenced by the presence of BT563: during presence of circulating BT563 cells 
bearing CD25 were found in only 1/5 (20%) rejection-EMBs, whereas CD25+ cells were 
present in 6/8 (75%) of rejection-EMBs after BT563 treatment. Using the quantitative 
immunohistochemistry score, significant differences in presence of numbers of CD3 and 
CD8 positive cells were found in rejection biopsies taken during or after BT563 
treatment (figure 3). 
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Figure 3. Quantitative immunohistochemistry of biopsies with an acute rejection during or after BT563 
treatment. Significant differences between mean scores of biopsies during versus after BT563 treament 
were found for CD3 (p=O.04; Unpaired Student's t-test) and COB (p=O.004). 
RT-PCR analysis of the same EMBs showed the presence of intragraft mRNA 
expression for IL-2 and IL-4 during rejection in 8/13 (62%) and 9/13 (69%), respectively. 
In non-rejecting EMBs, IL-2 and IL-4 mRNA expression was found significantly less 
frequently: 8/35 (23%; p=O.001) for both. Circulating BT563 antibody influenced the 
expression of IL-2 mRNA in rejection biopsies: during BT563 IL-2 mRNA expression 
was found in 2/5 (40%) vs 6/8 (75%) after BT563 treatment. For IL-4, these 
percentages were 2/5 (40%) and 7/8 (88%). Messenger coding for the IL-15 gene was 
constitutively expressed in all EMBs, regardless of rejection-status. For B-actin, mRNA 
levels were comparable in EMBs during and after BT563 induction therapy (Mann-
Whitney U test). With competitive template RT-PCR techniques, the relative amount 
of functionallL-2R and TCR-CB mRNA compared against the house-keeping gene B-
actin were estimated. As shown in figure 4, rejection biopsies taken during BT563 
treatment contained a factor 3 to 4 less IL-2R mRNA than rejection biopsies that 
occurred after BT563 treatment. 
87 
TCR-cf3/B-actin I L-2R/.f3-actin 
100 100 
•• 
0 
~ • .~ 
'" 
c 10 ~ 10 • 
." • c • 0 
• 
." 
'l' 0 
.... • 
III ¥ co J, 
- • • co -~ • • a: • a: '" .. •• 0 ..J 
~ • • Q) 
• Q) 0.1 .2: > 0.1 
." 
'" '" 
0; ~ ~ 
0.01 0.01 
during BT563 after BT563 during BT563 after BT563 
Figure 4. Quantitative RT-PCR results showing a higher amount of IL-2R mRNA in acute rejection 
biopsies taken during 8T563 treatment compared to acute rejection biopsies taken after BT563 treatment. 
IL-15 mRNA expression was found in all rejection EMBs, irrespective of BT563 
treatment. Therefore, we performed quantitative RT-PCR analysis in order to detect an 
in vivo effect of BT563 on intragraft IL-15 mRNA levels. However, using the competitive 
template RT-PCR, we found comparable IL-15 mRNA levels in rejection EMB during 
and after BT563 treatment (figure 5). 
DISCUSSION 
In previous studies with the anti-IL-2R MoAb BT563, we showed that within 1 hr after 
the administration of BT563, no IL-2R a-chain positive cells can be detected in 
peripheral blood (20). Despite this clear effect of BT563 on peripheral blood 
lymphocytes, EMBs taken at the end of the prophylactic treatment period showed acute 
rejection in 13/29 (45%) patients of a previously performed study of prophylactic 
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treatment with this anti-IL-2R MoAb (group B) (11). In view of a study using BT563 
induction treatment after kidney transplantation, in which a significant decrease in the 
incidence of early acute rejections was found, and in view of data from animal 
experiments where a synergistic effect was found for the combination of cyclosporine 
and anti-IL-2R MoAbs, the patients from group A in this study received BT563 induction 
treatment combined with cyclosporine from day 0 after heart transplantation (9, 14,15). 
As is shown in figure 2, the incidence of acute rejection in group A was (non-
significantly) lower compared to that in group B. Again, acute rejections were found in 
the absence of IL-2R positive cells in peripheral blood. Immunohistochemistry of the 
rejection biopsies showed CD25+ cells in 7/13 (54%) EMBs. In the EMBs with rejection 
occurring during BT563 induction treatment, CD25+ cells were only present in 1/5 
(20%). Using RT-PCR on EMB material, we found positive IL-2 mRNA expression in 
8/13 (62%) of rejecting patients. In acute rejection EMBs during BT563 treatment, 
however, IL-2 mRNA could be shown in only 2/5 (40%). In contrast, 
immunohistochemistry of the EMBs of the patients in group B demonstrated the 
presence of CD25+ cells in 8/10 (80%) of these biopsies during acute rejection (21). 
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Figure 5. Relative mRNA levels are depicted as ratio of r.,-actin. Quantitative RT-PCR analysis showed 
comparable intragraft IL-15 mRNA levels in rejection EMS during and after BT563 treatment. 
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Clearly, the administration of cyclosporine from day 1 after transplantation has resulted 
in a stronger blockade of the IL-2 pathway. However, this also means that apparently 
blockade of the IL-2/IL-2R complex alone is not sufficient to prevent patients from 
rejecting allografts. This parallels the observation that IL-2 knock-out mice are capable 
of allograft rejection as well (22,23).Other cytokines apparantly take over the activation 
of the rejection cascade, demonstrating again the difficulties we experienced as a result 
of the redundancy of the cytokine network. Others have suggested IL-15 to be a 
potentially important cytokine in this respect (24). IL-15 and IL-2 have overlapping 
biological functions. IL-15 mediates ils function through the 11- and v-chain of the IL-2R 
and its own IL-15a chain (25). In contrast to IL-2 and IL-4, IL-15 is produced by 
macrophages and other non-T-cells. During cardiac rejection, these macophages 
(CD68+ cells) are abundantly present wilhin the graft, suggesting that IL-15 can 
participate in this process (figure 3). The MoAb we used was murine and non-
humanized. Whether our resulls would have been better had a humanized antibody 
been used is uncertain. Up to now, published data on humanized anti IL-2R MoAbs are 
scarce (26,27). Data presented at the 16~ annual meeting of the American Society of 
Transplant Physicians in Chicago in May 1997 showed excellent efficacy of these 
agents with respect to the prevention of acute rejection after kidney transplantation. We 
found effective blockade of the IL-2I1L-2R pathway wilh our MoAb. It is unlikely that 
blockade of this pathway by a humanized antibody would improve the results. However, 
there are indications that humanized antibodies do not only act through receptor site 
blockade, but also by destruction of activated T-cells by antibody dependent cytotoxicity 
(27). If that mechanism of action contributes strongly to the effects of humanized 
monoclonals that would explain their effectiveness in a redundant cytokine network. 
In conclusion, despite combining cyclosporine and an anti-IL-2R MoAb (BT563) from 
day 1 after heart transplantation, we found an acute rejection rate of 39% in weeks 1 
and 2. Most of these rejections occurred in the absence of activated lymphocytes 
expressing IL-2 and/or IL-2R. Apparently, other cytokines such as IL-15 have taken 
over the activation of the rejection cascade. 
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Chapter 6 
THE INTRAGRAFT CYTOKINE mRNA PATTERN REFLECTS THE 
EFFICACY OF STEROID ANTI-REJECTION THERAPY 
This chapter is based 00 articles published io: 
J Heart Lung Transplant 1996;15:1184-1193 
Carla C. Baan, Hubert G.M. Niesters, Aggie H.M.M. Balk, Bas Mochtar, 
Pieter E. Zondervan, and Willem Weimar 
Transplant Proc 1996;28(6):3239-3240 
Carla C. Baan, Hubert G.M. Niesters, Aggie H.M.M.Balk, Bas Mochtar, 
Pieter E. Zondervan, Teun van Gelder, and Willem Weimar 
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ABSTRACT 
We studied the effect of anti-rejection therapy on intragraft cytokine mRNA expres-
sion. Therapy consisted of 3 doses of 1 g of intravenous methylprednisolone (MP). 
We determined its effect on intragraft mRNA expression of immunoregulatory (/L-2, 
IL-4) and inflammatory cytokines (IL-1B, IL-6, TNF-a), and the high affinity IL-
2Receptor (IL-2R, p55 chain) in endomyocardial biopsy (EMB) specimens from 
cardiac allograft recipients. 
By reverse-transcriptase-polymerase chain reaction (RT-PCR) methods, we detected 
mRNA transcription for IL-2 in 56% of the pre-treatment EMB (n=16), for IL-4 in 31%, 
and for IL-6 in 56% of the specimens, and IL-2R, IL-1B, IL-6, TNF-a were constitu-
tively expressed. Individual cytokine mRNA profiles were not helpful in differentiating 
between rejections that proved to be either MP resistant (n=9) or MP sensitive (n= 7). 
After successful anti-rejection therapy, the overall intragraft mRNA expression was 
down regulated. None of the post-treatment EMB taken from six patients with MP 
sensitive rejections expressed the IL-2 gene, in contrast to 88% of the EMB obtained 
from eight patients with MP resistant rejections (p=0.005). Moreover, intragraft IL-4 
and IL-6 mRNA transcripts were hardly detectable (both 17%) in MP reversible 
rejections, but in ongoing rejections IL-4 mRNA expression was found in 62% 
(p=0.14), and for IL-6 in 88% of the EMB (p=0.03). Semiquantitative analysis showed 
that the intragraft IL-2R, IL-1B and TNF-a mRNA levels were lower in post-treatment 
EMB from MP reversible rejections than in EMB from MP irreversible rejections 
(p=0.03). 
Our data suggest that the efficacy of anti-rejection therapy with MP is reflected in 
intragraft cytokine mRNA profiles. 
INTRODUCTION 
Glucocorticosteroids (GC), like methylprednisolone (MP) are powerful immunosup-
pressive and anti-inflammatory agents routinely used to prevent and treat allograft 
rejection (1,2). However, many patients fail to respond to high dose Lv. systemic MP 
anti-rejection therapy (3). Nevertheless, more than 30 years after the introduction of 
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GC as anti-rejection therapy, its in vivo immunosuppressive action on events within 
the transplanted organ is poorly defined (4). Analysis of these events might provide 
more insight in the in vivo mode of action of steroids and may contribute to a better 
understanding of mechanisms controlling steroid resistant rejection episodes. 
In vitro studies have shown that GC inhibit the expression of cytokine mRNA from 
both lymphocytes (IL-2, IFN-y) and antigen presenting cells (IL-1, IL-6, TNF-a, [5-
10]). Also mRNA coding for the high affinity IL-2Receptor (IL-2R, p55 chain) is 
inhibited (11). GC bind to intracytoplasmatic receptors that translocate GC to the 
nucleus, where the steroids affect the glucocorticosteroid response element and/or 
activating protein-1 binding site (2,5,12). This blocks the transcription of cytokine 
genes, and the production of cytokines is suppressed. Analysis of intragraft mRNA 
expression by reverse-transcriptase-polymerase chain reaction (RT-PCR) methods 
showed that, after clinical heart transplantation, the inflammatory cy10kines (IL-11.\, 
IL-6, TNF-a), the immunoregulatory cytokines (lL-2, IL-4), and the high affinity IL-2R 
are upregulated in the transplanted organ during rejection (13-16). 
No clinical data are available on the in vivo inhibitory effects of anti-rejection therapy 
with MP at the transcriptional level of these cytokines within the transplanted organ. 
A different cytokine mRNA pattern may be expressed, or the baseline level of 
cytokine mRNA transcription may be different between steroid-sensitive and steroid-
resistant rejections. In patients with asthma or rheumatoid arthritis, steroid resistance 
has been associated with simultaneous production of IL-2 and IL-4 (17,18). Alterna-
tively, the differential effects of MP on the inhibition of the cytokine mRNA transcrip-
tion in vivo may underlie the immunosuppressive efficacy in rejection. We analyzed 
local cytokine mRNA expression by RT-PCR in endomyocardial biopsy specimens 
(EMB) before and one week after start of the first MP anti-rejection therapy. We 
measured intragraft mRNA expression of IL-2, IL-2R (p55 chain), IL-4, IL-11.\, IL-6, 
and TNF-a, and the expression of mRNA coding for the constant region of the 1.\ 
chain of the T-cell receptor (TCR-CI.\) in relation to the expression of the cellular 
house keeping keratin gene. 
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PATIENTS AND METHODS 
Heart transplant recipients 
Patients underwent transplantation between 1992-1994 and received early prophylactic immunosup-
pression with 8T563, a murine anti-interleukin-2 receptor monoclonal antibody (CD25, Biotest Pharma, 
Dreieich, Germany) or with OKT3 (Ortho Pharmaceutical Corp, Raritan, NJ). Maintenance Immunosup-
pressive therapy consisted of cyclosporin A (whole blood trough levels were kept between 350-500 
ng/ml in the first post-operative months) and low-dose steroids. No additional therapy was given. 
Rejection was histologically diagnosed in EMS according to the criteria of the International Society for 
Heart and Lung Transplantation (ISHLT, (19)). Rejection therapy was instituted in case of moderate 
rejection (i,e., diffuse inflammatory process and myocyte damage, ISHL T grade 3A). Anti-rejection 
therapy consisted of 1 g MP administrated intravenously on 3 consecutive days. Steroid resistant 
rejection was defined, after one course of MP by persistent inflammatory Infiltrates combined with 
myocy! damage of a similar or greater degree than that by which the diagnosis of cellular rejection was 
initially made. For the present stUdy, we analysed EMB from 16 patients before (pre-treatment) and 
one week after start of MP therapy (post-treatment control EM B). We only studied biopsy specimens 
obtained from the first acute rejection episode. We analysed one specimen before and one specimen 
after MP anti-rejection therapy from each patient. Post-treatment control EMB demonstrated seven 
rejecllons that were steroid sensitive and 9 that were steroid resistant. One patient died within 3 
months pTX from bacterial infection and was excluded from the analysis of the one year rejection 
incidence. 
RNA preparation and eDNA synthesis 
For RT-PCR analysis, EMB were snap-frozen in liquid nitrogen and stored at ·80°C. Messenger RNA 
extraction and transcription was performed as described previously (15,16). Briefly, total RNA was 
extracted from snap-frozen samples by a modification of the guanidinium method as described by 
Chomczynski and Sacchi (18). EMB were homogenized in 500 j.Jl 4 M guanidinium-isothiocyanate in 
the presence of 20 lJg poly A (Boehringer Mannheim, Germany). The solution was extracted once with 
phenol, phenol-chloroform-isoamylalcohol (25:24:1) and chloroform-isoamylalcohol (24:1), respectively. 
Total RNA was precipitated with 600 ~I 2-propanol and 35 ~I 3 M sodium acetate (pH 5.2) at -20°C for 
18 hours. Precipitates were pelleted at 10.000xg at 4°C and washed once with 500 III ice-cold 80% 
ethanol. Air-dried pellets were resuspended In 50 IJI diethylpyrocarbonate treated-H20. Total RNA was 
denaturated for 5 min at 80°C and then chilled on ice. First strand cDNA synthesis was performed from 
25 ~I of the isolated RNA with 0.25 ~g hexanucleotides (Promega Corporation, Madison, WI) and 
transcribed with 500 U Moloney murine leukemia virus (MML V) reverse transcriptase (Gibco-BRL, 
Gaithersburg, MD) at 42°C for 90 min in a total volume of 50 lJl. The reaction mixture contained of 10 
~15x MMLV-RT buffer (250 mM Tris-HCI pH 8.3, 15 mM MgCI" 375 mM KCI), 2.5 ~I dNTP (10 mM), 
200 U of RNAsin (Promega) and 5 ~I (0.1M) on. 
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PCR amplification and Southern blot analysis 
Sequence specific primers (Clontech Laboratories, Palo Alto, CAl were used for amplification of the 
human cytokine genes. The presence of T-cells was determined by amplification of the gene coding for 
the B chain constanl region of the TCR (15). PCR primers delecting transcripts for the human house 
keeping gene keratin were used as an internal control to monitor mRNA extraction and eDNA amplifi-
cation (15). All primers were located next to splice sites to be able to discriminate for mRNA only. For 
qualitative analysis, 5 ~I cDNA sample was added to 95 ~I PCR mixture containing 10 mM Tris-HCI pH 
8.3, 50 mM KCI, 1.5 mM MgCI" 0.2 mM of each dATP, dCTP, dTTP, dGTP, 2 U Taq DNA polymerase 
(Promega) and 50 pmal of 5' and 3' sequence specific primers. Each reaction mixture was overlaid with 
50 ~I mineral oil (Sigma, SI. Louis, MO) prior to PCR reacllon in a DNA thermal cycler (Biomed-60, 
Germany) under the following conditions. After a 5 min 94°C denaturation step, samples were sub-
jected to 40 cycles of denaturation at 94°C for 1 min, annealing at 60°C for 2 min, and extension at 
72°C for 3 min. The last cycle was extended with 7 min at 72°C. Positive control samples were 
produced by stimulating 10' human spleen cells with 1% phytohemagglutinin (PHA)-M (Difco, Detroit, 
MI) for 4 h at 3rC. Messenger RNA from this positive control was extracted as described above. 
Negative controls consisted of omission of reverse transcriptase from the cDNA synthesis reaction for 
each EMB followed by amplification in PCR with the complete range of cytokine primers, and the use of 
and diethylpyrocarbonate treated-H,o as no-template reaction. After amplification, 16 ~I PCR product 
was electrophoresed through 2% agarose gel, transferred to a Hybond-N+ membrane (Amersham, 
Aylesbury, UK) by electroblolling and hybridized with y"P labelled specific probes which are located 
across the splice-site (15). Hybridization was detected by autoradiography. EMS were screened for IL-
2, IL-2R (p55 chain), IL-4, IL-1B, IL-6, TNF-a and TCR-CB mRNA expression. 
Semiquantitative RT·PCR 
For semiquantitave analysis, cDNA samples were titrated (10-fold dilutions) and aliquots of each 
dilution were amplified using the conditions as described previously. The amount of target cDNA 
present was expressed as end point of the titration. Corrections were made for the integrity of the 
mRNA isolated and the efficiency of cDNA synthesis, which both may vary for each isolation. II was 
expressed as arbitrary mRNA eqUivalents, defined as the highest dilution showing positive Signal. To 
estimate the relative initial amount of mRNA in EMS, aliquots of titrated cDNA samples were amplified 
using specific primers for keratin to correct for the described variables. To determine the relative 
amount of TCR-CB, IL-2R, IL-1B, and TNF-a mRNA in EMB, the level of target mRNA was corrected 
for the expression of the keratin gene, which was assumed to be expressed In a constant level In the 
EMB. 
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KERATIN 
before, after control 
Figure 1. Comparison of keratin mRNA expression in EMS specimens from two patients before and 
after MP anti-rejection therapy and positive control (PHA-M activated spleen cells). Semiquantitative 
analysis of keratin mRNA expression in EMS obtained from a patient with a steroid-resistant first 
rejection episode (top) and from a patient with a steroid-sensitive first rejection episode (bottom). Lane 
1 through 4 keratin mRNA expression before MP-treatment: lane 1, undiluted DNA; lane 2, 10-fold 
diluted DNA; lane 3, 100-fold diluted DNA; lane 4, 1000-fold diluted DNA. Lane 5 through 8, keratin 
mRNA expression after MP treatment: lane 5, undiluted DNA; lane 6, 10-fold diluted DNA; lane 7, 100-
fold diluted DNA; lane 8, 1000-fold diluted DNA Lane 9 through 11 positive control, lane 9, undiluted 
DNA; lane 10, 10-fold diluted DNA; lane 11, 100-fold diluted DNA. Before and after MP treatment the 
tilres of keratin mRNA in different EMS derived from one patient were comparable, showing the 
integrity of the mRNA of these specimens. 
Controls 
To exclude interassay and intraassay variability, amplification of titrated DNA of PHA-M activated 
spleen cells were included in each assay. These control cells expressed all cytokines tested. Experi-
ments with a variation in the titre of more than one i0-fold dilution step of keratin or cytokine mRNA 
levels in the positive control were excluded. Relative yields of keratin mRNA were comparable between 
EMB taken before (n=16) and after (n=14) MP treatment, indicating an equivalent of intact mRNA 
isolated in each EMS. Before and after MP treatment we measured a median keratin level of 10 input 
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mRNA equivalents (ranged between 10 to 100 input mRNA equivalents; p=O.72, Mann Whitney U test). 
This indicated that MP had no effect on mRNA expression of the house-keeping gene keratin. More-
over, before and after MP treatment the difference in the titre of keratin mRNA between individual EMS 
derived from one patient varied not more then one dilution step, showing the integrity of the mRNA in 
these specimens (figure 1). The keratin mRNA levels were converted to equal arbitrary keratin mRNA 
equivalents in to verify that equal amounts of mRNA were compared. Relative amounts of initial TeR-
C~, IL-2R, IL-1~, and TNF-" mRNA in EMS were individually normalized to the corresponding keratin 
mRNA levels, which permitted more accurate comparison of these gene transcript levels, Cytoklne 
mRNA expression was analysed only in EMS with keratin mRNA expression. 
Statistical analysis 
For qualitative cytokine analysis, data were analysed by Fisher's exact test for small sample sizes. For 
semiquantitative analysis, the levels of cytokine expression were compared by use of the Mann 
Whitney U test. P-values ~O.05 were considered to be statistically significant. 
RESULTS 
Patient populations 
The baseline characteristics of the studied patients are shown in table 1. The time of 
occurrence of the first acute rejection episode was not significantly different between 
steroid-resistant and steroid-sensitive patients (p~ 0.05, Mann Whitney U test). 
Steroid-resistant patients had their first acute rejection at day 24 post-transplant 
(pTX, median: range 6 to 36) and steroid-sensitive patients at day 32 pTX (median: 
range 13 to 58). However, one year follow-up of these patients showed that rejection 
occurred in more patients in whom the first rejection episode was MP resistant and 
that in the same patient group the median number of rejection episodes was greater 
(p=0.04, Fisher's exact; p=0.01 Mann Whitney U, respectively; see table 1). During 
rejection only 2 of 16 patients were hemodynamically slighlly compromised; one 
patient in whom the rejection proved to be MP sensitive and one patient with an MP 
resistant rejection showed signs of congestion. In both patients echocardiography 
showed thickening of the left ventricular walls and signs of impaired diastolic func-
tion. None of the 14 other tested patients had evidence of diastolic dysfunction 
during the rejection episode stUdied. 
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Table 1. Characteristics of the patient groups with a steroid-sensitive or steroid-
resistant first rejection episode 
Characteristic Steroid sensitive Steroid resistant p.value 
Patient (n) 7 9 
Age. years (mean) 45 (range 14-62) 45 (range 25-61) NS 
Gender (mlQ 710 811 NS 
Primary disease 
Ischemic heart disease (n) 4 6 NS 
Cardiomyopathy (n) 3 3 NS 
Mismatch (mean ± SO) 
HLA-A 1.1±0.7 1.3 ± 0.7 NS 
HLA-B 1.7±0.5 1.6 ± 0.5 NS 
HLA-OR 1.4 ± 0.5 1.6 ± 0.5 NS 
Day of first rejection (median) 32 (range 13-58) 24 (range 6-36) NS 
Patients with recurrence 
of rejection (n) 3 9 0.04' 
Rejection incidence first year after 
transplantation (median) 1.8 (range 1-3) 3.7 (range 2-5) 0.01' 
NS, Not Significant 
lOne patient who died within 3 month of transplantation of infection was excluded from the analysis 
Intragraft mRNA expression in pre-treatment and post-treatment EMB spec i-
mens 
For all EMB (n=30) tested the results of intragraft mRNA expression are summarized 
in table 2 for patients with successful anti-rejection therapy and in table 3 for patients 
with ongoing rejection in their control biopsy. Representative examples of qualitative 
RT-PCR analysis of intragraft mRNA expression in pre-treatment and post-treatment 
EMB are shown in figure 2. 
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Flgur. 2. Southern btot analysis of RT·PCR amplified TCR·C~. Il-2R (p55 chain), Il-2, Il-4 Il-6, Il· 
11!, and TNF-a transcripts in EMB specimens before (lane 1) and after MP anti-rejection therapy (lane 
2), negative H20 control (lane 3), and in the positive control (PHA-M activated spleen cells; lane 4). 
Left, EMB specimens obtained from a patient with a steroid-resistant first rejection episode. Right, EMS 
specimens obtained a patient with a steroid-sensitive first rejection episode. 
With the data unstratified for the efficacy of MP therapy, we detected no differences 
between the expression of cytokine mRNA profiles of pre·treatment or post·treatment 
EMS. In pre·treatment EMS we measured in 56% (9/16) IL-2 mRNA expression 
versus 50% (7/14) in the post·treatment EMS. We detected IL-4 in 31% (5/16) and 
43% (6/14), respectively, and IL-6 in 56% (9/16) and 57% (8/14), respectively. Mes· 
sengers coding for TCR·Cj3, IL-2R (p55 chain), IL-1B, and TNF·a genes were also 
detectable in most of the post·treatment EMS (table 2 and 3). In an attempt to differ· 
entiate between mRNA expression levels of the persistently expressed genes, we 
performed semiquantitative RT·PCR analysis to estimate the relative initial amounts 
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of mRNA. Aliquots of 10-fold-diluted DNA samples were amplified with specific 
primers for keratin, TCR-Ci3, IL-2R (p55 chain), IL-1r.., and TNF-a. This 
semiquantitative analysis also showed no significant differences in intragraft TCR-
Ci3, IL-2R, IL-1r.., and TNF-a mRNA levels between pre-treatment and post-treat-
ment EMB. 
Analysis of intragraft mRNA expression in pre-treatment EMB specimens in 
relation to steroid anti-rejection therapy 
IL-2, IL-4 and IL-6 mRNA transcripts were expressed in a slightly higher proportion of 
EMB derived from grafts from patients with rejections that later proved to be MP 
irreversible compared to rejections that were MP sensitive. In these pre-treatment 
EMB obtained from patients that with steroid resistant rejections, we measured a IL-2 
mRNA signal in 67% of the EMB (6/9) versus 43% of the EBB (3/7) in the steroid 
sensitive rejections. For IL-4 44% (4/9) versus 14% (117) and for IL-6 67% (6/9) 
versus 43% (3/7) respectively (table 2 and 3). However, these differences did not 
reach statistical significance and therefore overall pre-treatment mRNA profiles were 
not predictable for the efficacy of anti-rejection treatment with MP. 
Analysis of intragraft mRNA expression in post-treatment control EMB speci-
mens in relation to steroid anti-rejection therapy 
When we analysed our results in relation to the efficacy of MP treatment as judged 
by the histological diagnosis of rejection in the control EMB, we found significant 
differences. After MP treatment, none (0/6) of the EMB taken from patients with MP-
sensitive rejections expressed the IL-2 gene, in contrast to 88% (7/8) of the EMB 
obtained from patients with MP-resistant rejections (p=0.005, table 2 and 3). More-
over, intragraft IL-4 and IL-6 gene transcripts were hardly detectable (both 17%) in 
the MP reversible rejections, but in the ongoing rejections IL-4 mRNA transcription 
was found in 62% of the EMB (p=0.14), and IL-6 was detected in 88% of the EMB 
(p=0.03). In post-treatment EMB, TCR-Ci3, IL-2R, IL-1r.., and TNF-a mRNA tran-
scripts were still detectable in most of the EMB (table 2 and 3), and consequently 
semiquantitative PCR analysis was performed. 
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Table 2. Messenger RNA expression of the constant region of the B-chain of the 
TCR (TCR-C!3), cytokines, and IL-2R (p55 chain) in EBB specimens before and after 
successful anti-rejection therapy with MP', as detected by Southern blot analysis of 
polymerase chain reaction-amplified DNA 
patient TCR-CP IL-2 IL,2R IL-4 IL-1B IL-6 TNF-c< 
before frea/ment 
Ve + + + + 
Ka + + + + + + + 
Ko + + + + 
Vr + + + + + + 
Fr + + + + + 
Ma + + + + + 
Pe + + + 
+/total 7f7 3/7 717 1/7 617 317 7f7 
after treatment 
Ve + + 
Ka + + + + 
Ko + + + 
Vr + + + + 
Fr + + + + + 
Ma + + + + + 
+/total 6/6 0/6 5/6 1/6 4/6 1/6 6/6 
/I successful anU·rejection therapy with MP: before treatment, EMS specimens with infiltrates and 
myocyte damage, rejection grade 3: after treatment; EMS specimens with or without infiltrates but 
without myocyte damage, rejection grade 0 and 1 according to Billingham et at (19) . 
. , no signal; +, positive signal 
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Table 3. Messenger RNA expression of the constant region of the l\-chain of the 
TCR (TCR-CIl), cytokines, and IL2-R (p55 chain) in EM8 specimens before and after 
unsuccessful anti-rejection therapy with MP", as detected by Southern blot analysis 
of polymerase chain reaction-amplified DNA 
patient TCR-Cp. IL-2 IL-2R IL-4 IL-1B IL-6 TNF-cx 
before treatment 
Ki + + + + + 
La + + + + + + + 
Be + + + + 
Ze + + + 
Kn + + + + + + + 
So + + + + + 
Ro + + + + + + + 
Wa + + + + + + + 
So + + + + + + 
+/lolal 9/9 6/9 9/9 4/9 8/9 6/9 9/9 
after treatment 
Ki + + + + + + + 
La + + + + + + 
Be + + + + + + + 
Ze + + + + + + 
Kn + + + + + + + 
So + + + + + + 
Ro + + + + + + + 
Wa + + + + + 
+/lolal 8/8 7/8 8/8 5/8 8/8 7/8 8/8 
fI unsuccessful antHejection therapy with MP: before and after treatment; EMB specimens with 
infiltrates and myocyte damage, rejection grade 3, according to Billingham et al. (19). 
~, no signal; +, positive signal 
In control post-treatment EM8 obtained from MP-reversible rejections we measured 
a significantly lower level of transcription for TCR-CIl. mRNA compared to MP irre-
versible rejections (p=O.03; figure 3). Comparison of intragraft IL-2R, IL-1l\, and TNF-
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a mRNA levels between MP-sensitive and -resistant rejections revealed significantly 
different mRNA levels in each instance (IL-2R, IL-1 Band TNF-a, p=0.03; figure 3). 
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Figure 3. Titres were normalized for keratin mRNA expression. After MP anti-rejection therapy the 
corrected transcript levels for TCR-CIl, IL-2R, IL-1f1, and TNF-a were significantly lower in EMS 
specimens of sensitive (8) rejections compared to MP resistant (R) rejections (p=O.03: Mann Whitney 
U test). 
DISCUSSION 
By the definition of persistent rejection after one course of MP, the overall incidence 
of resistance to steroid anti-rejection therapy in our heart transplant centre is 33% 
(3). One year follow-up of these patients showed that steroid-resistance was associ-
ated with recurrence of rejection later on. The development of steroid-resistant acute 
rejection was, however, not correlated with diastolic dysfunction of the transplanted 
heart. Clinically evident impaired graft function was only found in one of nine patients 
with a steroid-resistant first rejection episode. 
In the rejection process, cytokines produced by allograft infiltrating cells mediate and 
105 
regulate the immune response towards the transplantated organ. In an attempt to 
clarify the mechanisms responsible for steroid resistance, we measured cytokine 
mRNA profiles in EMB during rejection, before and after MP therapy was given. As in 
our previous studies, we found that mRNA of the cytokines IL-2 and IL-6 are 
frequently expressed in transplanted hearts during acute rejection (15,16). These 
data suggest that cells transcribing the IL-2 gene or the IL-6 gene (or both) playa 
significant role in the rejection process. During acute allograft rejection a substantial 
number of both Iymphocyles and monocytes infillrate the allograft (19,21). It is 
reasonably to assume that a significant part of IL-6 mRNA expression is derived from 
infiltrating monocytes. However, results of the current retrospective study of mRNA 
profiles in EMB during rejection suggest that cytokine mRNA expression patterns 
prior to the first gift of anti-rejection therapy cannot predict the outcome of steroid 
anti-rejection therapy. More importantly, we did find that the efficacy of MP anti-
rejection therapy is reflected by intragraft cytokine mRNA expression. Successful MP 
anti-rejection therapy resulted in an overall decrease of cytokine mRNA expression, 
but it was most prominent for IL-2 and IL-6. Intragraft mRNA expression in grafts with 
ongoing rejections remained upregulated or even increased. The inhibition of 
cytokine mRNA expression was accompanied by a significant decrease of TCR-C~ 
mRNA expression, which confirms the histopathological analysis of the post-
treatment control EMB. 
There are various possibililies for GC to exert their immunosuppressive effect. In 
vitro studies showed that GC can specifically suppress transcription of the IL-2 gene 
of activated T-cells by blocking two transcriptional control sites: the nuclear factor of 
activated T-cells and activating protein-1, both present at the promotor site of the IL-
2 gene (7,22,23). GC are also able to inhibit signal transduction through the IL-2R of 
activated T-cells which was shown by Paliogianni et al. in mitogen-stimulated 
peripheral blood mononuclear cells (24). GC may suppress T-cell activation through 
inhibition of the cytokine production by antigen presenting cells. In these cells GC 
bind to a specific intracellular steroid receptor, migrate to the nucleus at or near 5' 
flanking DNA of responsive genes, and directly inhibits cytokine gene transcription of 
the accessory cells (2,5). T-cells also have an intracellular steroid receptor, and 
consequently GC can directly affect T-cells through this pathway. After successful 
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MP treatment we found an overall down regulation of intragraft mRNA expression of 
itnmunoregulatory and inflammatory cytokines. In control post-treatment EMB, this 
was not observed in MP resistant rejections. An explanation could be a reduced GC 
receptor binding affinity of T-cells as has been described in association with a poor 
responses to systemic MP therapy in asthma (25). In vitro incubation of T-cells with 
the combination of IL-2 and IL-4 maintained glucocorticoid receptor binding affinity at 
a reduced level resulting in a diminished effect of MP on T-cell proliferation (17,25). 
In the current study, simultaneous intragraft IL-2 and IL-4 mRNA expression was 
only detectable in 117 (14%) of the EMB obtained from MP reversible rejections, in 
contrast to 4/9 (44%) EMB of the MP irreversible rejections. This suggests that also 
after clinical heart transplantation the combination of these cytokines might influence 
the glucocorticoid receptor binding affinity. Also interindividual variability of MP 
pharmokinetics has been reported (25,26,27). The occurrence of acute rejection was 
associated with short half-life of MP. This variability in pharmacokinetics could also 
contribute to a lack of immunosuppressive efficacy. 
Immunoregulatory (IL-2) and inflammatory (IL-6) cytokine genes were associated 
with allograft rejection. Results of cytokine mRNA profiles in the pre-treatment EMB 
suggested that cytokine patterns cannot predict the outcome of MP anti-rejection 
therapy. After MP treatment, intragraft cytokine mRNA expression profiles were 
significantly different between MP reversible and ongoing rejection episodes. In 
contrast to the ongoing rejections, MP reversible rejection was associated with a 
significant inhibition of intragraft cytokine and TCR-CI3 mRNA expression. The in vivo 
observation that MP inhibits the transcription of both immunoregulatory and 
inflammatory cy10kines within the transplanted organ confirms previous in vitro 
observations. We conclude that measuring intragraft cytokine mRNA profiles by the 
RT-PCR technique is an objective way to monitor the efficacy of MP anti-rejection 
therapy. 
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Chapter 7 
THE NATURE OF ACUTE REJECTION IS ASSOCIATED WITH 
DEVELOPMENT OF GRAFT VASCULAR DISEASE AFTER CLINICAL 
HEART TRANSPLANTATION 
This chapter is based on articles published in: 
J Heart Lung Transplant (in press) 
Carla C. Baan, Cecile T.J. Holweg, Hubert G.M Niesters, Teun van Gelder, 
Wendy M. Mol, Pieter E. Zondervan, Bas Mochtar, Aggie H.M.M. Balk, and 
Willem Weimar 
Transplant Proc 1997;29:2529-2530 
Carla C. Baan, Cecile T.J. Holweg, Hubert G.M Niesters, Teun van Gelder, 
Wendy M. Mol, Bas Mochtar, Aggie H.M.M. Balk, and Willem Weimar 
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ABSTRACT 
To determine mechanisms triggering graft vascular disease (GVD) after heart 
transplantation, we studied parameters reflecting both early and late intragraft 
allogeneic reactions. Using RT-PCR analysis, mRNA expression of IL-2, IL-4, IL-6, 
IL-10, IFN-y, PDGF-a, and TGF-B, was measured in endomyocardial biopsies 
(EMB) obtained from 34 recipients during the first acute rejection episode for 
rejectors (n=29) or at a comparable time post-transplant for non-rejectors (n=5), and 
at time of assessment of GVD by coronary angiography at one year (n=34). At time 
of assessment of GVD, mRNA expression of IL-2, IL-4, and IL-6 were hardly 
detectable, while messengers coding for IFN-y, IL-10, TGF-B, and PDGF-a genes 
were constitutively expressed. Moreover, intragraft mRNA patterns of cy10kines and 
growth factors between patients with GVD (n=17) or without GVD (n=17) were 
comparable. In contrast, during the first acute rejection episode a completely 
different pattern was found. Development of GVD was associated with IL-2 mRNA 
expression and not with the other cytokines analysed. IL-2 mRNA was present in 
77% of rejection EMB taken from patients with GVD versus 33% of the EMB from 
patients without GVD (p=O.03) and not detectable in EMB from non-rejectors. Also 
non-immunological risk factors such as longer ischemia time (median 193 vs 141 
min; p=O.002) and higher donor age (median 32 vs 23 y; p=O.02) were associated 
with GVD. But no relation was found between these non-immunologic risk factors 
and IL-2 positive acute rejections. Non-specific risk factors and IL-2 positive 
rejections may independently trigger GVD after clinical heart transplantation. 
INTRODUCTION 
Long-term results of clinical organ transplantation are strongly influenced by graft 
failure due to chronic transplant dysfunction also known as chronic allograft rejection 
(1,2). After heart transplantation, the chronic rejection process is manifested by 
inflammation followed by accelerated allograft arteriosclerosis named graft vascular 
disease (GVD). This chronic process is characterized by concentric narrowing of 
arterioles i.e. intimal thickening with proliferation of smooth muscle cells. Another 
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feature is the irregular thickening of the donor coronary wall that affects the entire 
length of the vessel including the small branches (3). The latter feature makes GVD 
accessible to diagnostic procedures through EMB. The pathogenic mechanism that 
triggers and maintains this chronic process is subject of many studies. Both humoral 
and cellular alloimmunity may cause chronic allograft rejection (4). Moreover, 
multiple non-immunological risk factors may also contribute to the development of 
GVD (4). Potential non-immunological risk factors include prolonged ischemia time, 
reperfusion injury, cyclosporin dosage, transplant size, lipid abnormalities, age and 
gender of the donor. Potential immunological contributors are HLA incompatibility, 
. CMV infection and disease, panel reactive antibody, and number and intensity of 
acute rejection episodes (4-7). During transplantation, ischemia and reperfusion 
damage cause injury to the endothelium of the transplanted heart (8). As a result of 
the non-specific injury activation of the complement and coagulation cascades takes 
place and damaged endothelial cells release various cytokines and growth factors 
(9-11). These soluble mediators (e.g. IFN-y, tumor necrosis factor-a, IL-1, IL-6, 
PDGF-a) stimulate smooth muscle cell proliferation contributing to the intimal 
thickening that produces obstructive lesions (10-12). Moreover, cytokines and 
growth factors are potent activators of monocytes/macrophages and vascular 
endothelium upregulate expression of HLA antigens and adhesion molecules, and 
promote T-cell adhesion (10). The upregulated expression of HLA class I and II 
antigens on endothelial cells increases the immunogenicity of the graft, thereby 
promoting allogeneic responses. Several immunological factors influencing the 
induction of GVD have been found in experimental studies. These studies show that 
early immune responses to the allograft are associated with chronic allograft 
rejection later on. Firstly, Nakagawa and colleagues demonstrated a direct relation 
between acute rejection and GVD in the cardiac rabbit model (13). Secondly, in the 
Lewis-to-Fisher F344 rat cardiac allograft model, Russell et al. found significant 
mRNA expression of IFN-y, monocyte chemoattractant protein-1 and IL-6 within the 
interstitium in the first weeks after transplantation (14). In the early period after 
transplantation, acute rejection is a severe immunogenic complication. A correlation 
between acute rejection and HLA matching has been extensively reported but the 
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effect of HLA matching on chronic rejection is controversial (15,16). Acute cellular 
rejection is attended with high intragraft production of cytokines (e.g. IL-2, IL-4, IL-6, 
IL-10, IFN-y) and growth-factors (basic fibroblast growth factor) produced by 
infiltrating T-Iymphocytes or macrophages (17-21). Libby et al. hypothesized that 
these cellular immune responses via the cytokine cascade trigger the development 
of GVD (22). However, despite numerous studies, the relation between acute 
rejection and the development of GVD after clinical heart transplantation remains 
controversial (6,7,23-25). Most of these studies related the number of acute rejection 
episodes with long-term graft survivaJ but did not characterize these early allogeneic 
immune responses in more detail. Acute rejection episodes are the result of various 
immunological responses that can be identified by different cytokine patterns. 
In the current study, we tried to associate these cytokine profiles accompanying 
acute rejections with the development of GVD. Therefore, intragraft mRNA 
expression of cytokines and growth factors involved in early and late immunogeneic 
immune responses were analysed. Using RT-PCR analysis, we measured mRNA 
expression of IL-2, IL-4 and IL-6 during acute rejection and at one year post-
transplant in endomyocardial biopsies (EMB) obtained from patients with and without 
GVD. In addition, the role of IFN-y, IL-10, PDGF-a, and TGF-B in the process of 
GVD was studied. Contribution of other risk factors on the development of GVD after 
clinical heart transplantation was also analysed. 
METHODS 
Patients 
We analysed mRNA expression of cytokines and growth factors in EMS obtained from 17 consecutive 
heart transplant patients with GVD lesions and 17 recipients (controls) without signs of GVD at one 
year after transplantation. Control patients were carefully matched for age, gender, date of 
transplantation (within 6 weeks), anti T-eel! induction therapy, and original disease. Table 1 
summarizes base-line characteristics of these patients at the time of transplantation. Patients were 
transplanted between November 1991 and August 1994 and received early prophylactic 
immunosuppression with BT563 (n=11), a murine anti-interleukln-2 receptor monoclonal antibody 
(CD25, 8iotest Pharma, Dreieich, Germany) or with OKT3 (n=22; Ortho Pharmaceutical Corp, Raritan, 
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NJ) or with rabbit ATG (n=1). Maintenance immunosuppressive therapy consisted of cyclosporin A 
and low~dose steroids. Acute rejection was histologically diagnosed and scored by the pathologist 
P.E.Z. in EMB according to the criteria of the International Society for Heart and Lung Transplantation 
(26). EMB are laken weekly during Ihe firsl6 weeks, biweekly during Ihe nexl monlh, monlhly for Ihe 
next four months and less often thereafter. Anti~rejection therapy was instituted in case of moderate 
rejection (multifocal aggressive infiltrates andlor myocyte damage, ISHL T grade ~ 3A). GVD was 
defined as all vascular wall changes, including minor irregularities, assessed by visual analysis of 
coronary angIography at one year post~transplant and had been routinely interpreted by the 
cardiologisl A.H.M.M.B. (6). For Ihe presenl sludy, we analysed EMB laken from 34 palienls allime of 
assessment of GVD at one year post~transplant and during their first acute rejection episode for the 
rejeclors (n=29) or al a comparable period posl-Iransplanl for Ihe non-rejeclors (n=5). 
RNA preparation and cDNA synthesis 
For RT-PCR analysis, EMB were snap-frozen in liquid nitrogen and stored at -80°C. Messenger RNA 
extraction and transcription was performed as described previously (17). Briefly, total RNA was 
extracted from snap-frozen samples by a modification of the guanidinium method, as described by 
Chomczynskl and Sacchi (27). EMB were homogenized in 50.0 ~I 4 moUl guanidinium-isothiocyanale 
in the presence of 20 iJg poly A (Boehringer, Mannheim, Germany). The solution was extracted once 
wilh phenol, phenol-chloroform-isoamylalcohol [25:24:1) and chloroform-isoamylalcohol [24:1), 
respeclively. Tolal RNA was precipitated with 600 ~I 2-propanol and 35 ~I 3 moUl sodium acelale (pH 
5.2) at -20°C for 18 hours. Precipitales were pelleted a110.000xg at 4°C and washed once wilh 500 ~I 
Ice-cold 80% ethanol. Air-dried pellets were resuspended in 50 iJl diethylpyrocarbonate treated-H20. 
Total RNA was denaturated for 5 min at 80°C and then chilled on ice. First strand DNA synthesis was 
performed from 25 ~I of Ihe isolaled RNA with 0.25 ~g hexanucleolides (Promega Corporalion, 
Madison, WI) and transcribed with 500 U Moloney murine leukemia virus (MMLV) reverse 
Iranscriplase (Gibco-BRl, Gaithersburg, MD) at 42°C for 90 min in a lolal volume of 50 ~I. The 
reaclion mixlure consisled of 10 ~I 5x MMlV-RT buffer (250 mmoUl Tris-HCI pH 8.3, 15 mM MgCI" 
375 mM KCI), 2.5 ~t dNTP (10 mM), 200 U of RNAsin (Promega) and 5 ~I (O.1M) OTT. 
PCR amplification and Soulhern blot anatysls 
Sequence specific primers (Clontech laboratories, Palo Alto, CAl were used for amplification of the 
human cytokine genes. PCR primers detecting transcripts for the human house-keeping gene keratin 
were used as an internal control to monitor mRNA extraction and DNA amplification. For qualitative 
analysis, 5 ~I DNA sample was added 10 95 ~I PCR mixture containing 10 mM Tris-HCI pH 8.3, 50 mM 
KCI, 1.5 mM MgCI" 0.2 mM of each dATP, dCTP, dTIP, dGTP, 2 U Taq DNA polymerase (Promega) 
and 50 pmol of 6' and 3' sequence specific primers. Each reaction mixture was overlaid with 50 J.l1 
mineral 011 (Sigma, st. louis, MO) prior to PCR reaction in a DNA thermal cycler under the following 
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conditions. After a 5 min 94°C denaturation step, samples were subjected to 40 cycles of denaturation 
at 94°C for 1 min, annealing at 60°C for 2 min, and extension at 72°C for 3 min. The last cycle was 
extended with 7 min at 72°C. Positive control samples were produced by stimulating 106 human 
spleen cells wilh 1% PHA-M (Difco, Detroit, MI) for 4 h at 37'C. Messenger RNA from this positive 
control was extracted as described above. Negative controls consisted of omission of reverse 
transcriplase from the DNA synthesis reaction for each EMS followed by amplification in PCR with the 
complete range of cytokine primers, and the use of and diethylpyrocarbonate treated-H20 as no-
template reaction. After amplification, 16 lJl PCR product was electrophoresed through 2% agarose 
gel, transferred to a Hybond-N+ membrane (Amersham, UK) by electrobloWng, and hybridized with 
y32p label/ed specific probes which are located across the splice-site. Hybridization was detected by 
autoradiography and indicated the presence of mRNA expression in the original biopsy. EMS taken 
during acute rejection were screened for IL-2, IL-4, and IL-6 mRNA expression and the one year EMS 
were analysed for cytokine mRNA expression of IL-2, IL-4, IL-6, IL-10, IFN-y, TGF-B and PDGF-«. 
Competitive template RT-PCR for keratin and IL·10 
To estimate the relative initial amount of fUnctional IL-10 in EMS, a competitive template RT-PCR 
assay was used and comparison was made against the house-keeping keratin gene. Keratin is 
assumed to be expressed at a constant level In EMS (28). To oblain a standard curve for IL-10 and 
keratin, known amounts of Internal control fragment were added in different dilutions to constant 
amounts of sample DNA for competitive co-amplification. The internal control was designed to 
generate a PCR product of a different size to allow differentiation between the amplified target and 
internal standard. Five and 10-fold dilutions of the keratin competitor template, ranging from 1 fg to 
1000 fg in 5 ~I, were co-amplified with 0.5 ~I aliquots of sample DNA. Following PCR, using condilions 
as described previously, the amplification products were analysed by gel electrophoresis and the 
amount of products by the internal control and targets are determined for each individual reaction. The 
relative ethidium bromide intensity on gel was measured by lUminescence with a DC-40 camera in 
combination with analysis software (Kodak, Rochester, NY). The logarithm of the ratio targeUinternal 
control is graphed as a function of the logarithm of the internal molar amount of the standard and at 
ratio 1, the starting concentration of keratin DNA prior to PCR is assumed to be equal to the known 
starting concentration the competing internal control. 
Statistical analysis 
The described immunologic and non-immunologic variables were selected, and the influence of these 
variables on the development of GVD was then assessed. For qualitative RT~PCR analysis, Fisher's 
exact test was used for small sample sizes. An unpaired Mann-Whitney U~test was used to define 
differences between continuous variables in subgroups. P. values ::;:0.05 were considered to be 
statistically significant. 
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Table 1. Baseline characteristics of 34 heart transplant recipients. 
gender age heart age Ischemic Induction 
recipient (y) disease donor (y) lime (min) therapy 
l'tilhGVD 
at I-year 
M 65 lHD 26 210 OKT3 
2 M 59 lHD 32 176 BT563 
3 M 
" 
CMP 32 240 8T563 
4 M 64 lHD 39 230 OKT3 
5 M 61 lHD 25 19B BT563 
6 M 56 lHD 20 147 8T563 
7 M 51 lHD 21 147 8T563 
8 F 62 lHD 35 210 OKT3 
9 M 51 CMP 44 220 OKT3 
10 M 60 CMP 35 170 OKT3 
11 M 44 lHD 33 210 OKT3 
12 M 59 lHD 42 230 8T563 
13 F 57 CMP 31 149 OKT3 
14 F 48 lHD 3B 193 8T563 
15 M 51 CMP unknown 178 OKT3 
16 M 58 lHD 24 138 ATG 
17 M 55 lHD 42 127 OKT3 
l'tithoutGVD 
a/I-year 
M 59 CMP 26 110 OKT3 
2 M 46 lHD 32 107 8T563 
3 M 51 lHD 17 135 OKT3 
4 M 60 lHD 41 142 OKT3 
5 M 64 lHD 24 125 8T563 
6 M 64 lHD 21 118 OKT3 
7 M 64 lHD 37 196 8T563 
8 M 61 lHD 21 160 OKT3 
9 M 41 lHD 25 106 OKT3 
10 F 45 CMP 20 210 OKT3 
11 M 33 lHD 23 150 OKT3 
12 M 25 CMP 23 120 OKT3 
13 M 54 CMP 3B 150 OKT3 
14 F 34 CMP 28 141 8T563 
15 M 58 lHD 15 152 OKT3 
16 M 14 CMP 16 190 OKT3 
17 M 61 CMP 23 140 OKT3 
y, years; min, minutes; M, male; F, female; IHD, ischemic heart disease; CMP, cardiomyopathy 
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RESULTS 
Intragraft mRNA expression at one year post·transplant 
Messenger RNA expression of the house· keeping gene keratin was chosen as a 
marker for the tolal quantity of mRNA extracted. No statistical difference was found 
in the amount of reversely transcribed DNA for keratin between biopsies obtained 
from patients with GVD (n=17) and those without GVD (n=17) at one year. For 
patients with GVD the level of keratin mRNA expression varied from 5 to 500 fg and 
for patients without GVD from 5 to 200 fg (p=0.61 Mann Whitney U·test). This 
indicated that an equivalent of functional mRNA was isolated, which is corrected for 
reverse transcription and the efficacy of each reaction. We analysed EMS derived 
from heart transplant recipients (n=34) at 1·year post-transplant, for the expression 
of IL·2 and IL-4, predominantly expressed by infiltrating lymphocytes, and IFN·y, IL· 
6, IL·10, TGF·I> and PDGF·a all produced by various cell types. A typical example of 
mRNA expression 1 ·year after transplantation is shown in figure 1. 
Figure 1. Expression of mRNA of keratin, cytokines and growth factors in an endomyocardial biopsy 
(EM B) obtained from a patient with graft vascular disease (GVO) at one year post-transplant. DNA 
was amplified by peR and the products were electrophoresed on an agarose gel stained with ethidium 
bromide. In this EMS, peR products of predicted size were observed for the house~keeping gene 
keratin, and for the cytokines IL-6, IL-10 and IFN-y, and the growth-factors POGF-a and TGF-B. 
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Figure 2. Analysis intragraft mRNA expression of the cytokines ILR 2, IL-4, IL-6 and IL-10 and the 
growth factors, IFN-y, PDGF-o, and TGF-r1 at time of assessment of graft vascular disease (GVO) by 
coronary angiography at one year after heart transplantation. Data are expressed as the percentage of 
specimens containing mRNA coding for the above mentioned genes. No significant differences were 
found between patients with GVO and those without. None of the mediators analysed was 
discriminatory for GVD (p>O.05). 
At time of assessment of GVD, we found that mRNA expression of IL-2, IL-4, and IL-
6 were hardly detectable while messengers coding for IFN-y, IL-10, TGF-B, and 
PDGF-a genes were constitutively expressed. Intragraft mRNA expression of IL-2 
was present in 12% (4/34), IL-4 in 3% (1/34), and IL-6 in 15% (5/34) of the EMS. 
The intragraft mRNA profiles of the tested cytokines and grow1h-factors between 
patients with GVD (n=17) or without GVD (n=17) were comparable (figure 2). In 
addition, the level of IL-10 mRNA transcripts was comparable between both patient 
groups (figure 3). For patients with GVD the IL-10 (fg)/keratin (fg) ratio varied from 
0.002 to 0.128 and for patients without GVD from 0.001 to 0.787 (p=0.76). 
Intragraft mRNA expression during first AR episode 
Early periods post-transplant (median 23, range 6-337 days post-transplant) from 
both rejectors and non-rejectors Were studied and results were related to GVD later 
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on (table 2). From 4 out of 5 non-rejectors, EMB were analysed for the presence of 
IL-2, IL-4 and IL-6 mRNA expression. These EMB were collected between 24-32 
days after transplantation. In these specimens neither IL-2 nor IL-4 mRNA 
expression was detectable but IL-6 mRNA transcripts were present in 3 out of 4 
EMB tested. Twenty-nine out of 34 recipients were treated for acute rejection within 
the first year after transplantation (table 2). From 1 out of these 29 rejectors no first 
rejection EMB was available for analysis. We measured intragraft mRNA expression 
of IL-2, IL-4, and IL-6 in EMB (n=13) from patients with GVD and in EMB (n=15) 
from patients without GVD. During their first acute rejection episode, the intragraft 
cytokine mRNA profiles were significantly different between patients who were found 
to have or have no coronary GVD lesions at one year post-transplant. Analysis 
showed that development of GVD was associated with IL-2 mRNA expression 
during early acute rejection (figure 4). Intragraft IL-2 mRNA expression was present 
in 77% (10/13) of the EMB from patients with GVD at one year vs only 33% (5/15) of 
the EMB from patients without GVD (p=0.03). Development of GVD was not related 
to early intragraft mRNA expression of IL-4 or IL-6. 
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Immunologic and non-immunologic risk factors 
Flgur. 3. IL-10 eDNA I keralin eDNA 
ratio in endomyocardial biopsies 
(EMS) obtained from palients with 
graft vascular disease GVD (GVO+) 
or without GVD (GVD-) one year 
after heart transplantation. 
Patient demographics, stratified according to patients with and without GVD at 1-
year are shown in table 1 and 2. Of the non-immunologic risk factors, both higher 
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donor age and longer ischemic time were posilively correlated with the development 
of GVD at one year (table 1). Recipients with GVD were transplanted with older 
donor hearts (median 32 y, range 20-44 y vs median 23 y, range 15-41 y; p=0.02) 
and had longer ischemia time (median 193 min, range 127-240 min vs median 141 
min, range 106-210 min; p=0.002). For patients with and without GVD the 
triglyceride levels were comparable: median 1.82 mmol/L, range 0.71-6.95 mmol/L 
and 2.13 mmol/L, range 1.03-4.25 mmol/L, respectively. 
100 I!IIIGVD+ l1li GVD-
II) 80 p=O.03 Q) 
'iii 
0. 
0 60 :0 
Q) 
€ 40 II) 
0 
0. 
'*' 
20 
0 
IL-2 IL-4 IL-6 
Figure 4. Cytokine mRNA analysis in rejection EMB from patients with (n=13) and without (n=15) 
angiographic evidence of graft vascular disease (GVO) at 1~year after heart transplantation. Data are 
expressed as the percentage of specimens containing mRNA for ILw 2, IL-4 or IL-6. The proportion of 
rejection EMS expressing IL-2 mRNA was significantly higher in patients with GVD compared to 
patients without GVD (p=O.03, Fishe~s exact). Development of GVD was not correlated with early 
intragraft mRNA expression of IL-4 and IL-6 (p>O.05). 
However, none of the immunologic dependent risk factors analysed, including 
number of HLA mismatches, panel reactive antibody at time of transplantation, CMV 
serology of donor/acceptor, day of first rejection, and number of acute rejection 
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episodes during the first year after transplantation, was found to be associated with 
an increased risk of developing GVD (table 1 and 2). 
Table 2. Immunologic risk factors for graft vascular disease (GVD) at i-year. 
HLAMM PRA CMV serology first rejection acute rejection 
patient (N) (%) d/r (days) (N) 
wifhGVD 
at f-yee( 
1 6 0 -1- 0 
2 4 0 -1- 19 
3 6 0 -1+ 0 
4 5 0 -1- 30 3 
5 5 0 -1+ 7 3 
6 6 0 -1+ 6 3 
7 5 0 -1- 19 3 
8 4 0 +1+ 0 
9 5 0 +1+ 67 5 
10 5 3 +1+ 34 1 
11 4 19 +1- 24 4 
12 5 4 -1+ 59 
13 2 5 +/- 29 5 
14 3 0 +/- 7 4 
15 5 NO -/- 36 4 
16 3 NO -/+ 36 3 
17 4 0 +1- 31 4 
withoul GVO 
a/1-yeef 
1 5 0 NO/+ 60 1 
2 4 0 +1+ 7 4 
3 4 0 -/+ 0 
4 4 0 -/+ 337 
5 5 3 ./+ 16 4 
6 5 0 NO/+ 7 3 
7 3 4 +/- 0 
8 4 0 NO/+ 24 3 
9 4 5 +/- 23 3 
10 6 0 +/+ 23 
11 5 0 -/+ 24 4 
12 4 4 ./- 16 5 
13 4 90 -/- 57 1 
14 6 15 +/- 6 5 
15 3 0 -/+ 23 2 
16 6 0 -/- 13 2 
17 6 0 +/+ 17 4 
GVD, graft vascular disease; MM, mismatches; PRA. panel reactive antibodies at time of 
transplantation; CMV, cytomegalovirus; N, number; d, donor; r, recipient; NO, not determined; 
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Relation between non-immunologic risk factors and Intragraft IL-2 mRNA 
expression 
The above described data show an association between intragraft IL-2 mRNA 
expression, longer ischemia time and higher donor age with development of early 
GVD. Nevertheless, it is evident that some data overlap between patients with and 
without GVD at one year. For instance, patients with short ischemia time can 
develop GVD at one year while intragraft IL-2 mRNA expression is not always found 
in patients with vascular lesions. Therefore, we analysed the interaction between 
non-immunologic risk factors and intragraft IL-2 mRNA expression (figure 5). In the 
IL-2 negative group, the data are clear, development of GVD was significantly 
associated with both prolonged ischemia time and higher donor age (A and C, 
p<0.01 and p<0.05, respectively). In the IL-2 positive group, this association is less 
pronounced. It seems that patients who received a transplant with relatively short 
ischemia time also develop GVD when the acute rejection is associated with 
intragraft IL-2 mRNA production (B). This suggests that non-immunologic risk factors 
and IL-2 positive acute rejections are independent risk factors involved in GVD 
development. 
DISCUSSION 
At our center, the angiographic incidence of GVD when even the smallest vessel 
wall irregularities are taken into account is 26 % at one year accumulating to 87 % at 
8 years post-transplant. Accordingly, intima thickening is an ongoing process that 
eventually leads to complete obstruction of the coronary arteries resulting in graft 
dysfunction. Using the sensitive intravascular ultrasound technique, the prevalence 
of GVD was even higher (29). GVD can be detected not only in coronary vessels but 
also in the smaller intra myocardial vessels, present in EMB, reflecting a more 
generalised vascular lesion in the graft (3,30). 
In the present study, we have examined the contribution of immunological and non-
immunologic factors to the development of GVD after clinical heart transplantation. 
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Figure 5. Analysis of the Interaction between non-immunologic and immunologic factors in relation to 
development of early graft vascular disease (GVO). In the absence of intragraft Il-2 mRNA 
expression, both prolonged ischemic time (A) and higher donor age (C) were associated with 
development of GVD at one year (p<O.01 and p<O.05, respectively, Mann Whitney U test). In contrast, 
in the presence of intragraft IL-2 mRNA expression, no significant relation between ischemia time (B) 
and donor age (D) was found (p>O.05). 
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Analysis of 17 consecutive heart transplant recipients with GVD and 17 controls 
without GVD at one year, showed that both non immunological an immunological 
factors are associated with the development of GVD. 
Older donor hearts, longer ischemia time and intragraft mRNA expression of IL-2 
during the first acute rejection episode correlated with diagnosis of GVD at one year 
post-transplant. Recently, conflicting data were reported concerning the contribution 
of donor age on the development of GVD (6,7,25,29,31). In the study reported by 
Drinkwater et aI., the 5 years incidence of GVD was comparable between patients 
who received hearts from donors older or younger than 45 years (31). Previously 
and in the present study, we found that development of GVD is associated with 
higher donor age (6). This is in line with data by Mehra et al (7), by Young et al (25) 
and by Rickenbacher et al (29). Apparently, older donor hearts are more vulnerable 
for factors that may initiate GVD. The ischemia time in patients with GVD was 
significantly longer compared to ischemia time in patients who remained free from 
GVD. It is known that ischemia causes damage to the endothelium of the graft (8). 
Yilmaz et al. clearly showed, in rat renal allografts, that prolonged ischemia time 
resulted in vascular arteriosclerosis (32).The response to injury hypothesis proposed 
that injury to the endothelium is the initiating event in atherosclerosis (33,34). 
Damaged endothelial cells release basic fibroblast growth factor, macrophage 
chemoattractant protein-1, IFN-y, IL-6 and PDGF (10,22,35) These multifunctional 
mediators contribute to smooth muscle cell proliferation. Shortly after 
transplantation, infiltrating macrophages are seen in both allo- and isografts, 
reflecting a general, non-immunological repair mechanism (36). In allografts 
upregulation of macrophage chemoattractant protein-1, IFN-y, and IL-6 mRNA 
transcripts is associated with macrophage activation (14). Macrophage 
chemoattractant protein-1 induces cellular infiltration into inflammatory sites. 
Characteristic for GVD after heart transplantation is the selective involvement of the 
eng rafted heart arteries with sparing of the host's native vessels, indicating that 
immunological mechanisms are involved in the pathogenesis of GVD (3). Repetitive 
endothelium injury by immunologically mediated responses contributes to the 
development of GVD (37). IFN-y secreted by the damaged endothelial cells, as a 
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result of ischemia, increases the expression of adhesion molecules and HLA 
antigens on endothelial cells. These cells are then targets for immune mediated 
injury, thereby promoting cellular allograft rejection. Furthermore, histocompatibility 
differences between donor and recipient influence the incidence of acute rejections 
(15,38), which in turn, are often associated wilh accelerated development of GVD 
(23,24). In the current study, the number of HLA mismatches, the day of first 
rejection and the number of acute rejection episodes were not correlated with 
development of GVD at one year. In contrast to transplantation of other organs, the 
diagnosis of acute rejection after clinical heart transplantation is solely based on 
routine histology and not on graft function. In liver transplantation, histological signs 
of acute rejection may be accompanied by a deteriorating as well as with a 
improving graft function (39). This discrepancy is reflected in the intragraft mRNA 
cytokine pattern found. Liver graft dysfunction is associated with intragraft IL-2 
mRNA expression while down-regulation of this immune response is mediated by 
locally produced IL-4. Also after heart transplantation the infiltrating cells may 
secrete different cytokines that determine the nature and the intensity of the 
rejection. To identify these factors we evaluated mRNA expression of IL-2, IL-4 and 
IL-6 in EMS obtained from rejectors during their first acute rejection episode and in 
EMS from non-rejectors taken at comparable period post-transplant. Only intragraft 
IL-2 mRNA expression correlated with GVD (p=0.03, figure 4). Intragraft IL-2 mRNA 
transcripts were not detectable in EMS obtained from the non-rejectors one-month 
after transplantation. Recently, we also reported that in vitro production of IL-2 and 
IFN-y by graft infiltrating T-Iymphocytes during the first 6 months after 
transplantation correlated wilh GVD at one year (40). Also Young et al. suggested a 
relation between the IL-2I1L-2receptor pathway and development of GVD (41). The 
prominent role for IL-2 and IFN-y in the pathogenesis of GVD was already 
hypothesized by Libby et al. who postulated that IL-2 and IFN-y might trigger a wave 
of macrophage-derived cytokines that subsequently could induce smooth muscle 
cell proliferation (22). In our patient population, additional analysis showed no 
relation between prolonged ischemia time or older donor hearts and intragraft IL-2 
mRNA expression (figure 5). These results suggests that non-immune risk factors 
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and IL-2 positivity are two independent mechanisms both leading to early GVD. But 
it does not exclude the possibility that in individual patients endothelium damage by 
these non-specific factors induce intragraft IL-2 mRNA expression which in turn 
triggers GVD. Nevertheless, also patients without acute rejections will develop GVD 
which indicates that other factors such as humoral alloimmunity might be involved in 
the pathogenesis of this disease as well (42). At time of assessment of GVD by 
coronary angiography at one year, the intragraft mRNA profile of cytokines (IL-2, IL-
4, IL-6, IL-10, IFN-y) and growth factors (TGF-B, PDGF-o), and also the level of 
cytokine mRNA expression (e.g. IL-10) was comparable between patients with and 
without GVD. Apparently events prior to the diagnosis of GVD playa role in its 
pathogenesis. In the early period after transplantation, grafts experience endothelial 
injury as a consequence of ischemic damage and allogeneic reactions. This is 
associated with an increased local production of various cytokines and growth 
factors, the pattern of which may determine the rapidity of the progression to GVD, a 
complication eventually affecting almost all heart transplant patients. 
In conclusion, this study links early non-immunologic and immunologic events with 
accelerated development of GVD. Our data show that prolonged ischemia time, 
higher donor age and IL-2 positive allogeneic reactions are associated with early 
development of GVD after clinical heart transplantation. 
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Chapter 8 
INTRAGRAFT IL-4 mRNA EXPRESSION IS ASSOCIATED WITH 
DOWN-REGULATION OF LIVER GRAFT REJECTION 
This chapter is published in: 
Clin Transplantation 1996;10:542-549 
Carla C. Baan, Herold J. Metselaar, Wendy M. Mol, Huug W. Tilanus, 
Jan M.N. IJzermans, Pieter E. Zondervan, Solko W. Schalm, 
Hubert G.M. Niesters, and Willem Weimar 
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ABSTRACT 
The mechanism underlying spontaneously resolving allograft rejection following 
clinical liver transplantation is unidentified. In this process, immunoregulatory T 
helper (Th)-2 cytokines like IL-4, often identified with down-regulation of the Th1 
dependent (IL-2) cell mediated response, might playa significant but unknown role. 
For this reason, we analysed mRNA expression by reverse transcriptase-
polymerase chain reaction (RT-PCR) in 57 biopsies derived from 19 recipients. 
Specimens included biopsies without evidence of rejection (n=36), biopsies with 
histological evidence of rejection (n=10) not followed by clinical signs of graft 
rejection, and biopsies with histological rejection that were accompanied with clinical 
rejection (n=11), defined by rising serum bilirubin and aspartate amino transaminase 
(ASAT) levels. Intragraft IL-4 mRNA expression significantly correlated with 
spontaneously resolving rejections. In 70% (7/10) of these biopsies, IL-4 mRNA was 
detectable while only 19% (7/36) of the biopsies without signs of rejection (p<0.01; 
Fisher's exact test) and 18% (2/11) of the rejection biopsies concurrent with graft 
dysfunction expressed the IL-4 gene (p=0.03). In contrast, IL-2 mRNA expression 
was not detectable in biopsies derived from the spontaneously resolving rejections. 
None (0/10) of these samples expressed the IL-2 gene which was not significantly 
different from the proportion of biopsies transcribing the IL-2 gene in the absence of 
rejection (11 %, 4/36). IL-2 mRNA expression was found more often in biopsies 
associated with graft dysfunction (36%, 4/11). These results show that IL-4, in 
contrast to IL-2 mRNA expression, is associated with spontaneously resolving liver 
rejection. This suggests that Th2 cells down-regulate the Th1 dependent cell 
mediated immune response after clinical liver transplantation. 
INTRODUCTION 
Acute cellular rejection is a common phenomenon after liver transplantation (1-5). 
The histological hallmark of acute cellular rejection is a combination of three 
characteristic features: (1) predominantly mononuclear portal inflammation; (2) bile 
duct inflammation and/or damage; and (3) subendothelial localization of 
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mononuclear cells in the portal and central veins (2,4). In most cases, these 
histological signs of rejection are associated with clinical signs of rejection, e.g. 
changes in the amount and colour of bile together with biochemical evidence of 
deteriorating liver functions (1-3). However, from routinely performed biopsies it is 
known that histologic signs of rejection not always correlate with a deranged liver 
function, necessitating additional immunosuppression (1-3). The cellular infiltration 
observed during the first weeks after transplantation may in some instances be self-
limiting and has no implication for ongoing or future graft damage (3-5). 
Characterization of these spontaneously resolving mononuclear cellular infiltrates 
could learn us more on the immunological processes leading to graft acceptance 
and would also be helpful in deciding when to refrain from or to initiate anti-rejection 
therapy. The rejection process is caused by a population of T cells that infiltrate the 
transplanted organ. The interaction between infiltrated activated cells and the 
allograft is mediated and regulated by locally produced cytokines. The graft can be 
infiltrated with functionally distinct subsets of T helper cells, termed Th1 and Th2, 
defined by their cy10kine repertoire (6-8). Th1 cells produce e.g. IL-2, IFN-y, TNF-a, 
TNF-J1, whereas Th2 cells produce e.g. IL-4, IL-5, IL-6, IL-10. After transplantation, 
the occurrence of graft rejection is primarily associated with increased production of 
Th1 cytokines (e.g. IL-2, IFN-y) while Th2 (e.g. IL-4, IL-10) cytokines may suppress 
allograft rejection (9-11). These Th2 cytokines down-regulate the cell mediated 
immune responses by inhibition of the production of Th1 cytokines (12-14). 
Therefore, it could be envisaged that also after clinical organ transplantation, locally 
released Th2 cytokines could prevent graft destruction by ameliorating allogeneic 
reactions. Detection of Th2 cytokines in grafts with spontaneously resolving 
histological signs of rejection would be compatible with this hypothesis. 
Several clinical studies have analysed the intragraft cytokine mRNA patterns (15-17) 
or cytokine protein production (18, 19) in liver biopsies. However, these reports were 
mainly focused on histological features of acute liver rejection, irrespective of the 
clinical outcome. In order to further understand the mechanisms involved in the so-
called self-limiting liver graft rejection, we analysed expression of IL-2 (Th1) and IL-4 
(Th2) mRNA, using the RT-PCR technique, within liver allografts showing 
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histological signs of rejection with and without clinical signs of rejection. 
MATERIALS AND METHODS 
Patient specimens 
Archival post-transplantation liver biopsy specimens (3-512 days post-transplant) from 19 patients (7 
males and 12 females) transplanted between 1991 and 1993 were selected. From these patients one 
or more biopsies were available for RT~PCR analysis. The primary indications for liver transplantation 
were acute liver failure (n=7), cholestatic liver disease (n=7), posthepatic liver disease (n=2), post 
alcoholic liver disease (n-=2), cryptogenic liver disease (n=1). Graft biopsies were taken according 
protocol or on indication in case of deteriorating liver function (table 1 n=21, and table 2 n=37). 
Immediately following procurement, a portion of each biopsy was snap-frozen In liquid nitrogen and 
stored at -80"C for RT-PCR analysis. The biopsy specimens were processed In standard fashion, 
stained with haematoxylin and eosin, periodic acid-Schiff, and Iron and had been routinely interpreted 
by the pathologist P.E.Z. For the present study, the biopsy specimens were reviewed by P.E.Z. and 
H,J.M, both blinded to clinical Information, All samples were obtained from patients who had received 
a HLA-mismatched cadaver donor liver. Standard Immunosuppression consisted of azathioprine, 
cyclosporin A and low-dose methylprednisolone. Biliary reconstruction was performed with aT-tube 
and bile was inspected daily to assess its quantity and quality. 
Management of rejection 
A clinical diagnosis of rejection was suspected and considered likely if: (1) there was an increase in 
bilirubin andlor transaminases in successive days; (2) there was a decrease in the amount and colour 
of bile; and (3) other events were excluded radiologically, microbiologically or virologically. Cellular 
rejection was reported according to the Snover criteria [2J. In brief, grade 0, lymphocytic or mixed 
portal infiltrate, < 50% damaged bile ducts, no endothelialitis; grade 1, as above, with endothelialitis; 
grade 2, lymphocytic or mixed portal infiltrate, > 50% damaged bile ducts, with or without 
endothelialitls; grade 3, acute rejection plus arteritis, paucity of bile ducts, or central hepatocellular 
ballooning with confluent dropout of hepatocytes. Treatment for acute cellular rejection was given If the 
clinical diagnosis was conside~ed to be probably correct and If there was histological evidence of 
cellular rejection. Patients received methylprednisolone for treatment of acute rejection at a dosage of 
1000 mg/day for 3 consecutive days and OKT-3 monoclonal antibodies for steroid-resistant or severe 
rejection. 
mRNA preparation and eDNA synthesIs 
Messenger RNA extraction and transcription was performed as described previously (20). Briefly, we 
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used a modification of the guanldinium method as described by Chomzynski and Sacchi (21). Total 
RNA was extracted from snap~frozen samples. liver tissue was homogenized In 500 ~I 4 M guanidine 
thiocyanate in the presence of carrier mouse 3T3 cells (ATCC, Rockville, MD) as described before 
(20). These carrier cells are not recognized by the primers used in the RT~PCR. The solution was 
extracted once with phenot, phenot-chloroform-isoamylalcohol [25:24:11 and chloroform-
isoamylalcohol124:11 respectively. Total RNA was precipitated with 600 ~I 2-propanol and 35 ~I 3 M 
sodium acetate (pH 5.2) at -20°C for 18 hours. Precipitates were pelleted at 10.000xg at 4°C and 
washed with 500 ~I ice-cold (_80°C) 80% ethanol. Air-dried pellets were resuspended in 50 ~I 
diethylpyrocarbonate treated-H,O_ Total RNA was denaturated for 5 min at 80°C and then chilled on 
ice. First strand cDNA synthesis was performed from 25 ~I of the isolated RNA with 0.25 ~g 
hexanucleotides (0.5 ~gl~l; Promega Corporation, Madison, WI) and transcribed with 2.5 ~I Moloney 
murine leukemia virus (MMLV) reverse transcriptase (200 U/~I; Gibco-BRL, Gaithersburg, MD) at 
42"C for 90 min in a total volume of 50 fJl. The reaction mixture contained 10 IJI 5x MMLV~RT buffer 
(250 mM Tris-HCI pH 8.3, 15 mM MgCI" 375 mM KCI), 2.5 ~I dNTP (10 mM) 0.5 ~I of RNAsin (400 
U/~I; Promega) and 5 ~I Dn (0.1 M). 
peR amplification and Southern blot analysis 
Sequence specific primers (Clontech laboratories, Palo Alto, CAl were used for amplification of the 
human cytokine genes. PCR primers detecting transcripts for the human keratin gene were used as 
an internal control to confirm successful RNA extraction and cDNA amplification (20). All primers were 
located next to splice sites to be able to discriminate for mRNA only. For qualitative analysis, five IJI 
cDNA sample was added to 95 ~I PCR mixture containing 10 mM Tris-HCI pH 8.3, 50 mM KCI, 1.5 
mM MgCI" 0.2 mM of each dATP, dCTP, dnp, dGTP, 2 U Taq DNA polymerase (Promega) and 50 
pmol of 5' and 3' sequence specific primers. For semi·quantitative analysis, cDNA samples were 
titrated (ten~fotd) and aliquots of each dilution were amplified. Each reaction mixture was overlaid with 
50 ~I mineral oil (Sigma, St. Louis, MO) prior to PCR reaction in a DNA thermal cycler (Biomed-60, 
Germany) using the fottowing conditions. After a 5 min 94"C denaturation step, samples were 
subjected to 40 cycles of denaturation at 94"C for 1 min, annealing at 60"C for 2 min, and extension at 
72"C for 3 min. The last cycle was extended with 7 min at 72"C. As positive control for the cytokines 
and keratin we used cDNA isolated from 106 Hut7S (ATCC; a human T cell·line with constitutive 
cytokine mRNA transcription). After amplification, 16 IJI PCR product was electrophoresed through 2% 
agarose gel, transferred to a Hybond-N+ membrane (Amersham, England) by electroblotting and 
hybridized with y32p labelled specific probes which are located across the sptice~site. Hybridization 
was detected by autoradiography and indicated the presence of mRNA expression in the original 
biopsy. To estimate the relative initial amount of target cDNA, aliquots of titrated cDNA samples were 
amplified using specific primers for keratin. After titration, the relative amount of target cDNA was 
determined by the highest dilution showing positive signal. Sequential biopsies from individual patients 
135 
were isolated at the same time and the titre of keratin cDNA in all liver biopsies varied not more then 
·one dilution step. There was no statistically significant difference in the amount of reversely 
transcribed cDNA for keratin between biopsies with Snover rejection grade >1 (n=21) and those with 
Snover rejection grade d (n=37; p= 0.57 Mann-Whitney-U test). To exclude Inter and Intra-assay 
variability, amplification of titrated cDNA of the HuT78 cell-line was Included in each analysis. The 
expression of mRNA for keratin in separately isolated control cell·line was highly reproducible as inter 
and intra assay variation did not exceed a single dilution step. In the present study, only biopsies with 
significant keratin gene expression were analysed. 
RESULTS 
In total 58 biopsies derived from 19 liver transplant recipients were analysed. We 
observed histological signs of rejection, i.e, Snover rejection grade >1, in 21 biopsies 
(table 1). In 11/21 biopsies this histological rejection corresponded with clinical signs 
of rejection with a rise in median serum bilirubin from 142 lJmol/l (range 39-225 
lJmol/l) to 178 lJmol/l (range 35-318 lJmol/l) and median ASAT levels from 58 U/I 
(range 12-234 U/I) to 90 U/I (range 14-230 U/I). This group therefore received anti-
rejection therapy. The remaining 10/21 biopsies with Snover >1 were not 
accompanied by a clinical diagnosis of rejection. Median serum bilirubin in this group 
decreased from 119 lJmol/l (range 28-276 lJmol/l) to 111 lJmolll (range 32-310 
lJmol/l) and median ASAT levels from 35 U/I (range 14-133 U/I) to 30 U/I (range 14-
90 U/I). This group did not receive anti-rejection therapy and subsequently showed 
no clinical or histological signs of rejection in the following 2 weeks (except patient 
Ra). The 37 biopsies with Snover < 1 (table 2) corresponded with median serum 
bilirubin changes from 48 lJmol/l (range 9-289 lJmol/l) to 42 lJmol/l (range 8-288 
lJmol/l) and median ASAT levels from 30 U/I (range 8-423 U/I) to 32 U/I (range 8-175 
U/I). In this group, Snover <1, anti-rejection therapy was given in one instance. In 
this biopsy histology did not correspond with deranged graft function. Histology of 
the Snover >1 biopsies was not different between biopsies obtained from patients 
with or without clinical signs of rejection. Respectively 6/10 biopsies of the 
spontaneously resolving rejections and 7/11 biopsies of the clinical rejections had 
Snover rejection grade, 2. 
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Table 1. Sample profile and cytokine mRNA expression in liver biopsies with histological evidence of 
rejection (Snover >1) not followed by clinical signs of graft rejection and biopsies with histological 
evidence of rejection accompanied with clinical significant rejection, defined by rising serum bilirubin 
and ASAT levels. 
biopsy\'! days IL-2' IL-4 control/lndication or protocol biopsy 
pTX' 
without clinical 
rejectfon 
Wi1 13 + controld 
Wi2 20 + protocoUHBV' 
Me1 9 controld 
Me2 14 protocoUHBVa 
My1 7 + protocol 
Ve3 24 + protocol 
Oe1 7 protocol 
He1 7 + protocol 
Ti1 26 + indicationlcholestasis e.c.i 
Ra2 12 + controld 
with clinfcaf 
rejection 
La1 7 protocol 
LaS' 207 indication 
La6 213 controld/ongoing rejection 
La7 21S + indication 
Ke2 13 indication 
Ra1 6 + protocol 
Ra3 19 indication 
Mi1 17 + indication 
Re2 7 + protocol 
Kr3 24 protocol 
Fo1 6 + + indication/ongoing rejection 
a biopsy description; composed of patient identification and biopsy number analysed 
• days post-transplant (pTX) 
C _ no signal, + positive signal after hybridization 
d biopsies taken after anti-rejection therapy with high doses methylprednisolone, biopsies were taken 
2-4 days after last gift 
a screening re-Infection HBV 
f patient self-weaned his cyclosporin A medication 
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Table 2. Sample profile and cytokine mRNA expression in liver biopsies without histological evidence 
of rejection (Snover :s:1) and without clinical significant rejection 
biopsya days IL-2' IL-4 control/lndication or protocol biopsy 
pTXb 
Wi3 206 protocoUHBVa 
Wi4 355 protocollHBVa 
Me3 21 prolocol/HBV' 
Me4 357 protocoUHBva 
My2 20 protocol 
My3 97 indication' 
Ve1 9 protocol 
Ve2 17 + protocol 
Ve4 31 + indication' 
La2 17 controld 
La3 25 + protocol 
La4 95 protocol 
Ke1 6 protocol 
Ke3 18 controld 
Mi2 41 + indication'/CMV 
Re1 3 + indication/preservation injury 
Re3 38 indication/preservation injury 
Kr1 7 protocol 
Kr2' 22 + + indicationf; rejection 
Kr4 36 indicationf 
Kr5 104 indication' 
Fo2 191 indicationf 
Fo3 405 indication! 
Bu1 23 + protocollHBva 
Bu2 87 protocollHBVa 
Bu3 358 protocollHBV" 
Ka1 9 + protocollHBVa 
Ka2 15 protocollHBVa 
Ka3 22 + protocol/HBva 
Ka4 43 protocoUHBV" 
Ka5 95 protocol/HBva 
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Ka6 
Ku1 
Ku2 
Ja1 
Br1 
512 
6 
20 
98 
40 + + 
protocoVHBV' 
protocol 
protocot 
indlcation'lCMV 
indication' 
Br2 50 + indication! 
a biopsy description; composed of patient identification and biopsy number analysed 
'days post-transplant (pTX) 
e w no signal, + positive signal after hybridization 
d biopsies taken after anti-rejection therapy with high doses methylprednisolone, biopsies were taken 
2-4 days after last gift 
e screening fe-infection HBV 
f biopsies were taken in case of deteriorating liver functions 
9 patient received anti-rejection therapy with high doses of methylprednisolone 
Alterations in mRNA expression profile were analysed in relation to histology 
(Snover <1 vs Snover >1), clinical criteria for diagnosis of rejection (treated 
rejections), and spontaneously resolving rejections (Snover >1 without graft 
dysfunction) 
Results of sequential liver biopsies are presented in table 1 (Snover >1 ) and table 2 
(Snover <1). Cytokine mRNA analysis showed that IL-2 gene expression was 
comparable when rejection was diagnosed on histological grounds (19%, 4/21 vs 
14%, 5/37) whereas IL-2 gene expression was seen more frequently when rejection 
was based on clinical grounds (42%, 5/12 vs 9%, 4/46). Interestingly, IL-2 mRNA 
expression correlated better with clinical than with histological criteria of rejection. IL-
4 gene expression also correlated with rejection, but only when histology Was used 
for rejection diagnosis. IL-4 mRNA was detected in 43% (9/21) of the biopsies with 
Snover >1 classification and in 22% (8/37) of the Snover <1 classified biopsies. In 
contrast, when clinical criteria were used for rejection diagnosis, a totally different 
pattern emerged. IL-4 mRNA transcripts were detectable in 25% (3/12) of the 
biopsies that were followed by anti-rejection therapy vs 30% (14/46) of the biopsies 
from non-treated patients. 
In the group without histological evidence of rejection (Snover < 1) as classified in the 
review study, anti-rejection therapy had been given in one patient, this biopsy was 
not included in the present study. Representative examples of intragraft cytokine 
mRNA expression of sequentially taken liver biopsies from a patient with a 
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spontaneously resolving rejection episode and from a patient with a clinical rejection 
episode before and after anti-rejection treatment are shown in figure 1A and 1 B 
respectively. Additional analysis showed that the detection of IL-4 mRNA correlated 
with un compromised graft function in spite of concomitant histological signs of 
rejection (figure 2). Significantly more of these biopsies expressed IL-4 mRNA (70%, 
7/10) compared to biopsies without any evidence of rejection (19%, 7/36; p<0.01, 
Fisher's exact test) or to biopsies with rejection in combination with clinical signs of 
rejection (18%, 2/11; p=0.03). In contrast, IL-2 mRNA expression was not detectable 
in biopsies with spontaneously resolving rejection. None (0/10) of these biopsies 
expressed the IL-2 gene which was not significantly different from the proportion of 
biopsies that expressed IL-2 in the absence of rejection 11% (4/36) whereas 36% 
(4/11) of the biopsies derived from the treated patients expressed IL-2 mRNA (figure 
2). 
Cytokine mRNA profile during rejection 
From 5 patients (Wi, Me, La, Ra, Kr) multiple biopsies were analysed. We found in 
2/5 patients that the intragraft cytokine mRNA profile changed during one rejection 
episode (patient La and Kr). These two patients had an ongoing rejection episode 
and consequentially samples were measured after treatment with 
methylprednisolone (table 1 and 2). The cytokine mRNA profile of patient Ra 
changed from IL-4 positive (Ra2) to IL-4 not detectable (Ra3) when histological 
rejection was accompanied with clinical rejection (table 1). 
DISCUSSION 
It has been reported by several groups that despite histological evidence of acute 
rejection in liver biopsies, treatment for rejection was not always necessary (1-3). In 
these instances patients had no associated liver dysfunction. However, a 
retrospective review of 8 liver biopsies specimens by Dousset et al (5) showed that it 
is even possible that patients with concomitant significant biochemical changes were 
able to resolve their allograft rejection without additional immunosuppression. 
Nevertheless, none of these studies could demonstrate a particular feature that 
could recognize or predict these spontaneous reversible rejections. 
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Figure 1. Southern blot analysis of RT-PCR amplified keratin, IL-2 and IL-4 transcripts from liver 
biopsies and positive control cell-line (HuT7S cells; a human T cell line with constitutive cytokine 
mRNA transcription). Keratin was used as a positive control for amplification. (left) Biopsies obtained 
from patient My taken at day 7 post-transplant (pTX), histological rejection spontaneously resolving; 
day 20 pTX, no evidence of rejection; day 97, no evidence of rejection. (right) Biopsies obtained from 
patient Re taken at day 3 pTX, no evidence of rejection; day 7 pTX, histological and clinical rejection, 
anti-rejection therapy given; day 38 pTX, no evidence of rejection. 
Analysis of the immune response in the rat showed that not only animals that reject 
their liver allograft but also those that eventually accept their transplant undergo 
tissue damage (22). In the rejecting animals graft loss was accompanied by 
increased biochemical markers of cholestasis. In the present study, we found that 
tissue damage was accompanied by graft dysfunction in half of the cases only, while 
in the remaining 50% no biochemical signs of rejection Were observed. This 
suggests that also after clinical liver transplantation tissue damage is part of a 
normal allogeneic response within the graft which can also be detected in the 
absence of graft dysfunction. This observation raises the question whether the 
infiltrates histologically observed in the absence of clinical rejection represent cells 
suppressing the allogeneic response. Cytokines regulate the immune response both 
during rejection episodes and during immunological quiescence. The same cytokine 
may, in these different situations exert either stimulatory or inhibitory effects. Still, 
monitoring of cytokines thought to be involved in rejection processes (Th1; IL-2) or to 
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be associated with maintenance of the allograft (Th2; IL-4), might provide insight in 
the complexity of the immune response after liver transplantation. In an attempt to 
correlate clinical complications after liver transplantation with systemic cytokine 
protein production, Kraus et al (23) showed that it was difficult to differentiate 
between graft dysfunction caused by allograft rejection or by other complications 
such as infections. Therefore, analysis of locally activated cytokines might give more 
insight in cytokines that playa role in the immune response after transplantation. 
We have analysed our data per individual biopsy and not per patient. Allograft 
rejection is a dynamic process and for this reason cytokine mRNA expression might 
change during the state of rejection. Moreover, intragraft cytokine expression could 
be influenced by anti-rejection therapy with high doses of corticosteroids. Therefore, 
biopsies taken after anti-rejection treatment during ongoing rejection episodes, are 
not comparable with specimens obtained before anti-rejection therapy. From in vitro 
studies there is evidence that corticosteroids inhibit cytokine mRNA transcription 
(24). However, in vivo the effects of anti-rejection therapy on the transcriptional level 
of these cytokines within the transplanted organ is unknown. In the qualitative study 
presented here, intragraft IL-2 mRNA expression was positively correlated with 
clinical signs of rejection and not with histological signs of rejection. In addition, IL-2 
mRNA expression was not detectable in grafts with spontaneously resolving 
rejections. Still, a considerable number of rejecting livers also did not express IL-2 
transcripts during the effector phase which suggests that the presence of IL-2 is not 
always required for acute cellular rejection (15). The proliferation of graft infiltrating 
IL-2 negative cells might be regulated by other cytokines than IL-2. IL-2 knockout 
mice reject their pancreatic islet cell allografts in the presence of IL-4, IL-? (a T-cell 
growth factor) and IFN-y mRNA transcripts (25). However, it is known that 
expression of the IL-2 gene is an early but transient activation marker with a brief 
spike expression after activation and therefore present during the early phase of 
development of rejection (26-28). Therefore, it could be assumed that biopsies 
already had expressed IL-2 before the overt manifestation of clinical and/or 
histological rejection. After clinical kidney transplantation, Dallman et al. (26) found 
that in patients in whom rejection was confirmed histologically, intragraft IL-2 gene 
expression preceded the clinical onset of rejection. 
After clinical liver transplantation we found that the intragraft cytokine mRNA profiles 
between spontaneously resolving rejections and those necessitating anti-rejection 
therapy were significantly different. In rodents, results of intragraft mRNA expression 
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were conflicting for liver allografts that were spontaneously tolerated or rejected in 
the absence of immunosuppression. Farges et al (29) showed that accepted 
allografts had lower intragraft IL-4 mRNA levels compared to rejected allografts 
while others found similar levels (30,31). However, long-term non-responsiveness in 
cyclosporin A treated rejectors was associated with significant IL-4 mRNA levels 
transcribed by graft infillrating cells after in vitro allogeneic stimulation (32). In the 
present study, the Th2 cytokine IL-4 was more frequently expressed in biopsies with 
histological proved rejection (Snover> 1 classification) indicating that infiltrated cells 
are responsible for the IL-4 gene expression. In contrast, IL-4 mRNA expression was 
not associated with clinical criteria of rejection. Most interestingly, biopsies from 
patients with stable biochemistry accompanied by histological signs of rejection 
expressed significantly more often IL-4 mRNA than biopsies from patients with 
deteriorating graft function concomitant with similar histology. This might implicate 
that functionally different cell populations, i.e. Th1 and Th2 cells, have both infillrated 
the allograft. A higher frequency of intragraft IL-4 mRNA expression in liver 
allografts with histological evidence of rejection was reported by Martinez et al (15). 
This could be due to the fact that they analysed intragraft IL-4 mRNA expression 
without reference to the associated liver function which we did. An alternative 
explanation might be that differences in immunosuppressive protocols have 
influenced the results, as we have not used anti-thymocyte globulin or FK506. It is 
evident that Th2 cytokines can antagonize synthesis as well as effector functions of 
Th 1 cytokines, and visa versa, significantly affecting the resull of the overall immune 
response (11-13). In the present study, IL-2 mRNA transcription was rarely observed 
in rejecting livers concomitant with IL-4 mRNA while, in contrast, in the 
spontaneously resolving rejections, a high incidence of IL-4 mRNA expression was 
seen in the absence of detectable IL-2 mRNA levels. In experimental 
transplantation, a state of tolerance has been characterized by several investigators 
as requiring the presence of Th2 cytokines, with relative dearth of Th1 cytokines in 
grafted tissue (9-11,33,34). Evidence for such a role of IL-4 in clinical kidney 
transplantation was recently reported by Kusaka et al (35). Peripheral blood cells 
from a chimeric renal transplant patient who discontinued all immunosuppressive 
drugs produced high amounts of IL-4 protein. These data suggest that circulating 
donor cells might control the specific immune response towards the transplanted 
organ by interfering into the cytokine cascade. After liver transplantation chimerism 
is a common phenomenon (36,37) and therefore this hypothesis might also be 
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relevant for our patients. However, it can not be excluded that other activation 
pathways or cytokine cascades are also involved in this phenomenon. In conclusion, 
our results show that the function of liver transplants remains unimpaired despite 
histological signs of rejection, provided IL-4 mRNA is expressed at the same time. 
This suggest that also in man, cells committed to Th2 function control cell mediated 
immune responses in vivo. 
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Figure 2. The biopsy without histological evidence of rejection as diagnosed during review taken from 
a patient with clinical evidence of rejection was omitted from the no-rejection group. Analysis was only 
done in biopsies both without histological and clinical evidence of rejection. IL-2 and IL-4 mRNA 
expression in liver allograft biopsies without histological and clinical evidence of rejection, in biopsies 
with spontaneously resolving rejections and in biopsies with cellular infiltrate in the subsequently 
treated patients. Data expressed as the percentage of liver biopsies containing mRNA for IL-2 or IL-4. 
The proportion of liver biopsies expressing IL·4 mRNA was significantly higher in the spontaneously 
resolving rejections compared to either treated rejections (p=O.03, Fisher's exact test) or to biopsies 
without evidence of histological or clinical rejections (p<O.01). The presence of IL-2 transcripts was 
characteristic for liver biopsies with rejection of subsequently treated patients 
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Chapter 9 
INCREASED INTRAGRAFT IL-15 mRNA EXPRESSION AFTER LIVER 
TRANSPLANTATION 
This chapter is based on the article published in: 
Clin Transplantation (in press) 
Carla C. Baan, Hubert G.M. Niesters, Herold J. Metselaar, Wendy M. Mol, 
Elisabeth H.M. Loonen, Pieter E. Zondervan, Huug W. Tilanus, 
Jan M.N. IJzermans, Solko W. Schalm, and WI/em Weimar 
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ABSTRACT 
Acute rejection is a T-cell mediated process associated with intragraft IL-2 production. 
However. the observation that rejection also occurs in the absence of IL-2 implies that 
T-cell activation is not merely dependent on locallL-2 production. IL-15. a macrophage 
derived cytokine associated wilh T-cell activation could also be involved in liver allograft 
rejection. To study T-cell/macrophage interactions at the molecular level. we measured 
intragraft mRNA expression of the T-cell derived cytokine IL-2 and the macrophage 
derived chemokine IL-15 in post-transplant liver biopsies (n=33) and in non-
transplanted control liver tissue (n=5) by competitive template RT-PCR. We analyzed 
biopsies without evidence of rejection (n=12). with spontaneously resolving histological 
rejection (n=10). or with histological rejection accompanied with clinical rejection (n=11) 
defined by rising serum bilirubin and aspartate amino transaminase levels. IL-15 mRNA 
expression was present in the majority of post-transplant liver biopsies (91%. 30/33) 
and was significantly upregulated as compared with non-transplanted liver tissue 
(p=0.005. Mann Whitney U test). However. the intragraft IL-15 mRNA levels did not 
differentiate between the 3 post-transplant biopsy groups. In contrast to intragraft IL-15 
mRNA expression. IL-2 mRNA transcription was measured in the minority of the post-
transplant liver biopsies (15%. 5/33). not detectable in control specimens and almost 
exclusively found in rejection biopsies concurrent with graft dysfunction (36%. 4/11 vs 
1/22; p=0.03. Fisher exact test). 
Our results show an increased intragraft IL-15 gene expression after liver 
transplantation. This phenomenon is independent of the clinical status of the allograft 
and indicates constant macrophage activation. When IL-15 is also produced during this 
process it may participate in T-cell dependent donor-directed immune responses. 
thereby explaining the occurrence of rejection in the absence of IL-2. 
INTRODUCTION 
A major manifestation of acute rejection is the mixed infiltrate of inflammatory cells in 
the transplanted liver. Phenotyping studies showed that infiltrates mainly consists of 
macrophages. T-cells. eosinophils and rarely 8 cells and NK cells (1.2). 80th infiltrated 
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macrophages and T cells are capable of expressing a large number of cytokines 
important for their function as a mediator in the host defence: the non-immune and 
specific immune response. During rejection, mRNA expression of both macrophage-
and T-cell derived cytokines are upregulated. Tumor necrosis factor-a, IL-113, and IL-6 
are mainly produced by macrophages, as a result of the non-specific inflammatory 
response. IL-2, interferon (IFN)-y, and IL-5 secreted by T-cells reflecting the specific 
immune response (3-7). Despite the fact that liver allograft rejection is mediated by T-
cells, these studies also showed that these rejection episodes are not always regulated 
by the classical T-cell activator IL-2. This observation suggests that other cytokines may 
induce T-cell proliferation and differentiation. Studies in experimental transplant settings 
showed that T-cell growth. factors produced by non T-cells are also able to induce and 
mediate rejection (8,9). 
IL-15, a recently described T-cell growth factor produced by macrophages and not by 
lymphocytes shares many biological activities with IL-2. Like IL-2, IL-15 stimulates the 
proliferation of natural killer cells, mitogen activated T-cells and cytotoxic T-cells, serves 
as a chemoattractant for T-cells, and has stimulatory activity for the induction of B-cell 
proliferation and differentiation (10-14). These remarkable similar biological activities 
can be explained by the fact that both IL-2 and IL-15 mediate their function through the 
common 13 and y chains of the IL-2 receptor apart from their own unique a-chain (10). 
Several investigators have described a role for IL-15 in a variety of diseases associated 
with monocyte infiltrate such as rheumatoid arthritis (15), responses to infection (16), 
and acute rejection after kidney transplantation (17). Therefore, we postulate that IL-15 
produced by liver infiltrated macrophages plays a significant role in T-cell recruitment 
and activation resulting in rejection. To test this hypothesis, we analysed intragraft IL-15 
mRNA expression in previously IL-2 characterized biopsies that were taken at different 
phases of an immune response and in control non-transplanted liver tissues (6). Using 
a competitive template reverse transcriptase-PCR (RT-PCR) method, we measured the 
amount of intragraft IL-15 mRNA expression in biopsies without evidence of rejection, 
in biopsies obtained with histological evidence of rejection and not followed by clinical 
signs of rejection, and in biopsies with histological rejection that were accompanied with 
clinical rejection. 
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MATERIAL AND METHODS 
Patients 
We analysed IL-15 and B-aclin mRNA expression in 33 liver biopsy specimens (6-206 days post-
transplant) obtained from 16 patients (6 male and 10 female). In these samples, IL-2 mRNA expression 
was determined as described recently (6). The primary indications for liver transplantation were acute liver 
failure, cholestaUc liver disease, posthepatitic liver disease, post alcoholic liver disease, and cryptogenic 
liver disease. Biopsies were taken according protocol or on indication in case of deteriorating liver function 
(table 1). Immediately following procurement, a portion of each biopsy was snap-frozen in liquid nitrogen 
and stored at -80°C for RT-PCR analysis. The biopsy specimens were processed in standard fashion, 
stained with haematoxylin and eosin, periodic acid-Schiff, and iron. 
All samples were obtained from patients who had received a HLA-mismatched cadaver donor liver. 
Standard immunosuppression consisted of azathioprine, cyclosporin A and low-dose methylprednisolone, 
As controls we used non-transplanted liver tissue obtained from 5 different individuals. 
Table 1. Characteristics of the liver biopsies and biochemical liver function parameters 
biopsy number of days pTX 1 bilirubin ~molll) 
group 
no-rejection 
histological rejection 
spontaneously resolving 
histological and 
clinical rejection 
biopsies 
12 
10 
11 
'. days post-transplant (pTX) 
Management of rejection 
median (range) median (range) 
24 (6 - 206) 46 (8 - 288) 
12(7-26) 111 (32 - 310) 
17(6-215) 178 (35 - 318) 
ASAT(U/I) 
""'"'" (""W) 
23(11-101) 
35 (14 -113) 
90 (14 - 230) 
A clinical diagnosis of rejection was suspected and considered likely if: (1) there was an increase in 
bilirubin and/or transaminases in successive days; (2) there was a decrease in the amount and colour of 
bile; and (3) other events were excluded radiologically, microbiologically or virologically. 
Cellular rejection was reported according to the Snover criteria (18), In brief, grade 0, lymphocytic or 
mixed portal infiltrate, < 50% damaged bile ducts, no endothelialitis; grade 1, as above, with endotheJialitis; 
grade 2, lymphocytic or mixed portal infiltrate, > 50% damaged bile ducts, with or without endolhelialitis; 
grade 3, acute rejection plus arteritis, paucity of bile ducts, or central hepatocellular ballooning with 
confluent dropout of hepatocytes, Treatment for acute cellular rejection was given if the clinical diagnosis 
was considered to be probably correct and if there was histological evidence of cellular rejection. Patients 
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received methylprednisolone for treatment of acute rejection at a dosage of 1000 mg/day for 3 consecutive 
days and r~ATG or OKT~3 monoclonal antibodies for steroid-resistant or severe rejection. 
mRNA Isolation and cDNA reaction 
For RT-PCR analysis, specimens were snap-frozen in liquid nitrogen and stored at -80"C. Messenger 
RNA extraction and transcription was performed as described previously (6). Briefly, total RNA was 
extracted from snap-frozen samples by a modification of the guanidinium method, as described by 
Chomczynski and Sacchi (19). Specimens were homogenized in 500 fJl 4 moUl guanidinium~ 
isothiocyanate in the presence of 20 fJg poly A (Boehringer, Mannheim, Germany). The solution was 
exlracled once with phenol, phenol-chloroform-isoamylalcohol [25:24:1[ and chloroform-isoamylalcohol 
[24:1), respeclively. Tolal RNA was precipilaled wilh 600 ~12-propanol and 35 ~13 moUl sodium acelale 
(pH 5.2) ai-20°C for 18 hours. Precipilales were pelleled a110.000xg a14°C and washed once wilh 500 
fJl ice-cold 80% ethanol. Air-dried pellets were resuspended in 50 fJl diethylpyrocarbonate treated-H20. 
Total RNA was denaturated for 5 min at 80"C and then chilled on ice. First strand cDNA synthesis was 
performed from the isolated RNA with 0.5 fJg hexanucleotides (Promega Corporation, Madison, WI) and 
transcribed with 1000 U Moloney murine leukemia virus (MMl V) reverse transcriptase (Gibco-BRL, 
Gaithersburg, MD) at 42°C for 90 min in a total volume of 100 fJl. The reaction mixture consisted of 20 fJI 
5x MMlV-RT buffer (250 mmoUl Tris-HCI pH 8.3, 15 mM MgCI" 375 mM KCI), 5 ~I (10 mM) dNTP, 400 
U of RNAsin (promega) and 10 ~I 0.1M DTI. 
Polymerase Chain Reaction 
Sequence specific primers were used for amplification of the human Il-15 gene (sense primer 5' CM GTT 
ATITCACTI GAG TCC GGAG 3' and anti-sense primer 5' TIC TMGAG TICATC TGA TCC MG 
G 3'). Recently, we described the intragraft IL-2 mRNA analysis in the above mentioned post-transplant 
biopsies (6). PCR primers detecting transcripts for the human house-keeping gene B-actin (Clontech 
Laboratories, Palo Alto, CAl were used as an internal control to monitor mRNA extraction and cDNA 
amplification. For qualitative analysis, 0.5 fJl cDNA sample was added to 99.5 fJl PCR mixture containing 
10 mM Tris-HCI pH 8.3,50 mM KCI, 2 mM MgCl, (ll-15) or 1.5 mM MgCl, (ll-2, ~-actin), 0.2 mM of each 
dATP, dCTP, dTIP, dGTP, 2 U Taq DNA polymerase (Promega) and 50 pmol of 5' and 3' sequence 
specifiC primers. Each reaction mixture was overlaid with 75 ~I mineral oil (Sigma, St. LouIs, MO) prior to 
PCR reaction in a DNA thermal cycler (Biomed·60, Germany) under the following conditions. For IL-15: 
after a 5 min 94 "C denaturation step, samples were subjected to 40 cycles of denaturation at 94 "C for 
1 min, annealing at eo"c for 1 min, and extension at 72°C for 1 min. The last cycle was extended with 7 
m"in at 72"C. For B-actin: after a 5 min 94"C denaturation step, samples were subjected to 40 cycles of 
denaturation at 94"C for 1 min, annealing at 60"C for 2 min, and extension at 72"C for 3 min. The last 
cycle was extended with 7 min at 72"C. Positive control samples were produced by stimulating 106 human 
spleen cells wilh 1% phylohemagglutinin (PHA)-M (Difco, Delroil, MI) for 4 h al3rC. Messenger RNA 
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from this positive control was extracted as described above. Negative controls consisted of omission of 
reverse transcriptase from the cDNA synthesis reaction for each biopsy followed by amplification in PCR 
with the IL-15 and ~~actin primers, and the use of diethylpyrocarbonate treated-H20 as no-template 
reaction. After amplification, 16 j,J1 PCR product was electrophoresed through 2% agarose gel, transferred 
to a Hybond-N+ membrane (Amersham, UK) by electroblotting, and hybridized with y"P labelled specific 
probes which are located across the splice-site (B-actin, Clontech LAbs; and IL-15 5'TGT CCT TCT GCA 
GAT TGA CM TGC CCG TCT 3'). Hybridization was detected by autoradiography and Indicated the 
presence of IL-15 and B-actin mRNA expression in the original biopsy. 
Competitive template RT-PCR 
To estimate the relative initial amountoffunctionallL-15 mRNA in biopsies a competitive RT-PCR assay 
was used and comparison was made against the house-keeping Il~actin gene. The latter gene is assumed 
to be expressed at a constant level in biopsies. To obtain a standard curve for IL-15 and !l-actin, known 
amounts of internal control fragment were added in different dilutions to constant amounts of sample 
eDNA for competitive co-amplification with specific primers. The internal control was designed to generate 
a PCR product of a different size to allow differentiation between the amplified target and internal standard. 
Dliutions of the competitor template, ranging from 5 ag to 5 fg were co-amplified with constant amounts 
of sample eDNA. Following PCR, using conditions as described previously, the amplification products 
were analysed by gel electrophoresis and the amount of products by the internal control and targets are 
determined for each individual reaction (figure 1A). The relative ethidium bromide intensity on gel was 
measured by luminescence with a DC-40 camera in combination with analysis software (Kodak, 
Rochester, NY). The logarithm of the ratio targelllnternal control is graphed as a function of the logarithm 
of the internal molar amount of the standard and at ratio 1, the starting concentration of IL-15 and B-aclin 
cDNA prior to PCR is assumed to be equal to the known starting concentration the competing Internal 
control (figure 18). The relative concentration of intragraft IL-15 gene transcripts were divided by the 
relalive concentration of !l-actln. This represents the amount of IL-15 mRNA transcripts corrected for the 
amount of mRNA used for reverse transcription and the efficacy of each reaction 
RESULTS 
Qualitative RT-PCR analysis showed that IL-15 mRNA expression is present in all 
control specimens and in the majority of the post-transplant liver biopsies. In none of 
the control specimens (n=5), IL-2 mRNA was detectable. In the post-transplant liver 
specimens, IL-15 mRNA transcripts were present in 91% (30/33) and IL-2 mRNA in 
15% (5/33) of the biopsies. We found no difference in the number of biopsies positive 
for IL-15 mRNA expression between biopsies without any signs of rejection, with 
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histological rejection not accompanied with clinical rejection, or with cellular infiltrate 
obtained from subsequently treated patients, 92% (11/12), 80% (8110), 100% (11/11) 
respectively. However, for IL-2 a different intragraft mRNA profile was seen. IL-2 mRNA 
expression was predominantly found in biopsies derived from treated patients (36%, 
4/11; p=0.03, Fisher's exact), not in biopsies with histological rejection only (0%,0/10), 
and seldom in biopsies without any evidence of rejection (8%, 1/12). 
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Figure 1A. After electrophoresis, the ethidium bromide stained agarose gel shows two peR products per 
lane representing discrete competitor (271 bp) and target (357 bp) for IL-15. 
Figure is. The log of the ratio amplified IL-15 to competitor IL-15 is graphed as a function of the log of 
the known amount of competitor added to peR reaction. At the point where target eDNA and internal 
control are in equivalence (i.e., ralio=1), the starting concentration of IL-15 eDNA prior to peR is equal 
to the known starting concentration of the competing internal control. 
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We performed quantitative RT-PCR analysis in order to detect differences in IL-15 
mRNA expression levels between the three post-transplant biopsy groups and the 
control specimens. Using the competitive template RT-PCR, we found no statistical 
difference among groups in expression of the positive control housekeeping gene Jl-
actin. This indicates that the integrity of the mRNA for the three biopsy groups and the 
control specimens is the same (p=O.81, Krusal-Wallis). Relative amounts of initiallL-15 
mRNA were individually normalized to the corresponding Jl-actin levels, which permitted 
more accurate comparison of IL-15 gene transcripts levels. The normalized IL-15 
transcript levels were clearly different between liver biopsies and control specimens. 
The level of IL-15 mRNA was at least 10-fold greater in post-transplant biopsies than 
in non-transplanted control specimens (p=O.005, Mann Whitney U test, figure 2). 
However, the increased IL-15 transcript level was not associated with rejection. We 
measured comparable intragraft IL-15 mRNA levels between non-rejection biopsies 
versus biopsies with histological rejection (p=O. 74, Mann Whitney U) or versus biopsies 
from patients with clinical rejection (p=O.88). Moreover, the IL-15 mRNA expression 
level was not elevated in the IL-2 negative rejections (figure 2). 
DISCUSSION 
In a previous study, we have shown that intragraft IL-2 and IL-4 mRNA expression 
could discriminate between different clinical circumstances after liver transplantation. 
Intragraft IL-2 mRNA expression was primarily found in biopsies associated with clinical 
rejection, while intragraft IL-4 mRNA expression was mostly measured in biopsies with 
spontaneously resolving rejections (6). In these biopsies we now have studied the 
contribution of intragraft IL-15 mRNA and compared the results with intragraft IL-15 
mRNA expression measured in biopsies at time of immunological quiescence and in 
non-transplanted liver tissue. 
Human IL-15, a cytokine with chemoattractant activity, is produced by 
monocy1es/macrophages, other non T-cell types and measured at low levels in heart, 
lung, liver and kidney. IL-15 exerts overlapping biological activities with IL-2. An 
important feature of both IL-2 and IL-15 is the capacity to induce generation of cy1otoxic 
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T-Iymphocytes responsible for graft destruction (12). Intragraft IL-2 production is 
associated with T-cell mediated allograft rejection (20). However, the fact that rejection 
also occurs in the absence of IL-2 implies that T-cell activation is not only the result of 
locallL-2 production (21). IL-15, could therefore be an important factor by which T cells 
recruit to the graft and become activated T-cells. 
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Figure 2.lntragraft IL~15 mRNA expression levels after clinical liver transplantation. IL-15 mRNA levels 
are depicted as a ratio of fl-actin mRNA. 
Quantitative analysis showed a significant increase of IL-15 mRNA expression in posHransplant 
specimens compared to non·transplanted control samples (p=O.005, Mann Whitney U test). Comparable 
intragraft IL-15 mRNA levels were measured in biopsies without rejection, in biopsies with histological 
rejection not followed by clinical signs of rejection, and in biopsies obtained from patients treated for 
rejection. Moreover, IL-15 transcript levels were not heightened in ILM2 negative rejecting specimens (0) 
compared to IL-2 positive rejecting specimens (M). 
In the current study, we demonstrated that IL-15 mRNA is expressed in the majority of 
the post-transplant liver biopsies, irrespective of the rejection state. Nevertheless, 
intragraft IL-15 transcript levels were not indicative for rejection. However, post-
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transplant IL-15 mRNA levels were significantly upregulated compared to non-
transplanted liver tissue (p=O.005, figure 2). These differences could be related to the 
origin of IL-15 mRNA production. In non-transplanted liver tissue, Kupffer cells may 
contribute to IL-15 mRNA expression, whereas after transplantation, apart from these 
tissue specific macrophages, also graft infiltrated cells may transcribe IL-15 mRNA. IL-2 
mRNA expression was almost exclusively measured in biopsies with cellular infiltrates 
obtained from patients that had to be treated for rejection. Moreover, we were unable 
to identify a relation between intragraft IL-2 mRNA expression and intragraft IL-15 
mRNA levels. This observation suggests that IL-15 does not compensate for the lack 
of IL-2 during liver allograft rejection, since no increased intragraft IL-15 mRNA levels 
were measured. However, we must be cautious drawing this conclusion. Relatively 
"low" intragraft IL-15 mRNA amounts may be biological active. IL-15 production is 
predominantly regulated at the post-transcriptional level. Studies by Bamford et al. 
suggest that IL-15 mRNA may exist in translationally inactive pools (22). Cells may 
respond to stimuli by releasing the quiescent IL-15 message followed by translation and 
IL-15 protein production. Therefore, comparable intragraft IL-15 mRNA levels do not 
naturally lead to comparable bioactive IL-15 protein levels in the graft. In contrast to IL-2 
mRNA transcription, the induction of IL-15 mRNA transcription can not be blocked by 
the immunosuppressive agent cyclosporin (23). Quantitative RT-PCR analysis in kidney 
biopsies showed that intragraft IL-15 transcript levels were increased in IL-2 negative 
clinical rejection episodes (17). Thus, indeed IL-15 may take over the role of IL-2 in 
clinical transplant settings. The discrepancy between the findings in liver and kidney 
transplantation can neither be explained by differences in the technique used nor on 
parameters of clinical rejection. Both studies used a competitive template RT-PCR 
method to determine intragraft IL-15 mRNA levels and in both instances clinical 
rejection was diagnosed by abnormal graft function which was confirmed by 
examination of a core needle biopsy. Variations in immunosuppressive strategies, 
organ specific immune responses or even a combination of these factors could be 
responsible for the observed differences. On the other hand, our data show that IL-15 
may not be such an important cytokine in the rejection process after liver 
transplantation. 
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The process whereby inflammatory cells are recruited to inflammatory sites such as an 
transplanted organs can be the result of chemokine activities (24). Chemokines 
upregulate adhesion molecules present on leucocytes and promotes the migration of 
the adherent cells across the endothelium. Recently, Adams et al. reported that 
macrophage-derived chemokines are involved in the recruitment of T-cells into the 
transplanted liver (25). These chemokines, macrophage inflammatory protein-1a and 
macrophage inflammatory protein-1B were already expressed within hours after 
transplantation. Histopathologic analysis in liver and kidney biopsies showed that 
inflammatory cells also infiltrate grafts with stable function (17,26). This ongoing level 
of inflammation might be responsible for the constant increased transcription of IL-15. 
Although it is impossible to distinguish Kupffer cells from graft infiltrating macrophages, 
it is likely that IL-15 is involved in inflammatory processes after transplantation such as 
recruitment and activation of T-cells. The importance of cytokine production by liver 
infiltrated macrophages was shown by Hoffmann et al (27). In this study, clinical 
rejection was characterized by a significant portal tract and central venous infiltration 
by TNF-a positive macrophages. Nevertheless, the mechanism whereby macrophage-
derived cytokines interact with T cells in acute rejection processes remains obscure. It 
is likely that other - presently unknown - macrophage, derived cytokines contribute to 
liver allograft rejection. 
In conclusion, contrary to IL-2, we found no indication for a significant role of IL-15 in 
the rejection process after clinical liver transplantation. The increased intragraft IL-15 
mRNA level after transplantation suggests that cells producing IL-15 playa critical role 
in the ongoing inflammatory response, it may constantly modulate T-cell influx. 
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Chapter 10 
SUMMARY AND DISCUSSION 
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SUMMARY 
Transplantation biology is an exiting and rapidly developing field with the intention to 
understand immune mediated mechanisms responsible both for rejection and for the 
induction of tolerance. Initially, two facets of the response to an allograft were 
studied: the cellular and the antibody response. The cellular anti-donor response 
was investigated in vitro by proliferation- and cytotoxicity assays. These studies 
showed that T-Iymphocytes are the key mediators of the donor-directed immune 
process. Recently, due to the enormous development in molecular biology, an 
immune response within the allograft can be studied ex vivo, thus, without in vitro 
manipulations. Moreover, this technology made it possible to study interactions 
between immune competent cells and transplanted tissue instead of just focussing 
on donor lymphoid cells which is characteristic for the in vitro assays. Interaction of 
the T-cell receptor with donor peptides, present in the groove of major 
histocompatibility complex molecules on the surface of antigen presenting cells, 
results in production of multiple transcriptional factors including cytokines, 
chemokines, growth factors and their receptors. These mediators typically function 
within an immunologic micro-environment after binding to their specific receptors on 
target cells. On basis of their cytokine production pattern T-cells can be divided into 
functionally different subsets (1). In experimental transplant immunology, type 1 cells 
are associated with cell mediated immune responses while type 2 cells may 
suppress the allogeneic immune response (2). So, the function of type 1 cytokines 
(IL-2, IFN-y) is antagonistic to the activity of type 2 cells (IL-4, IL-10). 
The studies presented in this thesis were initiated to elucidate those parts of the 
cytokine network that are involved in clinically significant issues: acute and chronic 
rejection, spontaneous down-regulation of an immune reponse, and the 
effectiveness of anti-rejection and prophylaxis treatment. In addition, we analyzed 
the kinetics of type 1 and type 2 mRNA and protein production by "primed" graft 
infiltrated T-Iymphocytes in comparison to the time course of T-cell activation by 
"naive" peripheral blood mononuclear cells. 
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Chapter 1 summarizes the current literature on cytokine measurements by RT-PCR 
in clinical transplant settings. It became evident that neither rejection nor graft 
acceptance are restricted to stringent intragraft cytokine mRNA profiles. Lack of a 
clear association is probably caused by a number of factors, contributed by both the 
donor as well as the recipient. Moreover, these factors may have an immunological 
(e.g. HLA, blood transfusions) and/or non-immunological (e.g. age, ischemia 
damage) background which all have the potential to interfere in the T-cell activation 
cascade resulting in different intragraft cytokine mRNA profiles. Analysis by RT-PCR 
also showed that apart from T-cell derived cytokines, historically associated with 
graft rejection, cytokines secreted by other cell types are involved in the 
inflammatory response after transplantation. Chemokines such as MCP-1, MIP, 
RANTES, produced by macrophages and activated endothelial cells may initiate the 
T-cell dependent alloresponse. 
In chaper 2 the aim of the thesis is formulated. 
Chapter 3 shows that the kinetics for IL-2 and IL-4 mRNA and protein production by 
"naive" peripheral blood mononuclear cells and by "primed" graft infiltrating 
lymphocytes are different. In comparison to peripheral blood mononuclear cells, 
donor-specific IL-2 and IL-4 mRNA and protein production by graft infiltrating 
lymphocytes was found immediately upon in vitro stimulation. After stimulation with 
donor antigens, detectable IL-2 protein levels secreted by graft infiltrating 
lymphocytes were already measured after 4 h versus 28 h by peripheral blood 
mononuclear cells. This implies that graft infiltrating lymphocytes are in a more 
"activated" state. In addition, these data suggest that "primed" T-cells home in the 
graft. During rejection, the activation grade of cytokine producing T-cell might vary 
between individual patients. This is based on the observation that each bulk culture 
of graft infiltrating cells had its own characteristic mRNA and protein profile. In these 
cultures, the donor-specific IL-2 mRNA signal was significantly higher than the IL-4 
mRNA signal resulting in abundant donor-specific IL-2 protein levels (p=O.002). 
The involvement of the above characterized cytokines (IL-2, IL-4) and of IL-6 and IL-
10 in acute immune responses was studied in routinely taken endomyocardial 
biopsies (EMB) after heart transplantation. In chapter 4 we demonstrate that, in 
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contrast to IL-10 mRNA expression, IL-2, IL-4 and IL-6 gene transcription are 
associated with immune responses after transplantation. A strong correlation 
between intragraft IL-2 mRNA expression and histologically proved rejection was 
found. In the majority of EMB taken during rejection IL-2 mRNA expression was 
present, whereas in EMB obtained during immunological quiescence IL-2 mRNA 
transcription was hardly detectable, 76% versus 4% respectively (p=0.001). 
Although, in this study, the presence of intragraft IL-4 and IL-6 mRNA expression did 
not discriminate between rejection and immunological quiescense, the results 
suggests that both IL-4 and IL-6 are involved rejection responses (lL-4, 62% versus 
35%; and IL-6, 81% versus 39%, respectively). We conclude with regard to cardiac 
allograft rejection, that analysis of IL-2 gene transcription is a good candicate to 
monitor the acute immune response on the molecular level. The combination of 
histology and molecular biology will provide detailed information of the rejection 
process, not only morphological features of rejection are determined but also the 
activation state of the graft infiltrating cells. 
Blockade of the IL-2 mRNA transcription by anti-IL-2R monoclonal antibodies may 
provide an opportunity to interrupt the T-cell activation cascade. The data presented 
in chapter 5 show that induction therapy with a mouse anti-IL-2R monoclonal 
antibody (BT563), directed against the a-chain of the IL-2R complex, hardly 
influenced the allogeneic immune response. Nevertheless, immunologic 
phenotyping and RT-PCR analysis showed that during rejection in the presence of 
circulating BT563, the IL-2/IL-2R signaling pathway is almost completely blocked, 
demonstrating that cardiac allograft rejection can be mediated by other growth 
factors than IL-2. On the other hand, BT563 therapy did not affect the intragraft IL-15 
mRNA expression, suggesting that IL-15 might have overtaken the function of IL-2 in 
the cardiac rejection process. 
At our center, intravenous gifts of high doses of glucocorticoids like 
methylprednisolone (MP) are given as first-line therapy for acute cardiac rejection. 
However, approximately 40% of the patients fail to respond to MP anti-rejection 
therapy (3). In chapter 6 we tried to identify patients who are either MP resistant or 
MP sensitive on basis of the intragraft cytokine profile, and studied the effect of MP 
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anti-rejection therapy on the cytokine transcriptional level. During the first acute 
rejection episode, before MP anti-rejection therapy was given, the individual cytokine 
patterns were not helpful in differentiating between rejection that proved to be MP 
resistant or MP sensitive. None of the analyzed cytokines (IL-2, IL-4, IL-1f1, IL-6, 
TNF-a) or the high affinity IL-2Receptor (lL-2R) were indicative for steroid resistance 
or steroid sensitivity. However, intragraft cytokine mRNA patterns clearly reflected 
the efficacy of steroid anti-rejection therapy. After successful anti-rejection therapy, 
the overall intragraft cytokine mRNA expression was down-regulated. Intragraft 
cytokine mRNA expression became hardly detectable (lL-2: 0%; IL-4: 17%; IL-6: 
17%) while a 10-fold decrease in the amount of mRNA of the constitutively 
expressed cytokines or cytokine receptors (IL-1B, TNF-a, IL-2R) was measured. In 
contrast, intragraft cytokine mRNA expression of ongoing rejections was not 
influenced by MP anti-rejection therapy (lL-2: 88%, p=0.005; IL-4: 62%, p=0.14; IL-6: 
88%, p=0.03) and IL-1I?o, TNF-a and IL-2R levels remained stable or even increased 
(p=0.03). This study shows that cytokine mRNA expression profiles in pretreatment 
EMS are not a good parameter to determine the subsequent efficacy of MP anti-
rejection therapy. However, these intragraft cytokine mRNA profiles are an 
extremely useful tool to determine the efficacy MP anti-rejection therapy and 
probably also of other immunosuppressive agents that act at the cytokine 
transcription level. 
The relation between intragraft cytokine production and the development chronic 
rejection in cardiac allograft recipients was studied in chapter 7. 
At our center, chronic rejection or graft vascular disease (GVD) is diagnosed by 
visual evaluation of the coronary angiogram at one-year posttransplant (4). One-year 
after transplantation, mRNA expression of IL-2, IL-4 and IL-6, IL-10, TGF-B and 
PDGF-a was not different between patients with GVD and their controls without 
GVD. In contrast, RT-PCR analysis showed that development of GVD is associated 
with intragraft IL-2 mRNA expression during the first acute rejection episode. IL-2 
mRNA expression was present in 77% of the EMS from patients with GVD versus 
33% of the patients without GVD a one-year (p=0.03). In the studied patient group 
also the non-immunologic factors older donor hearts and prolonged ischemia time 
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were found to be associated with GVD. Recipients with GVD were transplanted with 
older donor hearts (median: 32 y versus 23 y, p=0.02) and had longer ischemia time 
(median: 193 min versus 141 min, p=0.002). However, no relation was found 
between these non-immunologic initiators of GVD and IL-2 positive acute rejections. 
Thus, non-immunologic factors and allogeneic immune responses may 
independently trigger GVD. 
Chapter 8 deals with the issue: do cytokines playa role in processes responsible for 
down-regulation of acute cellular immune responses? To investigate this postulation, 
we analyzed IL-2 and IL-4 mRNA expression in biopsies obtained at time of 
spontaneously resolving liver rejection. This phenomena is characterized by 
histological signs of rejection that are not associated with deranged liver function 
parameters. Therefore, additional immunosuppression is not necessary. RT-PCR 
analysis demonstrated that the presence of IL-4 mRNA strongly correlated with 
uncompromised graft function in spite of concomitant histological signs of rejection. 
Significantly more of these biopsies (70%) expressed IL-4 mRNA compared to 
biopsies without any evidence of rejection (19%, p<0.01) or to biopsies concurrent 
with graft dysfunction (18%, p=0.03). In contrast, IL-2 mRNA expression was never 
detectable in biopsies with spontaneously resolving rejection and only occasionally 
in biopsies without any evidence of rejection (11 %) whereas a significant proportion 
of the biopsies of the treated patients expressed IL-2 mRNA (36%). These results 
suggest that cells committed to type 2 function control cell mediated immune 
responses. 
From the data described in chapter 8, it is obvious that a significant number of liver 
allograft rejections develop in the absence of IL-2 mRNA expression. Chapter 9 
shows that also the level of intragraft IL-15 mRNA transcription, a macrophage 
derived chemokine associated with T-cell activation, is not associated with cellular 
rejection after liver transplantation. However, irrespective of the rejection state, the 
posttransplant IL-15 mRNA levels were significantly upregulated compared to non-
transplanted liver tissue (p=0.005). These data imply that in the ongoing 
inflammatory response after transplantation, IL-15 may serve as a chemoattractant 
for T-cells. 
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CONCLUDING REMARKS AND FUTURE PROSPECTS 
The studies described in this thesis used the RT-PCR technique in an attempt to 
characterize acute and chronic immune responses by measuring intragraft cytokine 
mRNA profiles. Results of these studies were evaluated in relation to histology, graft 
function, and coronary angiogram. Specific intragraft mRNA profiles were found in 
clinically different complications. Especially the novel applications to predict the 
development of early stages of chronic rejection after heart transplantation (chapter 
7) and to discriminate between rejection and spontaneously resolving cellular 
infiltrates after liver transplantation (chapter 8) at the cytokine transcriptional level 
makes the RT-PCR technique an unique tool to monitor anti-donor immune 
responses in more detail. However, the review of the current literature (chapter 1) 
demonstrated that specific intragraft cytokine mRNA profiles may vary between 
patients, institutes, and are affected by immunosuppressive agents. One of the 
limitations of the RT-PCR technique is the lack of information about the cells that 
actually transcribe the cytokines. The recently developed in situ RT-PCR technique 
may resolve this limitation. This technique combines the advantages of in situ 
hybridization with the sensitivity of the RT-PCR, which makes it possible to localize 
rare mRNA expression within a heterogeneous cell population. 
The data described in chapter 6 suggest that intragraft cytokine mRNA profiles need 
to be studied at the earliest time peroid after transplantation. The inflammatory 
immune response caused by ischemia, perfusion and the surgical procedure may 
trigger the donor specific immune response via the cytokine cascade, thereby 
influencing graft function. Analysis of cytokine production shortly after 
transplantation may gain insight in the regulation of early allogeneic responses 
which in turn may initiate chronic rejection. Therefore, intragraft cytokine mRNA 
profiles have to be analyzed in relation to both morphological and clinical features of 
rejection. The findings reported by the group of Hutchinson suggested that even 
before transplantation cytokine analysis can be used to identify patients at risk for 
rejection. It was found that cytokine production is influenced by a genetic 
determinant (5). For instance, the G-to-A polymorphism at position -308 in the TNF-
a promotor induces increased TNF-a secretion. 
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In summary, intragraft cytokine mRNA profiles by the RT-PCR technique will provide 
the clinician additional information on the immunological activation status within the 
transplanted organ. 
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SAMENVATTING 
Voor patienten met een slecht functionerend hart of lever bestaat er vaak maar Mn 
behandeling, namelijk transplantatie. De eerste geslaagde klinische lever- en 
harttransplantaties werden respectievelijk in 1963 en 1967 uitgevoerd door 
respectievelijk Thomas Starzl en Christian Barnard (1,2). Na een hoopvol begin 
bleek het resultaat van orgaantransplantatie in de eerste jaren echter niet erg 
succesvol. Veel patienten overleden aan de gevolgen van afstotingen en infecties. 
Een belangrijke doorbraak in de transplantatie geneeskunde was het gebruik van 
cyclosporine A als afstotingsremmend geneesmiddel beschreven door Roy Caine in 
1978 (3). Verdere vooruitgang zoals de ontwikkeling van biopsieprocedures (4) en 
de introductie op grote schaal van anti-T cel geneesmiddelen (5) zorgden ervoor dat 
heden ten dage transplantatie als behandelingsvorm geaccepteerd is. 
Transplantatie-biologie is een vakgebied dat zich bezig houdt met onderzoek naar 
de oorzaken van afstotingen en de mogelijkheden van acceptatie van organen en 
weefsels. In eerste instantie werden twee facetten van de anti-donor reactiviteit 
bestudeerd: de cellulaire en de antilichaam respons. De cellulaire reactie tegen 
donorantigenen werd bestudeerd door middel van in vitro proliferatie- en 
cytotoxiciteitstesten met behulp van uit het transplantaat gekweekte cellen. Deze 
studies lieten zien dat ontvanger T-cellen een prominente rol vervullen bij de 
immuunrespons tegen donorcellen. Door de ontwikkelingen in de moleculaire 
biologie kan men nu deze immuunreacties ook rechtstreeks in het transplantaat 
bestuderen. Bovendien maak deze technologie het mogelijk om de interactie tussen 
immuuncompetente cellen van de ontvanger met getransplanteerde donorweefsel te 
onderzoeken. Interactie van de T-cel receptor met peptiden aanwezig in de groeve 
van het "major histocompatibility complex" van antigeen presenterende cellen 
resulteert in de produktie van diverse transcriptie factoren zoals cytokinen, 
chemokinen, groeifactoren, interferonen en hun receptoren. Deze mediatoren 
functioneren tijdens immuunreactiviteit na binding aan hun specifieke receptoren op 
de doelwitcellen. Cytokinen veroorzaken veranderingen in het celgedrag. Zij dienen 
voor de communicatie tussen cellen: vanuit het perifere bloed worden cellen het 
transplantaat ingetrokken (chemokinen), doen dienst als groeifactor, zorgen voor 
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proliferatie en differentiatie van cellen en beInvloeden de expressie van "Human 
Leucocyte Antigens" en andere oppervlaktestrukturen op cellen. Op basis van het 
cytokinen-produktiepatroon kunnen T-cellen worden onderverdeeld in functioneel 
verschillende subtypen. Vanuit experimentele transplantatie-immunologie werd het 
duidelijk dat type 1 cellen betrokken zijn bij cellulaire immuunreacties zoals acute 
afstotingen, terwijl type 2 cellen deze allogene responsen kunnen onderdrukken. 
Dus de functie van type 1 cytokinen (IL-2, IFN-y) is tegengesteld aan de activiteit 
van type 2 cytokinen (lL-4, IL-10). 
Hoofdstuk 1 bevat een samenvatling van de literatuur over cy10kinenbepalingen 
met behulp van de reverse transcriptase-polymerase chain reaction (RT-PCR) 
techniek in transplantaatbiopten. Dit overzicht laat duidelijk zien dat zowel afstoting 
als natuurlijke acceptatie van een orgaan niet tot stand komt via afgebakende 
cytokinen-mRNA-patronen. Dit kan diverse oorzaken hebben, waarbij niet aileen 
ontvanger- maar ook donorfactoren een rol spelen. Bovendien kunnen deze factoren 
een immunologische (bv. HLA verschillen, bloedtransfusies) en een niet-
immunologische (Ieeftijd, ischemie- en reperfusieschade) achtergrond hebben. Ook 
is duidelijk dat naast T-cel cytokinen ook mediatoren vanuit andere celtypen 
bepalend kunnen zij voor ontstekingsreacties na transplantatie. Voorbeelden zijn 
MCP-1, MIP, IL-6 en TNF-a, die door geactiveerde macrofagen en/of 
endotheelcellen geproduceerd kunnen worden en vervolgens afstotingsreacties 
kunnen uitlokken. 
Hoofdstuk 2 beschrijft de vraagstellingen van de in dit proefschrift beschreven 
studies. Kort samengevat: het doel was het onderzoeken van die gedeeltes van het 
cytokinen-netwerk, die betrokken kunnen zijn bij klinisch relevante vraagstukken 
zoals acute en chronische afstoting, natuurlijke onderdrukking van immuunreacties, 
en preventie of behandeling van een afstoting. Bovendien hebben wij ons 
afgevraagd hoe de kinetiek van type 1 en type 2 transplantaat infiltrerende T-
Iymfocyten en perifere Iymfocyten verliep op messenger RNA (mRNA) en eiwit-nivo. 
De analyse beschreven in hoofdstuk 3 laat zien dat er verschil bestaat in kinetiek 
van zowel IL-2 en IL-4 mRNA als van eiwit-produktie door "naIve" perifeer 
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mononucleaire celien vergeleken met die van "primed" transplantaat infiltraat 
infiltrerende Iymfocyten. Kort na in vitro stimulatie met donorantigenen 
produceerden de transplantaat infiltrerende Iymfocyten zowellL-2 en IL-4 mRNA en 
eiwit. Perifere mononucleaire celien waren daar niet toe instaat. Dit suggereert dat 
de transplantaat infiltrerende Iymfocyten al geactiveerde celien zijn. Verder kwam in 
deze studie naar voren dat, bij afstoting na harttransplantatie, iedere kweek van 
transplantaat infiltrerende Iymfocyten zijn eigen karakteristieke donor-specifieke 
mRNA en eiwit-produktiepatroon heeft. 
De studie beschreven in hoofdstuk 4 laat zien dat immunologische processen na 
harttransplantatie gepaard gaan met verhoogde cytokine-mRNA-produktie met 
name van IL-2, IL-4 en IL-6 in het getransplanteerde orgaan. Bovendien bleek dat 
IL-2 mRNA expressie voornamelijk aanwezig was tijdens acute afstoting, 76% 
versus 4% in biopten zonder afstoting (p=0.001). Voor IL-4 en IL-6 mRNA expressie 
werd slechts een trend waargenomen, terwijl IL-10 mRNA expressie altijd in de 
biopten kon worden aangetoond. Op grond van deze bevindingen concluderen wij 
dan ook dat de bepaling van IL-2 mRNA expressie in harttransplantatiebiopten een 
belangrijke bijdrage kan leveren voor diagnostische doeleinden. 
Het voorkomen van IL-2 mRNA transcriptie zou er toe kunnen leiden dat de T-cel 
activatie cascade wordt onderbroken. Hoofdstuk 5 beschrijft dat blokkade van de 
IL-2Receptor (CD25) door het monoklonale antilichaam BT563 resulteert in 
verminderde aantalien vroege acute afstotingen na harttransplantatie. In biopten, 
afgenomen tijdens de behandeling, werden slechts sporadisch IL-2 mRNA en CD25 
positieve celien aangetoond. Omdat ondanks blokkade van de IL-2/IL-2R route toch 
afstotingen optraden, blijkt dat het afstotingsproces naast IL-2 ook door andere 
cytokinen kan worden gereguleerd. Aangezien BT563 behandeling geen effect had 
op de T-cel groeifactor IL-15, doet dit vermoeden dat IL-15 de functie van IL-2 in het 
afstotingsproces kan overnemen. 
Het is duidelijk dat, ondanks verschillende, soms nog experimentele 
geneesmiddelen, harttransplantatie patiilnten vaak meerdere perioden van acute 
afstoting doorstaan. In eerste instantie worden deze behandeld met hoge doses 
stero·fden. Echter, bij veel patienten (± 40%) faalt deze behandeling en blijft het 
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afstotingsproces doorgaan. Hoofdstuk 6 beschrijft het effect van hoge doses 
stero'iden op de cytokinen-mRNA-expressie in getransplanteerd hartweefsel. V66r 
afstotingstherapie bleek het cytokinen-mRNA-expressiepatroon noch de mate van 
expressie te differentieren tussen steroid resistente en steroid gevoelige 
behandeJingen. Na afstotingstherapie werden wei significante verschillen gemeten 
tussen be ide afstotingsvormen. In biopten met histologisch aantoonbare 
doorgaande afstoting werd nog steeds IL-2 mRNA expressie aangetoond en wei in 
88% van de biopten, terwijl na succesvolle behandeJing in geen van de biopten IL-2 
mRNA werd gemeten (p=O.005). Ook IL-4 en IL-6 mRNA expressie was nauweJijks 
meer in deze biopten aantoonbaar (beide 17%), terwijl dit wei het geval was bij 
steroid resistente afstotingen waar IL-4 mRNA meetbaar was in 62% (p=O.14) en IL-
6 in 88% (p=O.03). Bovendien werd in biopten van succesvol behandelde 
afstotingen de mate van mRNA expressie van IL-1B, TNF-a, en IL-2R significant 
lager (p=O.03). Deze stu die laat zien dat het cytokinen-mRNA-expressiepatroon en 
nivo weJiswaar geen voorspellende waarde heeft voor de werkzaamheid van 
stero'iden als afstotingstherapie, maar dat het succes van de behandeJing hier wei 
aan af te lezen is. 
Op de langere termijn is chronische afstoting Mn van de belangrijkste complicaties 
na transplantatie. Na harttransplantatie manifesteert chronische afstoting zich als 
versnelde coronairsclerose. AI na een jaar zijn in 26% van de coronairen afwijkingen 
aantoonbaar. In hoofdstuk 7 wordt de bijdrage van immunologische en niet-
immunologische factoren beschreven op het ontstaan van deze versnelde 
coronairsclerose. Analyse van immunologische factoren liet zien dat op het moment 
van de diagnose versnelde coronairsclerose, Mn jaar na transplantatie, het 
cytokinen-mRNA-expressiepatroon in getransplanteerd weefsel niet differentieert 
tussen patienten met en zonder deze vaatafwijkingen. Daarentegen gaf het 
cytokinen-mRNA- expressiepatroon tijdens de eerste acute afstoting kort na 
transplantatie wei een aanwijzing voor de ontwikkeJing van versnelde 
coronairsclerose. MessengerRNA expressie van IL-2, maar niet dat van de andere 
cytokinen, was geassocieerd met chronische afstoting op een jaar. Bij patienten met 
versnelde coronairsclerose werd het IL-2 gen aangetoond in 77% van de biopten 
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tegen 26% van de samples alkomstig van paWinten zonder deze vaatafwijkingen 
(p=0.02). Ook niet-immunologische risicofactoren zoals koude ischemietijd (mediaan 
193 versus 191 min; p=0.002) en donorleeftijd (mediaan 32 versus 23 jaar; p=0.02) 
bleken geassocieerd met het ontstaan van versnelde coronairsclerose. Tussen de 
immunologische en niet-immunologische factoren werd echter geen relatie 
aangetoond. De in hoofdstuk 7 beschreven resultaten laten dan ook zien dat 
ischemie, donorleeftijd en IL-2 positieve acute afstotingen risicofactoren zijn die 
onafhankelijk van elkaar versnelde coronairsclerose kunnen induceren. 
"Kunnen cytokinen immuunprocessen ook onderdrukken" is de vraagstelling van de 
studie, beschreven in hoofdstuk 8. Om deze vraag te beantwoorden hebben wij 
een klinisch model onderzocht waarbij immunologische reacties niet automatisch 
leidde tot transplantaatfunctieverlies. Kort na levertransplantatie kunnen identieke 
histologische beelden passend bij acute afstoting zowel gepaard gaan met tekenen 
van levercelverval als met verbeterende biochemische leverfunctieparameters. In de 
bij deze histologische beelden behorende biopten hebben wij de cytokinen-mRNA-
expressie geanalyseerd. Wij vonden significante verschillen in biopten met 
histologische afstotingen alkomstig van transplantaten met en zonder biochemische 
verschijnselen van afstoting. IL-4 mRNA expressie werd in 70% van de biopten met 
spontaan verbeterende parameters aangetoond en slechts in 18% van de biopten 
met een vergelijkbare histologie alkomstig van transplantaten met verslechterde 
leverfunctieparameters. Bovendien werd in deze laatste transplantaten vaker IL-2 
mRNA gemeten: 36% versus 0% in biopten met infiltraat zonder klinische afstoting. 
Het antwoord op de vraag: "kunnen cytokinen de acute immuunrespons ook 
onderdrukken" is dus JA. De resultaten van deze studie suggereren dat type 2 
cellen in de getransplanteerde lever in staat zijn tot het onderdrukken van de type 1 
afhankelijke afstotingsreacties. 
Een ander opvallend resultaat van de studie beschreven in hoofdstuk 8 is, dat 
afstoting van levertransplantaten vaak plaatsvindt in afwezigheid van IL-2 mRNA 
expressie. Andere T-cel groeifactoren zouden hierbij dus een rol kunnen spelen. 
Hoofdstuk 9 beschrijft de analyse van IL-15 mRNA expressie in pre- en post-
transplantatie leverweefsel. In post-transplantatie biopten was het IL-15 mRNA 
173 
expressie nivo significant hoger dan in pre-transplantatie leverweefsel (p=O.005). 
Hoewel geen relalie tussen de mate van IL-15 mRNA expressie en afstoling 
gevonden werd, zou aileen al de aanwezigheid van de T-cel groeifactor IL-15 (in 
afwezigheid van IL-2 en IL-4 [zie hoofdstuk 8]) afstoting tot gevolg kunnen hebben. 
De studies, beschreven in dit proefschrift, laten zien dat met behulp van reverse 
transcriptase-polymerase chain reaction (RT-peR) technieken het mogelijk is om 
interaclies tussen de transplantaat infiltrerende cellen en het donorweefsel op 
mRNA nivo te bestuderen. Processen als acute en chronische afstoting, spontane 
onderdrukking van een immuunrespons en werkzaamheid van immunosuppress iva 
kunnen worden vervolgd aan de hand van karakteristieke cytokine-mRNA-
expressiepatronen in het transplantaat. 
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